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Although current antiepileptic drugs can effectively relieve most of the epileptic 
patients from episodes of seizure, still 40% of the patients are refractory to the current 
therapeutics. Hence development of new antiepileptic agents is urgently needed. Gou 
Teng and Tian Ma are two well-known Traditional Chinese Medicines (TCMs), 
widely used in oriental medicine to treat epilepsy, hypertension and migraine, but 
their scientific evidences to support their therapeutic applications in the above-
mentioned areas are limited. NMDA (N-methyl-D-aspartic acid) antagonism is an 
important mechanism for many successful antiepileptic and neuroprotective agents, 
such as MK-801, CPP, ketamine etc. Nowadays NMDA receptor antagonism still 
remains as an effective strategy for discovery of new antiepileptic and neuroprotective 
agents. Our aim is to search for active small molecules or molecular combinations 
from Gou Teng and Tian Ma, and to design and synthesize new NMDA receptor 
antagonists for the benefit of controlling seizures and protecting against neuronal 
damages. 
Conventional extraction and purification techniques were employed to obtain 
bioactive fractions, which were subsequently subjected to careful qualitative and 
quantitative chemical analysis. The standardized fractions, derived from Gou Teng 
and Tian Ma respectively, were tested on the maximal electroshock-induced seizure 
(MES) model in mice and on cell cultures that were inflicted by either hydrogen 
peroxide or serum-deprivation.  The indole-2-one (2-oxindole) template was utilized 
to prepare a series of 3-substituted derivatives which were later tested on cell cultures 
inflicted by hydrogen peroxide and on voltage-clamped Xenopus Oocytes expressed 
NR1/NR2B NMDA receptor.  
 vi 
The acquired fractions either alone or in combination did not prevent MES induced 
seizure activities on mice, but the phenolic fraction derived from Tian Ma was found 
to be rescuing cells from serum-withdrawal induced apoptosis. Two libraries based on 
2-oxindole derivatives were synthesized with acceptable yields, and one of the 
libraries was found to be acting as free radical scavengers to protect against cell death 
inflicted by hydrogen peroxide. One synthesized compound, namely compound 20 
(3112), was found to be a weak agonist acting at the glycine site of NMDA receptor 
based on the electrophysiological study on Xenopus Oocytes. Therefore, in this 
project it was found that Gou Teng and Tian Ma might be used more as 
neuroprotectants rather than as antiepileptic agents. In addition, some of the 
synthesized 2-oxindole derivatives that were initially designed as antagonists of 
Gly/NMDAR were acting as neuroprotectants against oxidative stress.  
In this project, the endeavour to search for potential antiepileptic and neuroprotective 
agents was made on both natural products and synthetic compounds. NMDA 
antagonism which was one of the mechanisms for Gou Teng to protect neuronal 
damage and also the rational basis on which the 2-oxindoles were synthesized served 
as the link. This was a trial that combined the passive process of isolating constituents 
from natural products and the active participation of design and synthesis of new 
compounds based on a well-defined target; this was an experiment that combined the 
diversified structures found in natural products and the synthetic library with limited 
structure diversity. It was believed that the most fruitful discovery of drugs should 
rely on both natural products and organic synthesis.  
Key words: Antiepileptic agents; Gou Teng (Ramulus Uncariae cum uncis); Tian Ma 
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1. Introduction  
1.1 General introduction 
Ancient Chinese people have utilized herbal infusion or concoction to treat epilepsy, a 
very common neurological disorder. Conceivably, their theory is mainly to tranquilize 
the over-excited brain activity, to relieve the muscle tension and ease the pain 
resulting from tonic-clonic tension. In modern medicine, epilepsy is defined as 
recurrent unprovoked seizures, and it can be idiopathic or acquired through 
neurological insults. Conventional therapy focuses on symptom relief by the 
employment of anticonvulsant drugs, and an emerging strategy, antiepileptogenesis 
aims to slow down and prevent the process of developing epilepsy as a consequence 
of initial brain injury. Neuroprotectants which prevent the neuronal damage caused by 
neurological insults play an important role in this new strategy. The common 
mechanism underneath antiepilepsy, antiepileptogenesis and neuroprotection involves 
N-methyl-D-aspartic acid (NMDA) receptor antagonism, which undoubtedly has 
become the target of many potential antiepileptic and neuroprotective drugs. 
In an effort to search for antiepileptic (anticonvulsant) and neuroprotective agents, 
two most famous traditional Chinese medicines (TCMs) which are monographed in 
Chinese Pharmacopoeia with antiepileptic effects, Gou Teng (Latin name: Ramulus 
Uncariae Cum Uncis) and Tian Ma (Latin name: Rhizoma Gastrodiae) have drawn 
our attention. Since 1970s, J.D. Phillipson and his co-workers have started the 
phytochemical study on the genus of Uncaria, and their focus was mainly on defining 
interesting structures of alkaloids1. The constituents of Tian Ma which are mainly 
small phenolic compounds were studied since the 1980s 2. On the basis of these 
phytochemical investigations, other researchers have either employed crude extracts 
2 
 
or single major constituents to study the pharmacological actions of these two herbs. 
The reported activity can vary greatly, from antiepileptic to antiproliferative; from 
vasodilating to neuroprotective. It is not so surprising since many types of structures 
have been found especially in Gou Teng. However, only the alkaloids found in Gou 
Teng and the phenolics found in Tian Ma have been shown to be effective in various 
pharmacological models, closely associated with antiepilepsy and neuroprotection.  
It is commonly observed that based on the Chinese medicinal principles, most 
prescribed recipes used for the treatment of epilepsy constitute both Gou Teng and 
Tian Ma. Moreover, a recent investigation has clearly indicated that co-application of 
extracts derived from Gou Teng and Tian Ma would significantly delay the onset time 
of wet dog shakes (WDS) in kainic-acid treated rats3. Besides, polypharmacy is a 
widely employed strategy in the pharmacotherapy of epilepsy due to the complexity 
in classification of epileptic seizures and the great variety of pathological 
mechanisms4. Thus, an investigation of the combined use of these two herbs in a well-
established animal seizure model would contribute to the understanding of the reasons 
underlying such combination in TCM practice, and would also provide lead 
compounds for further development of new antiepileptic and neuroprotective agents.  
In this project, the endeavour to search for potential antiepileptic and neuroprotective 
agents will be made on natural products, exemplified by both Gou Teng and Tian Ma, 
and synthetic compounds tentatively targeting at NMDA receptor. In the following 
sections, the current trend in drug discovery from natural products, previous 
phytochemical and pharmacological studies on Gou Teng and Tian Ma, NMDA 
antagonism as a rational strategy to discover new antiepileptic agents will be reviewed.  
1.2 Drug discovery from natural products 
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Natural products, including plants, bacteria, fungi and marine organisms, play a 
critical role in drug discovery. It is postulated that the chemical diversity of natural 
products is arising from the evolutionary pressure5, and such diversity is a prerequisite 
for the discovery of new chemical entities (NCEs). In addition, due to that natural 
products are produced in a biological environment, they are usually able to interact 
with a variety of macromolecular targets with fairly good binding affinity and 
selectivity6, which could explain why they have a better chance to become drug-like 
substances as compared to their synthetic counterparts. 
Notwithstanding the afore-mentioned advantages, a reduced interest in natural 
products has been observed in the past 10-20 years. Several reasons may account for 
this declining interest. First, high-throughput screening (HTS) which has recently 
emerged to greatly shorten the lead finding cycle time and enable a rapid production 
is more amenable to screen synthetic libraries than natural product libraries; second, 
the promise of combinatorial chemistry that a great variety of structures with “drug-
likeness” can be generated with less effort than natural products has diverted the 
attention of large pharmaceutical companies; third, the decision-makers in the large 
pharmaceutical companies has placed less focus on research in the area of infectious 
diseases, which traditionally has been a strong area of discovering new antibiotics 
from natural products7. However, combinatorial chemistry has not fulfilled its original 
promise of generating more high-value leads; only one de novo NCE (namely 
sorafenib) has resulted from combinatorial chemistry as reported to date and the 
number of NCEs hit a 24-year low in 20058. Besides, with the introduction of new 
technologies, such as hyphenated analytical instruments, LC-MS/MS, LC/MS/MS/MS, 
LC/MS/NMR (LC: liquid chromatography; MS: mass spectrometry; NMR: nuclear 
magnetic resonance) etc, have enabled natural product libraries to be screened readily 
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in high-throughput scale. On the basis of the strengths of natural products and the 
advancement in analytical technologies, nowadays natural products are gradually 










Scheme 1 Typical procedures for drug discovery from natural products. Natural 
products libraries are subjected to the HTS to obtain the bioactive sample which is purified 
by bioassay-guided fractionation to yield the pure bioactive compound. Through structure 
elucidation and conventional medicinal chemistry involving synthesis and structure-activity 
relationship (SAR) study, a future drug lead may be generated. 
A typical procedure for current drug leads discovery from natural products (shown 
above in Scheme 1), usually, starts with natural product libraries being screened in a 
high-throughput scale until bioactive extracts or fractions are obtained. Subsequently, 
the bioactive extracts or fractions undergo several rounds of bioassays and 
purification, typically known as bioassay-guided fractionation, till a novel bioactive 
compound is acquired, which can act as a drug lead for further drug development6. 
The following development involves total synthesis to meet the demands of larger 
Natural product libraries (mixture, 10-100s components; semi-fraction, 5-10 
components; or single pure constituent) 
High-throughput screening 
Bioactive concentrate sample 
Bioassay-guided fractionation 
Pure bioactive compound 
Novel bioactive compound 
Future drug lead 
Structure elucidation 
Evaluation of SAR “Shot-gun synthesis”, 
combinatorial synthesis 
? Robustness 
? Assumption: there must be a 
single bioactive component in 
the extract library. 
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quantity for the downstream research and diverted total synthesis which is to 
synthesize the analogues of the lead recently found in the natural products 9.   
This section is to review some challenges in the process of drug discovery from 
natural products, the strategies employed to overcome these challenges and the impact 
of new technologies on natural products developed as drug leads. 
1.2.1 Crude, pre-fractionated and pure natural products library 
The HTS has initially been designed for screening of a large number of pure 
compounds in the synthetic libraries, and it represents a big breakthrough that enables 
a rapid hit-to-lead phase and miniaturization in sample quantity demands. However, it 
also creates challenges in the area of natural products research.  
As is well-known, natural-product library itself is composed of samples which are 
either themselves mixtures – crude extracts (10-100s components), semi-pure 
mixtures (5-10 compounds) or single pure constituents6. The application of crude 
extracts on HTS is a time- and resource-intensive process with unsatisfactory hit-rate. 
First of all, to detect a substrate inhibitor in the HTS, it is ideal to screen a compound 
at the concentration close to its half-effective concentration (EC50); however, the 
relative concentration of each component in the crude extracts is usually unknown, 
which in most cases causes the concentration of trace components far below the 
detection level and that of the abundant components far above their EC50. Secondly, 
even though a bioactive extract is targeted, it still requires purification over several 
times and re-screening to yield the final pure compound which at times may not be a 
novel structure but the known one. Last but not the least, there are some unknown 
components which interfere with the readout of the assay due to that they might be 
fluoresce or absorbing at excitation or emission wavelength of the fluorophore6-7.  
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In case of single pure compounds, their development in drug discovery workflow is 
basically same as the compounds in the synthetic libraries, but the effort- and cost-
input to generate those pure natural product libraries are extremely more intensive 
than their counterparts in the synthetic libraries. In one case study, 4,000 pure, non-
redundant natural compounds were produced from 2,665 bacterial strains, 1,425 
fungal strains and 679 plant species has clearly shown us the new perspective in 
creating pure natural-product libraries10. To reduce redundancy, all samples 
underwent rigorous pre-profiling, profiling by using high pressure liquid 
chromatography (HPLC)-evaporative light scattering detector (ELSD); to assure drug-
likeness, LC-ELSD-MS was adopted to monitor molecular weight in the acceptable 
range; subsequently, these nearly non-redundant and drug-like samples were 
subjected to pre-fractionation and fractionation to yield over 6000 molecules, which 
were scrutinized to yield the final 4000 compounds. Though this is a successful case, 
preparation of pure natural-product libraries is a time-consuming process. Moreover, 
pure compounds prepared from natural products are frequently those with noticeable 
quantity, as a result trace components might be lost during purification and the 
chemical diversity of pure natural products library is thus limited. Finally, isolation of 
single compounds before screening may not be necessary although the robustness of 
biological results has been guaranteed.  
Another strategy is to use pre-fractionated natural products, and these pre-fractionated 
samples can be considered ‘screening-friendly’ 6 and not difficult to prepare as 
compared to pure natural-product libraries. The pre-fractionated sample can be 
defined as the semi (sub)-fractions prepared from the fractionation of a crude extract 
prior to biological evaluation, and the quantifiable criterion is that the number of 
constituents in one semi-fraction is normally no more than five7. One example in 
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dealing with microbial samples has clearly shown that pre-fractionated samples have 
greatly shortened the time-line from hit found to lead identification, and enhanced the 







Scheme 2 Pre-fractionated natural products library prepared from microorganisms. 7  
The crude extracts prepared from solid-phase extraction which were ensured for the 
production of the secondary metabolites by chemical and biological profiling were further 
fractionated on the prep-HPLC to generate 10 fractions for each crude extract.  
Pooled fermentations 
Solid-phase extraction 
Crude extracts, 1000s 
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Liquid fermentations of these microorganisms under two different conditions were 
pooled and followed by exhaustive solid-phase extraction; the resultant crude extracts 
were selected by chemical and biological profiling, by which the production of 
secondary metabolites was monitored such that the extracts with no secondary 
metabolites would be excluded. The extracts which had met the above-mentioned 
criteria were fractionated by preparative (Prep)–reversed phase (RP)-HPLC, and 10 
fractions were collected for each crude extract. The resultant semi-fractions were 
enriched for minor compounds, and represented reduced complexity as compared to 
crude extracts. Out of 2750 primary hits including crude extracts and fractions, 79.9% 
of active samples were found in fractions, suggesting that some samples would have 
been missed if only the crude extracts were screened.  
Another instance which utilized pre-fractionated plant extracts to generate natural-
product libraries has also indicated the applicability of pre-fractionation in HTS11. 
36,000 fractions which constituted 1~5 components were successfully prepared from 
a diverse collection of plants originated from 176 families and 561 genera. As 
exemplified by Taxus brevifolia, the schematic depiction of preparing the pre-
fractionated natural products library is shown below in Scheme 3. The plant had been 
extracted by different solvent system to yield organic and aqueous extracts, which 
were subjected to automated flash chromatography, polyamide cartridge and 
Centricon filter units such that 4 fractions derived from the organic extract and 1 
faction from the aqueous extract that were free of tannins and large molecular non-
druglike substances could be produced. These five fractions were further separated on 
parallel four-channel preparative HPLC to yield 40 sub-fractions for each flash 
fraction, which were sent for simultaneous analysis on parallel eight-channel HPLC-
ELSD-MS and assessment of anti-cancer activity. The authors found that this pre-
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fractionated natural products library was enabled to discover the active, otherwise 
undetected minor components. This point was even clearer that the flash fraction 
shown no activity but the sub-fractions prepared from the same flash fraction were 










Scheme 3 Pre-fractionated natural products library prepared from plants.11 The organic 
and aqueous extracts were divided into five fractions using flash chromatography and the 
resulting five fractions were further fractionated into 40 sub-fractions for each fraction by 
Prep-HPLC which were analyzed by an eight-channel LC-ELSD and shown to be composed 
of less than five compounds. 
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Pre-fractionation of crude extracts contributes to good quality of natural products 
library, which is suitable for the high-throughput paradigm currently popular in 
pharmaceutical industry. Moreover, in comparison with crude extracts, pre-
fractionated samples are beneficial for detection of potential minor compounds, and 
the follow-up to identify true hits has been simplified and greatly shortened. As 
compared with pure natural products library, pre-fractionation requires a relatively 
moderate time- and cost-input. Pre-fractionated natural products library which can 
better suit for the demands of HTS can be considered as an alternative of crude 
natural products library. 
1.2.2 The reductionist and holistic approach in drug discovery from natural products 
Any combination of drugs may lead to three types of interactions in bioactivity, 
namely additive interaction, synergistic interaction and antagonistic interaction.  
Natural products are well-known for their complexity in constituents, and the large 
number of constituents surely will result in the interactions between one another in 
some ways to affect the observed biological activities. That is why the extract as a 
whole has been said to be more or less different from the simple addition of single 
components contained within this extract in terms of pharmacological actions. The 
following section will discuss the interaction between naturally occurring compounds, 
and how this ubiquitous interaction challenges the application of the reductionist 
approach, exemplified by bioassay-guided fraction in drug discovery from natural 
products, moreover how a new emerging discipline–systems biology adopting the 
holism approach might turn out to be an effective solution to this challenge.  
1.2.2.1 Interplay between constituents in natural products 
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Polyphenols are abundant in our diets and many herbal remedies, thus they have been 
extensively studied either alone or in combination with regard to their 
chemopreventive activity. Incorporation of (-)-epigallocatechin gallate (EGCG) into 
lung cancer cell line PC-9 were reported to exhibit enhanced apoptotic activity due to 
co-treatment with (-)-epicatechin. Enhanced apoptotic activity was also observed in 
PC-9 when EGCG and other polyphenols derived from green tea were given together 
with (-)-epicatechin, which led to the conclusion that the whole green tea extract was 
more effective as cancer preventives than EGCG alone12. These polyphenols represent 
the compounds which happen to exist in one species, and other studies have also 
focused on the combined use of natural compounds which do not share their origin. 
EGCG, a well-known flavone in green tea, and curcumin, an abundant phenolic 
compound in the spice turmeric were investigated together in terms of their 
anticarcinogenic activity. In a newly established normal, premalignant, malignant 
human oral epithelial cell models, synergistic interaction was observed in cell growth 
inhibition when the two agents were used simultaneously. The effect required a 2-8 
fold reduction in the dose for EGCG and curcumin. The synergy was proposed to be 
due to their distinct mechanisms in inhibiting cell growth; EGCG blocked cells at G1 
phase, whereas curcumin blocked cells at S/G2M phase13.  
Besides the above-mentioned examples of synergy between polyphenols, another case 
has exemplified the positive interaction between three classes of structures, namely 
flavone, porphyrin and alkaloid14. The rising drug-resistance is the major challenge 
for development of new antimicrobials, and such resistance has been conferred mainly 
by ubiquitous multidrug resistance pumps (MDRPs). Berberine, a cationic alkaloid 
derived from Berberis fremontii was initially used as an antimicrobial agent that was 
later rendered ineffective due to the action of MDRPs found in the microbes. Based 
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on the theory that the inhibitor of MDRPs might be produced as well in B. fremontii 
that would assist in rendering the antimicrobial activity of berberine, a bioactivity-
guided fractionation was carried out in an attempt to isolate MDRPs inhibitor. Two 
components were obtained and identified from B. fremontii as 5’-
methoxyhydnocarpin-D (a flavonolignon) and pheophorbide A (a porphyrin). Though 
these two components did not possess any antibacterial activity, they completely 
inhibited the efflux of berberine from Staphylococcus aureus through MDRPs, hence 
greatly enhanced the accumulation of berberine in S. aureus. On the basis of this 
finding, the authors proposed that an effective strategy to fight against the generation 
of drug-resistant microorganisms would be to emulate nature by using MDRPs 
inhibitors to maintain the action of antibiotics14a. 
Synergy can also be observed in a mixture that contains more than two components. 
Four compounds found in Wedenia chinensis were shown to be effective in 
modulating the activation of the androgen receptor. A formulation composed of these 
four compounds in the same ratio as in the crude herbal extract was shown to require 
decreased effective concentration for each of these four compounds, thus suggesting a 
synergistic effect among them15. This study also clearly indicated the critical role of 
maintaining the native qualitative and quantitative composition of the herb, when 
purifying an extract until it contained only a few compounds. Notwithstanding, as in 
the above description, synergistic effects between natural products have been 
reviewed and emphasized, antagonistic effects have also been recorded16. 
Sulforaphane and 3,3’-diindolylmethane which are extensively found in cruciferous 
vegetables were studied together with regard to their impact on cell proliferation, cell-
cycle progression and apoptosis induction. By using different ratio of these two 
compounds, it was found that the combined effect was dependent on the total 
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concentration while it was independent of the proportion applied. At total 
concentration lower than 2.5 µM, the interaction of these two compounds as cytotoxic 
agents was antagonistic, but when the concentration was gradually increased to 40 µM, 
the interaction between these two compounds was changed from antagonistic to 
synergistic 16. These findings suggested that the combined effects were often 
unpredictable due to multiple factors, such as concentration, mixed ratio, even 
experimental design etc., even though individual constituent was thoroughly defined 
with respect to its mechanism of action.  
1.2.2.2 Bioassay-guided fractionation and systems biology based metabolomic 
approach 
Just as described above that the interactions between components in natural products 
are ubiquitous and often unpredictable, such complex interactions between natural 
compounds have created new challenges for drug discovery from natural products. 
First of all, in the current strategy, a reductionist approach has been adopted, typically 
exemplified by bioactivity-guided fractionation of the extract by using single-target 
based screening models17. Bioactivity-guided fractionation assumes that there must be 
one most potent constituent existing in the complex structure, after purification the 
most potent constituent will be obtained with the same activity as when it is still in the 
mixture. However, due to the existence of synergism and antagonism between natural 
compounds, the purification process may lead to loss of activity which has initially 
been observed in the crude extract. Secondly, since in most screening bioassay used 
for HTS a purified single protein is used to investigate the potential binding affinity or 
inhibitory effect, it is extremely difficult to observe the interplay between components. 
Although the whole animal study seems to be an appropriate alternative to investigate 
the response resulting from a complex interaction between the large numbers of 
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constituents acting at different pathways, however the high expense and time-input 
are definitely the obstacles for its use in HTS.  
In contrast to the reductionist approach employed in contemporary mechanism-based 
drug discovery, the complex interactions in a biological system can be studied in 
systems biology using a holistic approach. The approach will be able to discover new 
emergent functions and behaviours of the system resulting from interactions17. The 
theoretical foundation of systems biology is that human cells and tissues are 
composed of complex network with redundant, convergent and divergent signalling 
pathways. This viewpoint has inspired the efforts to search for small molecules which 
can simultaneously intervene at multiple points in the redundant signalling pathways, 
and the combined use of more than one small molecule is able to perturb the cellular 
signalling network in a more desired manner18.  
In the field of drug discovery from natural products, the emergence of systems 
biology has inspired new ideas that can facilitate the search for bioactive compounds 
which may be proven not effective in the single protein bioassay system and 
contribute to the understanding of how traditional herbs affect the organism at the 
holistic level19. It is natural to integrate systems biology with natural products 
research, since both are multi-component systems and the latter is able to affect more 
than one active site in a signalling pathway such that the desired intervention can be 
achieved. As is well-known, most diseases, except for some acute conditions such as 
infectious diseases, are multi-factorial, which means that treating a single target 
provides a partial treatment and in the majority of cases no cure or in case of chronic 
diseases, serious side effects occur. The interface to integrate natural products with 
systems biology is to use non-linear multivariate data analysis (MVDA). To begin 
with, a thorough chemical analysis on the natural products should be accomplished by 
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means of different techniques (such as LC-MS, gas chromatography (GC)-MS, NMR, 
infrared spectroscopy (IR) etc.), and then a bioactive study either done on cell lines, 
animal models or human volunteers should involve body fluids studies by the 
aforementioned techniques as well. MVDA enables visualization and interpretation of 
patterns in correlating a sample variable with a target variable such as bioactivity. 
Most of the times, the analysis of body fluids, such as blood, urine or saliva, will be 
enabled to obtain the profiling of metabolites upon drug treatment. This is known as a 
metabolomic study. In some cases, the protein composition can also be analyzed and 
profiled; hence a proteomic study may be useful.  
A study was carried out to compare the high resolution proton nuclear magnetic 
resonance (1H NMR) study of urine samples obtained from individuals with and 
without 2 weeks of chamomile tea ingestion. By utilizing chemometric methods, 
discriminant analysis with orthogonal signal correction was carried out. The authors 
concluded that there was a clear differentiation between the treatment and control 
groups on the basis that increased urinary excretion of hippurate glycine with depleted 
creatinine concentration was observed. They have further supported the metabolomic 
strategy in the application of assessing nutritional intervention 20.  
Based on the above description about drug discovery and development from natural 
products, it is not difficult to observe that there are two evident trends. One is still to 
look at natural products as a resource of diversified chemical structures where a novel 
structure with potent bioactivity may be purified and further used as a template for 
structural modification by modern organic synthesis to optimize its pharmacological 
activity. This strategy heavily relies on bioactivity-guided fractionation, a variety of 
separation techniques and utilization of modern organic chemistry. The other trend 
which is based on the emerging systems biology is to regard natural products as 
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inseparable medicinal unity, and to apply the holism approach on an evaluating 
system, in sub-cellular, cellular and organic level. The intervention of natural products, 
which are characterized by various techniques, is to be correlated with the genetic, 
proteomic or metabolomic change in the evaluating system. Although this strategy is 
not constrained to evaluate the multi-component natural products, its strength in 
correlating multi-component systems enables the study of natural products highly 
suitable.  
Admittedly, the reductionist approach centred on bioactivity-guided fractionation has 
contributed immensely to the discovery of many potent small molecules. However, 
with the emergence of systems biology, it has provided another perspective to develop 
the known structures and the combination of known structures in the search for novel 
activities. In this way, some folk medicinal herbs which have not been recognized as 
effective remedies can be better understood in terms of their mechanism of action by 
using the systematic approach. While keeping on the endeavour to search for NCEs 
from natural products as drug leads, selectively mixing known compounds or 
obtaining the extracts of natural products on a holistic organism will undoubtedly 
facilitate finding new clinically effective therapeutics and understanding how one 
multi-component system affects or corrects the homeostasis of the other organic 
system.  
1.2.3 A proposition – purifying one single chemical class from natural products 
However, it seems rather difficult to coordinate these two distinct strategies in drug 
discovery from natural products. When the focus is given to prepare pre-fractionated 
natural products library suitable for the HTS, all the constituents present in one 
species have been divided into 10s to 100s fractions normally based on their polarity 
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and their chromatographic behaviour on the column of Prep-HPLC. It is possible that 
some interactions between components might be lost together with this fractionation. 
While adopting metabolomic approach, the application of one multi-component 
system, such as the crude extract of a medicinal herb, on another multi-component 
system might never lead to the discovery of a single novel molecule as the future drug 
lead. Conceivably, there might be a way to incorporate these two approaches in order 
that both the favourable interaction between components and the most potent structure 
could be studied simultaneously. 
It is well known that one of the most distinguishing features of natural products is 
their frequent occurrence as suites or complexes of structurally related analogues6. 
The generation of structurally diversified congeners in natural products is being 
explained by a proposition called ‘screening hypothesis’ that the biological activity is 
a rare property for any molecule to possess and there might be a selective advantage 
for an organism to produce such diversity at low cost5. In other words, natural 
products might be producing a large number of molecules to perform their own SAR 
studies such that the most potent molecule could be generated and preserved among 
its relatives.  
On the basis of this common feature shared by natural products, it is possible to 
assume that the structurally related analogues derived from one chemical scaffold 
existing in natural products could possess similar biological activity only with varied 
potency. One example clearly showed that the mannopeptimycin complex produced 
by Streptomyces hygroscopicus possessed potent activity against Gram-positive 
bacteria21, and this complex was later found to consist of five compounds 
(mannopeptimycin α-ε) which shared a cyclic hexapeptide core  and exhibited 
variable antibacterial activities 22. Other numerous instances have also been shown 
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that a series of related structures was normally studied together to investigate their 
biological activities, such as catechins in green tea 23, alkaloids in Uncaria 
rhynchophylla 24, terpene trilactones in Ginkgo biloba 25and so on. Therefore, it would 
be rational to propose that one single chemical class in natural products should be 
purified from other chemical types. In so doing, the bioassay-guided fractionation 
could be performed after purifying this single chemical class in order to finally find 
the most potent compound. As for the study of the interactions between components, 
it is assumed that compounds derived from different chemical classes may have 
different pharmacological responses. Hence it is desirable to mix the different 
chemical classes to study their combined effects.   
The strength in this approach that each chemical class should be purified first is that 
the compounds with the common core structure are likely to have similar 
physicochemical properties which are beneficial to group and analyze them when 
extraction and separation are carried out. However, the drawbacks of this approach 
are apparent as well. First, purification of one chemical class from natural products 
may not be suitable for the HTS. Secondly, it may also ignore the possible interaction 
present in these structurally related structures. Last but not the least, the assumption 
underneath this supposition that one chemical class possessing similar biological 
responses may not always be true. Notwithstanding these obstacles, this supposition 
does represent a solution to coordinate two distinct perspectives in looking at natural 
product, a collection of diverse structures or an inseparable chemical unity. 
1.2.4 Hyphenated instrumentation applied in the analysis of natural products 
Just as mentioned above, though the acquisition of a NCE as a drug lead is the 
ultimate goal of drug discovery from natural products, the common interactions 
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between various types of compounds and the complex regulating mechanisms in 
diseases intervention have supported the use of some folk medicines without any 
purification or simple processing. The consumption of raw material has truly 
challenged the quality control of these herbal products, due to the great variability in 
chemical composition of these medicines. However, the advances in hyphenated 
instruments have greatly contributed to the analysis of complex chemical composition 
in natural products, such that consistency of products quality can be guaranteed. 
Furthermore hyphenated instrumental analyses are able to provide chemical 
information correlating with bioactivity studies. 
Classical techniques employed in profiling the chemical composition in natural 
products have turned out to be time-consuming and labour-intensive. On the other 
hand, hyphenated techniques allow simultaneous online separation and identification 
of the analytes, thus are able to provide a full profile of the chemical components of 
natural products in a rapid and efficient way. Currently, the more commonly used 
hyphenated instruments in the study of natural products include HPLC coupled with 
diode array detector (DAD), MS and NMR. LC-DAD is able to provide the UV 
spectrum of each isolated peak, providing preliminary information about the chemical 
classification of the compounds; MS is ideal in providing the molecular weight of the 
compound and MS tandem MS (MS/MS) can also give characteristic fragments for 
identification. Though UV and MS spectroscopies are helpful to characterize the 
known structures by comparison with spectra in the commercial libraries of 
compounds, their use however is very limited in characterizing unknown molecules. 
The development of new interface called flow probes allows the coupling of HPLC 
with NMR spectrometry, which though does not have matched sensitivity as LC-MS, 
provides valuable information that can be used to elucidate complex structures. Some 
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applications in profiling natural products by means of the hyphenated instruments will 
be briefly discussed below.  
One example is the on-line characterization of unstable cinnamic ester derivatives in 
the African plant Jamesbrittenia fodina (Scrophulariaceae). A preliminary metabolite 
profiling study performed with LC-DAD and LC-ESI-MS on the fractionated 
methanolic extracts revealed the presence of the common cinnamic ester derivatives. 
To solve two pairs of structures which could not be elucidated by MS and UV 
information, isolating work was carried out. However, it was found that even though 
successfully purified using preparative HPLC the purified structure would undergo 
isomerization to form a mixture again. Therefore, the fractions containing these two 
pairs of structures were analyzed by stop-flow LC-NMR through the comparison of 
coupling constants derived from 1H NMR spectra, and it turned out that these two 
pairs were mixture of E and Z geometric isomers 26.  
In another case, five major constituents in the ethanolic extracts of Belamcanda 
chinensis were identified by using LC-MS and LC-NMR. Preliminary analysis of the 
UV and MS spectra suggested that these five major constituents were likely to be 
isoflavonoids. Subsequently NMR gave full elucidation of these five major 
constituents. The authors found that the major compounds in the herbal extracts could 
be rapidly and efficiently characterized by the combined use of LC-MS and LC-NMR, 
although to characterize the minor compounds might require extra work, like 
fractionation and enrichment27. Absolute configuration of chiral carbons can also be 
confirmed by using on-line hyphenated techniques; and it was reported that the 
absolute configuration of chiral carbons of some indole alkaloids in crude extracts of 
Nandina domestica were identified by combined use of LC-MS/MS, LC-NMR and 
LC-CD analysis28.  
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LC-NMR is a powerful tool that is capable of rapidly identifying structures in a 
mixture, but it has not been widely applied due to the high cost of setting up 
equipment and low detection sensitivity. LC-MS and LC/MSn still remain as one of 
the popular techniques used for the on-line characterization of a mixture. Most of the 
samples that have been successfully analyzed by LC-MS were medicinal herbs or 
food supplements that are rich in flavonoids29, of which their fragmentation patterns 
have been extensively documented and thus have contributed to their fast 
identification using LC-MS. 
Just as is well-known, one active compound is unable to represent one medicinal herb, 
full chemical profiling of the medicinal herbs by means of hyphenated techniques is 
thus necessary. The information obtained will contribute not only to the fast search for 
drug leads from natural products, but also to providing chemical information of 
natural products required for metabolomic study. 
1.3 Two Traditional Chinese Medicines – Gou Teng and Tian Ma 
1.3.1 Phytochemical and pharmacological studies of Gou Teng 
Gou Teng (Ramulus Uncariae Cum Uncis) belongs to the Uncaria genus, Rubiaceae 
family. According to the Chinese Pharmacopoeia 30, its original sources include five 
species, Uncaria rhynchophylla, U. sinensis and U. hirsuta, U. macrophylla and U. 
sessilifructus, of which U. rhynchophylla is the most widely distributed. Gou Teng 
has been described in the Chinese Pharmacopoeia to possess sedative, hypotensive 
and anticonvulsant activity.  
The development in phytochemical and biological study of Uncaria genus has been 
recently reviewed31. The characteristic phytochemicals found in Uncaria genus are 
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indole and oxindole alkaloids, and most of the alkaloids have been extensively 
reviewed by Phillipson et al in 1978 1, though some minor alkaloids have 
continuously been discovered in recent studies. Another interesting group of 
structures in the Uncaria genus is the pentacyclic terpenoids, which are mainly based 
on ursolic, oleanolic or quinovic acid structures. The third type of structures is the 
flavonoids, which are commonly found in other natural products too. Extracts, 
effective fractions and single compounds found in Gou Teng (five original species) 
together with their corresponding bioactivity are also reported.  
Data from in vitro experiments demonstrated that the aqueous extracts of U. 
rhynchophylla have been shown to exhibit vasodilating effect on the rat aorta and this 
effect was believed to result from the release of endothelium-derived relaxing factor 
(EDRF), mainly nitric oxide (NO) 32. The extract of U. rhynchophylla derived from 
70% methanol was shown to possess protective effects on global cerebral ischemia, 
partly due to the inhibition of the induction  of cyclooxygenase-2, production of tumor 
necrosis factor–α (TNF-α) and NO 33. These examples represent crude extracts that 
did not undergo qualitative and quantitative analysis of their components and the 
identities of compounds responsible for the observed bioactivity were still unknown. 
Besides crude extracts, fractionated extracts composed of one type of structure, 
mainly the alkaloids, have also been extensively investigated in terms of their 
bioactivity associated with the Central Nervous System (CNS), cardiovascular and 
immune systems. Liu and his co-workers tested the alkaloidal fraction, derived from 
the aqueous ethanolic extracts separated from n-butanol and 5% ammonia solution, 
and found it inhibited superoxidative pressure induced by ferric chloride in 
epileptogenic foci. Therefore it was postulated that perhaps such antioxidant or free 
radical scavenging ability could attribute to its antiepileptic potential 34. Moreover, 
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another paper demonstrated that the alkaloidal fraction, prepared from acid-base 
processing and liquid-liquid extraction with chloroform, was able to protect against 
neuro-cell death, induced by glutamate, in rat hippocampal slices24. Different from 
other reports, these two investigations are commendable in that relatively pure 
fractions have been applied instead of crude extracts. The results are believed to be 
more reliable due to less interfering constituents. This has led us to believe that 
alkaloids rather than other structural types of phytochemicals found in Gou Teng 
would exhibit neuroprotective effects. However, the lack of qualitative and 
quantitative analysis of these pure fractions makes it impossible to understand the true 
identity of active components and the degree of their contribution. 
In contrast to the above-mentioned examples with no defined or standardized 
chemical composition, a few papers have reported the use of relatively pure 
preparations with known proportion of each compound, mainly alkaloidal fraction in 
their investigations. The authors 35premixed the pure compounds till an isomerisation 
equilibration could be achieved, since the spiro oxindole alkaloids were liable to 
isomerize36. Subsequently the percentage of each component in the equilibrated 
mixture was quantitatively determined. The pure alkaloidal fraction was divided into 
two categories based on the number of rings in the structure, pentacyclic oxindole 
alkaloids (POA) and tetracyclic oxindole alkaloids (TOA). Wurm et al 35afound that it 
was the POA instead of the TOA that induced human endothelial cells to release a 
regulating factor responsible for enhanced lymphocyte proliferation. In Winkler’s 
report35b, both the POA and the TOA were able to suppress the degradation of 
tryptophan and production of neopterin, suggesting their positive role in 
immunoregulation. Of note, these two pure alkaloidal preparations were acquired 
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from U. tomentosa; still it is necessary for the understanding of their actions since 
most alkaloids existing in Gou Teng belong to the TOA.  
Besides purified alkaloidal fractions, single pure alkaloids have also been investigated 
for their potential pharmacological activity. As for the indole type alkaloids, 
hirsutine37, geissoschizine methyl ether38 and dihydrocorynantheine37b have been 
respectively evaluated in terms of their vasorelaxant effect in rat aorta. This effect was 
proved to be associated with their negative regulation on cytosolic Ca2+ level and 
induction of NO. Corynanthe-type indole alkaloids, like yohimbine, corynantheine 
and dihydrocorynantheine,  were also evaluated for their leishmanicidal, 
antiplasmodial and cytotoxic potential39. As for oxindole type alkaloids (including 
pteropodine and isopteropodine40, rhynchophylline and its stereoisomer 
isorhynchophylline41), their direct effects on some metabotropic and ionotropic 
receptors, such as 5-hydroxtryptamine (5-HT2), muscarinic M1, NMDA receptor, have 
been carefully studied. The results showed that their antagonistic effect on these 
receptors could, to some extent, be contributing to their protection on neuronal 
damage. Rhynchophylline and isorhynchophylline turned out to be the compounds 
whose pharmacological actions have been well studied, and a review was written to 
systematically evaluate their effects on cardiovascular and central nervous systems42. 
Apparently, these investigations on single components are worth noting, because they 
have lent a great help to consolidate the conclusion that the active compounds found 
in Gou Teng are alkaloids, and the possible interaction between constituents was 
beyond the scope of these studies though. 
On the basis of the investigations above, the protective effects of alkaloids in Gou 
Teng against various brain insults and their modulatory activity in the glutamatergic 
systems strongly suggest their potential application in the treatment of epilepsy and 
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epileptogenesis. Nevertheless, so far there has been no report clearly exploring their 
anticonvulsant effect by using well-established animal model, and likewise there has 
been no clear investigation of antiepileptogenic effects of Gou Teng, even in an in 
vitro study.  The conceivable reasons could be that antiepileptogenesis is an emergent 
concept. Moreover no validated animal model of epileptogenesis has been established 
yet43.  
It is not difficult to notice that in the aforementioned investigations the biological 
actions of the total alkaloidal extracts and single components have usually been 
studied separately. There is actually one study done by Mohamed et al 44, who 
managed to simultaneously investigate, using purified single major compounds 
obtained from alkaloidal extract, the protection property of pure constituents and the 
extract against amnesia inflicted by the muscarinic receptor antagonist scopolamine. 
By comparing the extract with single component, Mohamed et al found that effective 
dose of mitraphylline and pteropodine was higher than the alkaloidal extract. The 
unique contribution of this work was that the correlation of the activity of the fraction 
with that of single constituents was studied in such a manner that a positive, neutral or 
negative interaction between components could be understood. However, this first 
trial was performed on another species in the same genus, the U. tomentosa, in which 
oxindole alkaloids were the predominant phytochemical component and this was not 
the case in the original species of Gou Teng where indole alkaloids were the major 
components. In addition, like all the other pharmacological studies on Gou Teng, this 
work did not analyze the alkaloidal extract with regard to the number, character and 
quantity of alkaloids. Without this analysis on the fraction as a means of quality 
control, it would be too premature to regard it as an alkaloidal fraction since probably 
only a minor part of the extract was alkaloidal with non-alkaloidal constituents 
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forming the majority of the composition, and it would also be difficult to produce a 
constant and reliable biological response. Therefore, in our opinion, it would be even 
more interesting and informative if the composition of alkaloidal fraction was known 
before any bioassay was carried out.  
As for the other two types of structures, the investigations were scanty and not 
systematic. Uncarinic acids and pentacyclic triterpene esters have been reported to 
possess cytotoxic activity, and this activity has been proposed to be due to the 
inhibition of phospholipase Cγ145. Some polyphenols, such as epicatechin, catechin 
and caffeic acid have been shown to be accountable for protective activity, exhibited 
by the aqueous extracts of U. sinensis against erythrocyte membrane hemolysis 
inflicted by 2,2-azo-bis-(2-amidinopropane)-dihydrochlroride46. Rutin, another 
flavonoid found in the leaves of U. hirsuta has been used for treatment of blood 
capillary ailments47. 
1.3.2 Phytochemical and pharmacological study of Tian Ma 
Gastrodia elata Blume is the only origin for Tian Ma, and its dried rhizome has been 
used as its medicinal part. Tian Ma, in contrast to Gou Teng, contains a less complex 
phytochemical composition. The major constituents do not have chiral centres and are 
mainly 4-hydroxybenzyl alcohol (4HA) derived phenols. A review 48has reported the 
potential use of this ancient medicinal herb as an antiepileptic agent.  
Differential methanol extracts of G. elata were found to prevent serum-deprived 
apoptosis of rat pheochromocytoma (PC12) cells through the activation of the 
serine/threonine kinase-dependent pathway and the suppression of c-jun N-terminal 
kinases (JNK) activity, suggesting its active role in neuroprotection49. The ethereal 
fraction of methanolic extract (EFME) derived from G. elata was believed to possess 
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the most biologically effective constituents. The protective activity of the EFME was 
believed to be due to the prevention of neuro-cell damage induced by several neuronal 
insults50. In one in vitro study where amyloid β-peptide inflicted cell damage in IMR-
32 cell line was used as a model to evaluate the protective activity of the EFME, and 
it was found that only the ether fraction instead of n-butanol, acetyl acetate and 
chloroform fractions could significantly reduce the cell death50b. In another report, the 
male ICR mice were administered orally with the EFME for two weeks before and 4 
days after kainic acid treatment. It was found that EFME did not affect the seizure 
activity of mice treated by kainic acid but it significantly delayed the onset time of 
seizures. In addition, the EFME was also found to significantly increase the number 
of viable pyramidal neuronal cells in the CA1 and CA3 regions of the hippocampus in 
kainic acid-treated mice as compared to control50c.  In a similar study, the authors 
established the transient global ischemic model by the occlusion of both common 
carotid arteries of gerbils for 3.5 min. Through comparison of the control and the 
EFME-treated group, it was found that administration of the EFME for two weeks 
significantly reduced neuronal damage induced by global ischemia 50a. These in vitro 
and in vivo studies have clearly indicated the potential application of the EFME of 
Tian Ma in the treatment of epilepsy and other neurodegenerative diseases.  
The standard active constituents in G. elata are believed to be gastrodin and its 
aglycone 4HA, therefore their pharmacological actions have been investigated more 
than the other minor components. In two papers, gastrodin and 4HA were shown to 
confer protection on a cerebral ischemic model inflicted by transient middle cerebral 
arterial occlusion (MCAO). One proposed that the protection was associated with 
increased expression of antioxidant genes51, while the other postulated that anti-
ischemia could be due to reduced extracellular glutamate level, which inhibited 
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release of Ca2+ and NO52. Besides the ischemic model, these two compounds were 
also demonstrated to be neuroactive in ameliorating amnesia induced by 
scopolamine53. Their effects which were associated with anti-seizure were shown to 
be attributed by the inhibition of the enzymes which are responsible for degradation 
of γ-aminobutyric acid (GABA), a well-known inhibitory neurotransmitter54. 4-
hydroxybenzaldehyde (4HD) is another major active compound, its antioxidative 
property and positive regulation of GABAergic neuromodulation were reported to be 
contributory factors to its anticonvulsive effect55. In addition to these major 
components, other minor constituents, mainly 4HA derived phenols, were tested for 
their relaxant effects on smooth muscles56. In a recent study, two new benzofurans 
were obtained and they were shown to inhibit DNA topoisomerases thus possessing 
antiproliferative activity57. In another investigation aimed at finding new compounds 
which could protect against serum-starved apoptosis in PC12 cells, two compounds, 
bis-(4-hydroxybenzyl) sulfide and N6-(4-hydroxybenzyl) adenine riboside were 
identified to be active58. 
1.4 Antiepilepsy, antiepileptogenesis and neuroprotection 
The ultimate goal of treating epilepsy using pharmacotherapy has been stated as “no 
seizures, no side effects” at a NIH–sponsored consensus conference in 2000, which 
ideally will be achieved by the combined exploitation of antiepileptic and 
antiepileptogenic drugs 59. Antiepileptic drugs (AEDs), employed for more than half 
century, represent the major strategy aiming at ameliorating and even eliminating 
symptoms that epileptic patients are suffering from. The most successful classes of 
drugs used for treating epilepsy include the barbiturates, benzodiazepines, hydantoins 
and carboxamides. These AEDs have been widely applied though, a significant 
fraction of patients are still experiencing uncontrolled seizures (refractory seizures), 
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accompanied by quality  life-threatened side effects 60. Based on the fact that epilepsy 
is one of the most common neurological disorders with an estimated 0.5~1% 
incidence; and that about 40% of the patients are refractory to existing therapeutics, 
hence, there is an urgent need for more efficacious therapeutic agents 60.  
The discovery of new antiepileptic drugs with an improved therapeutic index requires 
a better neuropathological understanding of those refractory seizures and the 
establishment of suitable animal models to mimic such new pathology. Currently 
known AEDs aim to ameliorate the symptoms of seizures, while an emergent new 
strategy, antiepileptogenesis aims to prevent or slow down the process of developing 
epilepsy. This new theory is based on the notion that initial seizure is responsible for 
the later developed recurrent seizures (epilepsy) 61. It is proposed that if these known 
AEDs failed to control the destructive epileptic activity, antiepileptogenic drugs 
would be supposed to fulfill the job that AEDs were unable to do, that is to hinder the 
progress of seizures and to avoid the recurrent seizures (epilepsy). Therefore, 
antiepileptogenesis is focused on repairing and correcting the lasting seizure–prone 
state as a result of initial CNS insults. Since epileptogenic state is a consequence of 
the initial brain injury62, including status epilepticus (SE), stroke and traumatic brain 
injury (TBI), the critical role of neuroprotection in antiepileptogenesis is therefore 
evident.  
The following briefly describes the three strategies in pharmacotherapy of epilepsy 
treatment, and the commonly used in vivo and in vitro models for the evaluation of 
new antiepileptic agents. 
1.4.1 Definition for antiepilepsy, antiepileptogenesis and neuroprotection 
30 
 
Epilepsy is a common chronic neurological disorder characterized as recurrent 
unprovoked seizures. Though nowadays surgery has appeared as an option for 
epileptic patients, pharmacotherapy still remains as the major strategy for treatment. 
Current and future pharmacostrategies of epilepsy treatment are based on three 
different but overlapping approaches: to terminate the emergency of SE by 
anticonvulsant (or antiepileptic) drugs, to modify epileptogenesis following brain 
injury in order to prevent chronic epilepsy, and finally to prevent reoccurrence of 
epilepsy in the established epilepsy63. There are three concepts derived from these 
approaches: antiepilepsy, antiepileptogenesis and neuroprotection.  
Antiepilepsy is to prevent and reduce epileptic seizures; neuroprotection prevents 
neuronal injury, and neuroprotectants can be antiepileptic agents if epileptic seizures 
are injurious or vice versa.  Antiepileptogenesis aims at preventing or slowing down 
the process of epilepsy development. Antiepileptic agents can become 
antiepileptogenic agents if seizures blocked by antiepileptic agents are epileptogenic. 
Furthermore neuroprotectants can also be antiepileptogenic agents if the injury 
prevented by neuroprotectants is leading to epilepsy64.  
1.4.2 In vitro & in vivo models for epilepsy, epileptogenesis and neuroprotection 
The discovery of AEDs relies heavily on the appropriate choice of animal models for 
the initial screening, since behavioral change of animals is one of the important end 
points to evaluate the efficacy of the treatment. Over 50 animal models have been 
utilized in the search for new AEDs, according to a review in 198965. Recent 
development has been focused on the establishment of animal models of 
epileptogenesis, which requires a latency period as a consequence of initial brain 
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injury, but this quiescence actually should display high-frequency synchronization in 
the brain till an epileptic focus is developed43, 60.  
At the present time, three in vivo models have been routinely used in AEDs discovery 
program, namely maximal electro-shock induced seizure (MES), pentylenetetrazol 
(PTZ) seizure model and Kindling model. White has examined these three models and 
discussed their strengths and limitations in screening for new AEDs60.  It is believed 
that each one of these three models cannot conclusively detect antiepileptic activity. 
Therefore different models should be utilized in order that true effect of the candidate 
compounds can be evaluated60. MES and PTZ models are frequently used to predict 
antiepileptic effect against generalized seizures. Their minimal requirements for 
equipment and technique expertise enable them amenable for high-volume screening, 
but it should be kept in mind that these two models are performed on neurologically 
normal rodents which is very different from epileptic brain in human. Kindling model 
has compensated for the limitation of MES and PTZ models. It is a model of focal 
seizures and predictive of partial epilepsy, and it requires repeated subconvulsive 
stimulation of the limbic brain region which results in a progressive increase in 
electrographic and behavioral seizure activity. Therefore Kindling rodents are not like 
neurologically normal rodents; likewise the establishment of the Kindling model is 
labor intensive and demands adequate facilities and resources.  
With the increase in the understanding of the molecular biology underlying 
epileptogenic process, several in vitro and in vivo systems have been studied to mimic 
the state between brain insults and recurrent epileptic activity, with the final goal of 
preventing the occurrence of epilepsy and to find disease-modifying therapy43, 62. 
While some systems have demonstrated overt seizure expression, others have only 
demonstrated electrographic seizures. Still some have only demonstrated chronic shift 
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towards enhanced excitability. The following table shows the in vivo and in vitro 
models utilized to study mechanisms of epileptogenesis and the search for therapeutic 
agents62.  
Table 1 in vitro & in vivo model for epileptogenesis 
Epileptogenesis model in vivo in vitro Insults on intact animals Insults on neurons 
SE-induced 
Pilocarpine, kainic acid, 
glutamate,  electrical 
stimulation 
Low Mg2+ hippocampal 
culture, STIB (stimulus 
train-induced bursting) 
Stroke-induced 
Focal ischemia by photo-
thrombotic cortical infarct, 
focal ischemia utilizing middle 
cerebral artery occlusion 
Sub-excitotoxic glutamate 
exposure to CNS neurons 
TBI-induced Fluid percussion injury Mechanic injury by stretching cultured neurons 
 
Since one rational component in the antiepileptogenic treatment regime can be 
neuroprotection66, the in vitro and in vivo models used for neuroprotection will also be 
discussed herein. Neuroprotection is a broad term, defined as mechanisms within the 
nervous system which protect neurons from undergoing apoptosis or degeneration. 
Currently, neuroprotective effects are usually evaluated on ischemic animal models 
and the infarct size is the end point for assessment 67. In addition to these in vivo 
studies, some cell culture models utilize primary cortical cultures that are exposed to 
some form of hypoxia/glucose deprivation 68. These primary cell cultures clearly 
mimic the in vivo conditions though; the percentage of cells killed in these 
experimental conditions may vary greatly. To circumvent this problem, some 
commercially available immortal cell lines together with the chemical insults have 
been recommended as fast screening tools to identify potential neuroprotective 
compounds 69.  The commonly used neuroblastoma cell lines include PC-12, SH-
SY5Y, IMR-32, HT-22, HT-4 and etc, which when given the appropriate insult such 
as β-amyloid peptide, glutamate, hydrogen peroxide, MPP+, serum-deprivation, 
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oxygen-deprivation, will induce cell apoptosis. The common mechanism underneath 
the induction of neuronal apoptosis following application of these insults is the 
elevated reactive oxygen species (ROS) level, high intravenous Ca2+ concentration.  
1.5 The role of NMDA antagonism in antiepilepsy, antiepileptogenesis and 
neuroprotection 
While the discovery of AEDs has been serendipitous70, rational drug design based on 
mechanism of epilepsy is what researchers have been constantly pursuing. Apparently, 
rational design is where scientists are able to put their thoughts into reality. The main 
targets of substances important in anticonvulsant and antiepileptogenic 
pharmacostrategies are ionic channels, the inhibitory GABA system and excitatory 
glutamate receptors63. Many successful examples exist for clinically effective AEDs 
targeting at Na+, Ca2+ ion channels and the GABAergic system, however, the excess 
in excitation inflicted by glutamate is involved in pathologies of not only epilepsy, but 
also hypoxic-ischemic brain injury and other neurodegeneration70. Therefore, 
selective modulation of excitatory glutamergic neurotransmission is closely associated 
with antiepilepsy, antiepileptogenesis and neuroprotection. NMDA receptor is one of 
the glutamate-activated ionotropic receptors, and its multiple modulating sites, high 
permeability to Ca2+ and wide distribution in the brain make it one of the most 
exciting drug targets.  
1.5.1 NMDA antagonism 
NMDA receptor is a macromolecular complex consisting of an excitatory amino acid 
(EAA) recognition site, a NMDA sensitive receptor-linked cation channel with a 
phencyclidine and Mg2+ binding site, and strychnine insensitive glycine and 
polyamine modulatory sites. The characteristics of NMDA receptor are 1) highly 
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permeable to Ca2+, 2) strong voltage-dependent blockade by extracellular Mg2+, 3) 
requirement for glycine as a co-agonist to a full activation71. Experimental substances 
which have shown to be competitive antagonists at the NMDA receptor are CPP, CGP, 
40116, and those acting non-competitively include MK-801, TCP and ketamine. In all 
in vivo animal models of epilepsy, substances such as ketamine and MK-801 
demonstrated strong seizure-suppressing effects72, although they also exhibited 
psychotomimetic adverse effects like confusion70. Furthermore, Stasheff et al 73 in 
1989 accomplished an initiative work with the ultimate conclusion that NMDA 
receptor antagonists were able to differentiate the process of epileptogenesis and 
seizure expression in a Stimulus Trains Induced Bursting (STIB) model, thereafter the 
contribution of NMDA receptor antagonism in antiepileptogenesis has been 
recognized. Though nowadays there is still lack of the established epileptogenic 
animal model to validate the antiepileptogenic potential of NMDA receptor antagonist, 
NMDA antagonism remains one of the major strategies to search for effective 
antiepileptic, antiepileptogenic and neuroprotective agents74. Antagonists targeting at 
Glycine site of NMDA receptor have received more attention than those acting at 
other sites since they have been found to possess higher specificity thus to have less 
side effects 75.  
1.5.2 Antagonists at the glycine site of NMDA receptor 
Since the discovery of glycine as co-agonist that fully activates the ionotropic NMDA 
receptor76, search for effective antagonists at this strychnine-insensitive glycine site 
has become a focus for many medicinal chemists and pharmacologists. It is well-
known that excessive activation of NMDA receptor by glutamate, a major excitatory 
transmitter in the vertebrate central nervous system, is closely associated with a 
number of acute and chronic neurodegenerative pathologies77. Such over-activation of 
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NMDA receptor can be blocked by competitive and non-competitive NMDA receptor 
antagonists, since the full activation of NMDA receptor requires the involvement of 
glycine, blockade at this glycine site is also able to diminish the over-activated 
receptor activity. Preferably, the blockade at glycine remains a better strategy since it 
gives fewer secondary effects as compared to blocking NMDA binding site itself. 
Hence, it has been expected that antagonists at strychnine-insensitive glycine site of 
NMDA receptor (Gly/NMDAR) would be potential neuroprotective agents78, and 
their therapeutic application could be used in the treatment of acute stroke, epilepsy 
and neuropathic pain75, 79.   
The functional NMDA receptor probably consists of tetrameric or pentameric subunit 
assemblies by NR1 and NR2 subunit, in which glycine and NMDA binding sites 
locate respectively. Furukawa and Gouaux have deciphered the crystal structures of 
NR1 S1S2 bound with glycine, D-serine and 5,7-dichlorokynurenic acid, which has 
provided the insight into the essential interaction required for effective binding 
between the core and the ligands80, and may also contribute to the development of 
new structures with potential antagonistic effects at the glycine site.  
Currently, there are at least 6 structural types identified as the antagonists of 
Gly/NMDA, kynurenic acid (KA) derivatives, 2-carboxyindoles (2CI), 2-
carboxytetrahydroquinolines (CTHQ), 4-hydroxy-2-quinolones (HQ), quinoxaline-
2,3-diones (QXDO) and 3-hydroxy-1H-1-benzazepine-2,5-diones (HBAD) 75, 79.  The 
first three types, due to the presence of the carboxylic group, are rather hydrophilic 
thus difficult to diffuse through blood brain barrier (BBB) to reach required effective 
concentration in the brain; whereas the latter three structural types represent improved 
lipophilicity though, their further development is still hampered by poor BBB 
permeability or unfavorable oral bioavailability. Hence, there is an urgent need to 
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design novel structures with selective and specific antagonistic effects at 
Gly/NMDAR. 
Previous structure-activity relationship studies have suggested a putative 
pharmacophore for antagonists at Gly/NMDAR81.  Based on the structures of CTHQ, 
it has been defined that the requisite pharmacophore needs to have the following 
components (shown in Figure 1), a size-limited hydrophobic region which is fulfilled 
by quinoline or indole, usually favorably substituted by halogen atoms, a hydrogen 
acceptor always exemplified by 3-substituted carbonyl group, a hydrogen donor 
fulfilled by amine in the quinoline or indole ring, a bulk tolerance site placed at 5 Å 
above the plane of aromatic ring, a negative charged group, usually a carboxyl group 






















Figure 1 Qualitative pharmacophore for antagonists at Gly/NMDAR based on the 
structure of CTHQ. The required interactions between ligands and the glycine binding site 
of NMDA receptor are proposed. 
Incorporating a new series of structures, HQ which represents better oral 
bioavailability has led to the development in this pharmacophore model that β-
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dicarbonyl system acted as a vinylogous carboxylic acid bioisostere assists cell 
membrane permeability since the negative charge could be delocalized over five 
atoms in the corresponding anions; and 3-phenyl ring π system is able to interact with 









Figure 2 A developed pharmacophore model based on structure of HQ. β-dicarbonyl 
system (marked as red) acted as a vinylogous carboxylic acid bioisostere together with 3-
phenyl ring is proposed to participate in the interaction with the positively charged group on 
the receptor. (A is H-bond acceptor; + is a receptor cation.) 
Study of currently known antagonists at Gly/NMDAR75, 79 implied three chemical 
scaffolds in those antagonists, namely, 2-carboxy- or 2-oxo-1,2,3,4-tetrahydro-
quinoline and 2-carboxy-indole (shown in Figure 3).  Another template structure 
which is related to these three scaffolds but has not been used for the synthesis of 
potential antagonists at Gly/NMDAR is 2-oxindole. Substituted 2-oxindoles have 
been reported in several patents that they possess analgesic and anti-inflammatory 
activity 83.  Substituted 2-oxindoles are also widely distributed in naturally-occurring 
alkaloids, which have been reported to have a variety of pharmacological activities 
associated with neuroprotection24, 41b, presumably due to the antagonistic effects of 
these alkaloids on muscarinic M1, 5-HT2 and NMDA receptors 40-41, 41c. The 
structural resemblance between 3-substituted 2-oxindoles and HQ initiates us to 
wonder whether this 2-oxindole could be employed as a new core structure to 
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generate a series of compounds that specifically target at Gly/NMDAR to exert 


































































































Figure 3 Substituted 2-oxindoles proposed as potential antagonistic effect at 
Gly/NMDAR. Three basic chemical scaffolds were generalized based on the currently 
known antagonists at Gly/NMDAR, namely 2-carboxy- or 2-oxo-1,2,3,4-tetrahydro-quinoline 
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and 2-carboxy-indole. Two alkaloids found in Gou Teng have been reported to behave as 
antagonists at NMDA receptor. It is hypothesized that 2-oxindole derivatives with 
appropriate substituents could be used as antagonists at Gly/NMDAR. 
1.6 Summary 
In the process of drug discovery from natural products, three types of natural products 
libraries have been analyzed, namely crude, pre-fractionated and pure natural products 
libraries, with regard to their strengths and limitations in the application in the HTS. 
To best suit for the demands of HTS, fractionated-extracts library has been valued 
more since it has maintained the integrity of the natural products without sacrificing 
the robustness of screening results. Subsequently, a great variety of interactions 
between components in one or more natural products have been reviewed; such 
complexity in the interactions between natural products supports the combined use of 
multiple components and also corresponds to the theoretical principles of systems 
biology. Therefore natural products, as a multi-component system, could be better 
understood using this systematic approach. On the basis that a series of structurally 
related structures possesses similar biological activity, it has been proposed that one 
chemical class derived from one chemical scaffold should be purified, which could 
facilitate the search of the most potent molecule through bioassay-guided 
fractionation and the investigation of interactions between different chemical classes. 
In addition, the advances in the hyphenated instrumentation used in analysis of natural 
products have been briefly described. These techniques will definitely facilitate 
defining a natural product in terms of its chemical identity and quantity.  
Next, the previous phytochemical and pharmacological studies of Gou Teng and Tian 
Ma have been described. it has been found that alkaloids are the active compounds of 
Gou Teng, and are responsible for pharmacological applications of Gou Teng in CNS 
and cardiovascular system, though some flavonoids have also shown to be effective in 
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the treatment of ailments in cardiovascular system. As for Tian Ma, it was found that 
phenolic compounds, particularly phenolic compounds derived from 4HA are the 
major active compounds. Their neuroprotection has been validated by in vitro 
ischemic model or cultured cell model inflicted by serum starvation or other 
neurotoxins, and their antiepileptic potential has been indicated in their positive role 
in GABAergic system.  
To discover and develop new AEDs based on the rational drug design, the glycine site 
on the NMDA receptor has been described and proposed to be the potential drug 
target for potential antiepileptic and neuroprotective agents. An examination of 
currently known antagonists at the Gly/NMDAR initiates us to propose 2-oxindole as 
the chemical scaffold with the potential antagonistic effect at this target site.  
1.7 Hypothesis and Objectives 
On the basis of the above review, the herbs Gou Teng and Tian Ma are conferred with 
great promise as effective antiepileptic, antiepileptogenic and neuroprotective drug 
candidates. However, validated animal model of epilepsy has not been recruited in 
previous studies, and the neuroprotective potential of the two herbs has never been 
systematically explored in neuronal cell culture models before. In addition, 
considering the fact that these two herbal medicines are usually prescribed together in 
one formula, it will be of great interest to understand their combined effects as 
compared to their individual use.  Furthermore, due to the structural similarity 
between the core structure, 2-oxindole, of the alkaloids found in Gou Teng and the 
currently known antagonists that bind at the Gly/NMDAR, it is desirable that new 
structures with potential antiepileptic and antiepileptogenic activity could be 
synthesized by using 2-indolinone as a template structure. 
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Therefore, the main objective of this thesis is to investigate whether there is a 
possibility that the alkaloids found in Gou Teng, together with the modified structural 
analogues of the alkaloids, and the phenolics found in Tian Ma may possess 
antiepileptic and neuroprotective properties. To achieve this objective, specifically, 
the thesis is set out to 
1) Obtain standardized alkaloidal and phenolic extracts derived from Gou Teng 
and Tian Ma respectively; 
2) Assess the antiepileptic activity of the two extracts separately and in 
combination using the MES-induced seizure model in mice; 
3) Assess the neuroprotective potential of the two extracts by using a neuronal 
cell line which is insulted by various kinds of neurotoxins; 
4) Synthesize new structures which are based on 2-oxindole as the chemical 
scaffold with varied substitution at positions 3 and 6; 
5) Evaluate the newly synthesized compounds (selected from 4) on Gly/NMDAR 
expressed on Xenopus Oocytes; 
6) Evaluate the neuroprotective potential of the newly synthesized compounds on 
a neuronal cell line which has been insulted by various kinds of neurotoxins. 
This combinatorial approach to study antiepileptic and neuroprotective activity of 
Gou Teng and Tian Ma may provide some insight into the rationale underlying the co-
prescription of Gou Teng and Tian Ma in traditional medicine; and at the same time 
may yield more effective lead compounds which may be developed as new class of 
AEDs. Synthesis of analogues that may have propensity to bind to the Gly/NMDAR 
as antagonists based on 2-oxindole as the scaffold that may generate new structural 
leads for AEDs development, and may further substantiate the use of NMDA receptor 
antagonists as antiepileptogenic and neuroprotective agents. 
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In this study, only the alkaloids found in Gou Teng and the phenolics found in Tian 
Ma will be included for the evaluation of antiepileptic and neuroprotective activity, 
despite the fact that there are other chemical classes present in Gou Teng and Tian Ma 
too. One consideration is that in the previous investigations these two classes of 
constituents have been shown the activity closely associated with antiepilepsy and 
neuroprotection. The other concern is that fewer chemical classes are recruited; the 
more easily the test samples will be combined in the bioassay to assess the interaction 
between different chemical classes in terms of bioactivity.  
Although in this study there will be no direct bioassay employed for the assessment of 
antiepileptogenic activity, neuroprotective activity evaluated on the immortal 
neuronal cell line may be relied on as an indicator for antiepileptogenic activity. 
Moreover, the antagonistic effects on NMDA receptor will also be investigated, 












2. Results and Discussions 
2.1 The standardized extracts derived from Gou Teng and Tian Ma  
2.1.1 Methodology 
To prepare the standardized extracts from these two traditional herbs, the following 
general scheme (Scheme 4) was adopted to obtain each extract and to analyze the 












                           
Scheme 4 Methodology adopted to obtain the standardized extracts from Gou Teng 
and Tian Ma.  Fractionation is initially performed on crude extracts by means of liquid 
extraction based on the physicochemical properties of the compounds of interest. 
Subsequently this sub-fraction is analyzed by tandem instruments in terms of chemical 
composition, and is also subjected to column chromatography to obtain the major single 
constituents fully characterized by spectroscopic analysis. 
As proposed in section 1.2.3, one single chemical class of constituents was purified 
based on their physicochemical properties, such as molecular size, pKa, logP etc. 
Subsequently, hyphenated analytical instruments, LC-MS and GC-MS were utilized 
to verify the majority of the components in the fractionated extracts to be the target 
Herbs 
Crude extracts (methanolic, alcoholic, aqueous and etc.) 
Fractionated extracts 
Based on pKa, polarity, molecular size and etc. 
Analyzed by LC-MS, GC-MS Preparative column chromatography 
Chromatogram and mass spectrums Single components 
Structure elucidation 
MW and other 
characteristic fragments 
NMR, IR, MS and etc. 
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compounds in order to reduce the interference components as far as possible. To 
investigate whether there was any difference in biological activity between the 
fractionated extract and the major components contained within, preparative column 
chromatography was employed to isolate the major compounds from the fractionated 
extract, which together with the isolated compounds was evaluated for their biological 
responses in a bioassay. The interaction in terms of the bioactivity (be it additive, 
positive or negative) between components was derived by using several mathematical 
formula or functions, such as the median-effect function84, isobolographic analysis85, 
Loewe’s additivity18b and Bliss independence18b. 
In the following section, purification of the fraction consisted mainly of alkaloids 
from Gou Teng would be described, and a thorough analysis of chemical identity and 
quantity of this fraction using LC-MS and LC-UV was carried out.  
2.1.2 The standardized alkaloidal extract from Gou Teng  
As mentioned in section 1.3.1, crude extracts, purified fractions and single alkaloids 
derived from Gou Teng have been shown to be protective against various neuronal 
insults and capable of modulating glutamatergic system, which is strongly indicative 
of their application in the treatment of epilepsy and other neurodegenerative disorders. 
Alkaloids, rather than terpenoids and flavonoids which are the other two major 
phytochemical classes found in Gou Teng, have been identified to be contributory 
towards antiepilepsy and neuroprotection. Hence, the primary aim of this study was to 
obtain the alkaloidal fraction from Gou Teng. The most distinctive property of 
alkaloids different from terpenoids and flavonoids is their slightly higher pKa value, 
which can be exploited for isolating pure alkaloids from other two types of 
compounds.   
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2.1.2.1 Preparation of the alkaloidal extract 
The procedures to prepare the alkaloidal extract are shown in Scheme 5. Calcium 
hydroxide was only slightly soluble in water, thus its saturated solution was used to 
adjust the mixture to an appropriate pH value, which enabled the liberation of the free 
base, as well as to react with tannins present in herbs to produce insoluble calcium salt. 
The repeated base-acid processing was aimed at purifying the alkaloids based on their 













Scheme 5 Preparation of the alkaloidal extract from Gou Teng. The alkaloidal extract 
2.8 g was obtained from 4 kg Gou Teng through liquid-liquid separation on the basis that 
alkaloids are soluble in acidic aqueous solution (2% H2SO4) whereas insoluble in slightly 
alkali aqueous solution (dil. ammonia solution).  
There was a risk that isomerization could happen to oxindole alkaloids present in Gou 
Teng while treated with acid and base, but this possibility was excluded by the 
comparison of methanolic extract with the alkaloidal extract by HPLC, and it was 
found that there was no significant change with regard to the relative proportion of the 
Gou Teng 4 kg 
Moistened by saturated Ca(OH)2 
Filter, collect filtrate and reduced to 
dryness under vacuum 





Extracted by 2% H2SO4 
Organic layer Aqueous layer 
Basified with conc. NH4OH 
Aqueous layer Organic layer 
Alkaloidal extract 2.8 g 
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major alkaloids. Probably, such isomerization would be suppressed when these 
alkaloids existed in an equilibrated chemical mixture, and that is, isomerization only 
occurred to a single pure isolated compound in a certain solution36. Toluene was 
selected as the extracting solvents over chloroform, ethanol and methanol, considering 
it could have selectively better solubility for compounds with benzene ring, such as 
the indole and oxindole alkaloids in Gou Teng.   
2.1.2.2 Qualitative analysis of the alkaloidal extract by LC-ESI-MS  
The obtained alkaloidal extract was analyzed initially by LC-MS, and it was found to 
contain 5 major and 2 minor components (Figure 5). Their molecular weights (MW) 
were estimated under positive ion mode using electrospray ionization (ESI) source 
(Table 2). A typical EMS scan for peak 1 is shown in Figure 4. Since the alkaloids 
found in Gou Teng were present as stereoisomers, MS or MS/MS was not able to 
identify each component, only the possible structures were proposed as shown in 
Table 2.  
 
Figure 4 EMS spectrum of peak 1 in the TIC of the alkaloidal extract. The EMS 
spectrum indicates the molecular ion peak at m/z 367.200. 
 +EMS: 24.011 min from Sample 1 (412-2) of 412-2.wiff (Turbo Spray) Max. 1.0e6 cps.





























Figure 5 Total ion chromatogram (TIC) of the alkaloidal extract (A) and UV spectrum 
of the alkaloidal extract (B). Five major components (1-5) and two minor components (6-7) 
are present in the alkaloidal extract.  





in TIC Possible structures 
366 1, 3 Hirsuteine, Corynantheine, epiallo-corynantheine, geissoschizine methyl ether 
368 2, 6 Hirsutine, dihydrocorynantheine 
382 4 Corynoxeine, isocorynoxeine 
384 5 Rhynchophylline, isorhynchophylline 
352 7 Pentacyclic ajmalicinoid alkaloids 
 
This preliminary study of chemical composition by LC-ESI-MS indicated that nearly 
all those detectable components present in this alkaloidal extract belonged to 
corynantheidine type alkaloids, which in a sense suggested that liquid-liquid 
TIC of +EMS: from Sample 1 (412-2) of 412-2.wiff (Turbo Spray) Max. 1.5e7 cps.
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extraction was successful in isolating alkaloids out of other chemical classes, but it 
remained unknown whether all alkaloids had been recovered since such purification 
of one chemical class might come with the loss of many minor constituents. It was 
known that Gou Teng did constitute more than these seven alkaloids 31, though 
probably these seven components could represent the major alkaloids found in Gou 
Teng.  
2.1.2.3 Isolation and characterization of single alkaloids from the alkaloidal extract 
Since the identities of the alkaloids were undetermined by LC-MS, to characterize 
each component, the alkaloidal extract (1 g) was subjected to silica gel 
chromatography by using chloroform/acetone (9:1 to 7:3) or ethyl 
acetate/isopropanol/25% ammonium solution solvent system (80:15:5) 1, 86 where 6 
single constituents were isolated. Due to the presence of many chiral centers in the 
compounds, characterization of the absolute configuration of the chiral centers would 
be very interesting. In the case of corynantheidine type alkaloids (Figure 6A), there 
would be three chiral centers, C-3, C-15 and C-20. Naturally-occurring alkaloids are 
only present as H-15α 87, thus there are four stereoisomers due to different 
conformations at H-3 and H-20, and by analogy with yohimbine skeleton 
nomenclature they have been categorized as normal (3α, 15α, 20β), pseudo (3β, 15α, 
20β), allo (3α, 15α, 20α) and epiallo (3β, 15α, 20α) (Figure 7). Normal- and allo- 
adopt trans-quinolizideine form whereas pseudo- and epiallo- adopt cis-
quinolizideine form on the basis of ring C/D juncture.  In the case of pentacyclic 
indole alkaloids with the closed ring E (see Figure 6B), C-19 was also present as a 
chiral center, which complicated the situation as it would give rise to eight possible 
stereoisomers87.  Besides, in the pentacyclic indole alkaloids which include 
yohimboid and ajmalicinoid alkaloids, epiallo- could adopt either cis- or trans- 
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quinolizideine form depending on the substituents on ring E. If no substituents present, 
trans-quinolizideine form was preferred whereas if there were substituents present in 
ring E cis-quinolizideine would be more desired since otherwise the ring E 





























Figure 6 General structures of corynantheidine and ajmalicinoid type alkaloids (A) The 































Figure 7 Configurations for corynantheidine, yohimboid and ajmalicinoid type indole 
alkaloids. Four stereoisomers exist due to the different configuration of H-3 and H-20; 
epiallo- configuration was structurally unstable arising from the substituents on the ring E 
thus to give an equilibrated form of both cis- and trans- quinolizideine. 
NMR spectral data has long been employed to differentiate these four stereo-chemical 
configurations 87-89. In the 1H NMR spectra, the most distinctive multiplet of H-3 in 
pseudo- alkaloids would appear at 4.4-4.5 ppm, since in the pseudo- configuration, H-
3 would not be shielded by the neighboring nitrogen ion pair, and thus would be 
shifted to a downfield chemical shift environment as compared to the other isomers 
(See Figure 7 for the relative position between H-3 and the adjacent nitrogen in these 
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four configurations). Although H-3 in epiallo- configuration should also not be 
shielded by the nitrogen ion pair, due to less stability in the structure the observed 
NMR spectrum was the equilibrated conformers involving both cis- and trans-
quinolizideine87-88, the H-3 still showed up at about 3.4 ppm. The other important 
information in 1H NMR included coupling constants, which could greatly facilitate 
the judgment of the relative configuration between the neighboring protons in the 
rigid ring systems. However, this information normally would be hidden in lots of 
overlapping peaks. Application of consecutive double resonance operations would 
permit all the protons to be discovered and the coupling constants to be determined 87, 
and the coupling constants could provide information for the relative position of the 
protons on the two neighboring carbons. However, the easiest way to differentiate 
these four stereoisomers (normal-, pseudo-, allo- or epiallo-) was to rely on carbon 
nuclear magnetic resonance (13C NMR), which gave distinctive peaks for nearly each 
stereoisomer in a much wider range as compared to 1H NMR. In 13C NMR, the 
chemical shifts of C-3 and C-6 could be used for conformational and configurational 
assignments. For the D/E trans- compounds, the δ (C-3) and δ (C-6) values of 59-61 
ppm and 21-22 ppm, respectively, were indicative of the normal- and allo-
configuration. While δ values of 53-54 and 16-17 ppm, respectively, were indicative 
of the pseudo- and epiallo- configuration.  In the case of epiallo- configuration, if a 
cis-quinolizideine form was adopted, C-3 and C-6 would appear at 54-55 and 16-17 
ppm, respectively, which was similar to the pseudo- configuration. If the trans-
quinolizideine form was preferred, then the δ values of 54-55 and 21-22 ppm, 
respectively, would be observed. In the case of mixtures, the chemical shifts of 53-55 
and 16-22 ppm for C-3 and C-6 respectively could be observed. The shielding of C-6 
in the cis-quinolizideine form was a consequence of this carbon’s 1, 4-diaxial 
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interaction with C-21 and the resultant steric γ effects from carbon-hydrogen bonds 
(Figure 8). These carbons were easily distinguishable in the 13C NMR spectrum, 











Figure 8 The steric γ effect derived from the hydrogen-hydrogen non-bonded 
interaction.  (A) The involvement of a hydrogen with another proximate hydrogen is the 
consequence of the rigid ring system. (B)An example in the corynantheidine type alkaloid 
where the axial H-6 and the axial H-21 are involving the interaction due to the proximity, 
explains the upfield shifting of C-6 in the 13C NMR. 
Compound 1, which was acquired as a brown powder, exhibited a [M+1] at m/z of 
369.2 using ESI source. In connection with 1H NMR and 13C NMR data, a formula 
C22H28O3N2 was derived, which was corresponding to the corynantheidine type 
alkaloids. The characteristic peak located at 4.45 ppm in the 1H NMR spectrum of 
compound 1 accounted for the 3β configuration of H-3, since in the 3α configuration, 
the shielding effect caused by N-4 would shift H-3 upfield to around 3.3 ppm. 
Therefore, the structure of this compound could be either the pseudo- (3β, 15α, 20α) 
or epiallo- (3β, 15α, 20β) configuration which was believed to adopt a cis-
quinolizideine form. In the 13C NMR spectrum, the C-6 located at 16.9 ppm (Table 3) 
was also supporting the pseudo- configuration, and further comparison with reported 
13C NMR data confirmed the pseudo- conformation89c, thus compound 1 was 
identified as hirsutine.  
Compounds 2 and 3 exhibited the same [M+1] peak at m/z of 367.3, and they had one 





was determined as C22H26O3N2. In a similar way, the presence of H-3 at 4.45 ppm 
together with the coupling constant of 12 Hz for J15,20, suggested that compound 2 
would be assigned with a pseudo- configuration, the only difference was the 
appearance of three unsaturated protons at 4.8-5.4 ppm, indicating that the ethyl group 
in hirsutine was converted to a vinyl group, thus compound 2 was identified as 
hirsuteine. As for compound 3, there was only one proton present at 5.41-5.43 ppm in 
the form of alkene proton, indicating an ethylidene instead of a vinyl group. The 
compound was hence characterized as geissoschizine methyl ether. The common 
doublet (J = 7.2 Hz) present at approximately 7.5 ppm in these three compounds was 
due to the trans- configuration between methoxy and methoxycarbonyl group90. 
Compound 4 exhibited [M+1] peak at m/z of 383.2, with a D2O exchangeable proton 
at 8.9 ppm in the 1H NMR spectrum and a carbonyl group at 180 ppm in the 13C NMR 
spectrum, suggested that this was an oxindole alkaloid rather than an indole alkaloid. 
The proton at 3.27 ppm was assigned to H-3, indicating the normal- or allo- 
configuration. Furthermore, the chemical shifts of 75.0 ppm and 122.4 ppm in 13C 
NMR spectrum were diagnostic of the spiro carbon in the oxindole alkaloids, which 
were consistent with that of rhynchophylline. Hence this structure was ascertained to 
be corynoxeine, with a vinyl group at C-18 and C-19 similar to compound 2. 
Compound 5 was characterized as corynantheine, since the two distinctive peaks in 
the 13C NMR spectrum located at 21.7 ppm and 60.0 ppm (as shown in Table 3), were 
assigned to C-6 and C-3 respectively, which supported the normal- configuration; 
further comparison with the reported 13C NMR data were also justifiable for 
corynantheine with the normal- configuration89c.  
Compound 6 exhibited [M+1] peak at m/z of 353.3, and was initially categorized as an 
ajmalicinoid alkaloid (pentacyclic indole alkaloid). The 13C NMR spectrum of this 
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compound showed some broadening peaks, the missing C-6 signal and C-3 located at 
54.6 ppm, all strongly indicative of the epiallo- configuration. In addition, H-20 and 
H-15 were correlated in 2D- nuclear overhauser effect spectroscopy (NOESY) 
spectrum, indicating H-20 was positioned as α configuration, which also supported 
the epiallo- configuration. Moreover, H-15 and 18-methyl were also correlated in 2D-
NOESY. Hence 18-methyl was positioned as α configuration similar to H-15. 
Collectively, this compound was characterized as akuammigine.  
The 13C NMR chemical shifts of isolated alkaloids are listed in Table 3. It was easy to 
observe the distinction of C-3 and C-6 between normal-, pseudo- and epiallo- 
configurations. Akuammigine, as an epiallo- ajmalicinoid alkaloid, had a few peaks 
missing or broadened in 13C NMR spectrum. As explained in one report88, this 
alkaloid could be involved in a fast equilibrium of conformers (Figure 9) in 
deuteriochloroform solution at room temperature. When applied at cold temperature, 
one carbon signal at room temperature was split into two signals, strongly indicative 
of the presence of two conformers, adopting trans- and cis- quinolizideine forms. 
Therefore among the four conformers only the pseudo- conformer would purely 
constitute cis- quinolizideine to give the most distinctive H-3 signal at approximately 
4.5 ppm in 1H NMR spectrum in contrast with δ values of 3.3-3.7 ppm as observed in 









Table 3 13C NMR chemical shifts (δ/ppm) of isolated indole and oxindole alkaloids 
   GME  HS  HT  CT  Aku  Cor  
   indole  oxindole  
   normal-  pseudo-  pseudo-  normal-  epiallo-  normal-  
C-2  134.0  133.2  132.9  134.8  132.8 b  181.8  
C-3  61.7  54.1  54.0  60.0  54.6  75.0  
C-5  58.8  51.2  51.2  52.9  52.3  56.1  
C-6  21.4  16.9  16.9  21.7  19.2 b  34.8  
C-7  108.3  107.8  107.8  108.0  106.8 b  54.8  
C-8  127.3  127.9  127.8  127.4  127.4  133.7  
C-9  119.2  117.9  117.9  118.1  117.9  123.1  
C-10  121.2  121.1  121.2  121.2  119.2  122.4  
C-11  120.5  119.2  119.2  119.3  121.3  127.8  
C-12  110.7  111.0  111.1  110.7  111.0  109.6  
C-13  134.8  135.9  135.9  136.0  135.9  141.2  
C-14  34.2  31.7  31.0  33.4  30.8  28.8  
C-15  36.4  34.9  34.0  38.6  30.8  38.5  
C-16  112.5  111.8  111.6  111.6  107.7  111.6  
C-17  159.6  159.7  159.6  159.8  155.3  159.7  
C-18  13.0  11.3  115.2  115.5  18.5  115.4  
C-19  118.1  24.2  139.4  139.3  73.2 b  139.4  
C-20  136.1  39.0  43.0  42.8  37.3  42.0  
C-21  64.5  50.7  51.2  61.3  50.3 b  58.7  
C=O  168.6  168.9  168.7  169.1  167.8  168.6  
COOMe  51.4  51.4  51.3  51.3  51.1  51.1  
CHOMe  61.7  61.4  61.4  61.5  _  61.4  
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Figure 9 Structures of six isolated alkaloids plus rhynchophylline, a purchased 
reference compound. (Quantities in mg shown in the parentheses.) 
Through analyzing the 1H NMR and 13C NMR spectra of these 6 isolated alkaloids 
and comparing with the previous NMR data, they were identified and abbreviated as 
the following, geissoschizine methyl ether (GME: 90mg), hirsutine (HS: 110mg), 
hirsuteine (HT: 80mg), corynoxeine (COR: 6.2mg), corynantheine (CT: 7.5mg) and 
akuammigine (AKU: 4.3mg) (Figure 9). The presence of major indole alkaloids and 
minor oxindole alkaloids was also consistent with the medicinal origins of Gou Teng, 
which was in great contrast with another famous species, U. tomentosa, which was 
composed mainly of pentacyclic oxindole alkaloids. It was also clear based on the 
isolated quantities that three corynantheidine type alkaloids, GME, HS and HT 
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constituted more than 50% (w/w) of the alkaloidal extract, implying their major 
contribution to the observed pharmacological activities.  
2.1.2.4 Quantitative analysis of the alkaloidal extract by LC-UV 
To accurately determine the quantities of the isolated alkaloids in the extract, an LC-
UV method would still be required. Considering the purity, five alkaloids, GME, HS, 
HT, rhynchophylline (RHY) and COR, three indole and two oxindole alkaloids, were 
used as reference standards to quantify these five compounds in the alkaloidal extract. 
In the mean time, to compare the alkaloidal extract with the crude extract in terms of 
the quantities of these five alkaloids, the crude extract of Gou Teng was also prepared 
by exhaustive extraction in acidic methanol (1% conc. HCl in methanol) in reflux. By 
a gradient elution using 0.1 M ammonium acetate and methanol as mobile phase, five 
compounds were baseline separated and detected under the wavelength of 254 nm. 
Ammonium acetate was added to increase the ionic strength and thus to improve the 
retention of alkaloids on a C18 column (Figure 10).  
Figure 10A 

















Figure 10 LC chromatograms of the alkaloidal extract and the acidic methanolic 
extract of Gou Teng (A) the alkaloidal extract; (B) the acidic methanolic extract of Gou 
Teng; (Peak 1, GME; 2, HS; 3, RHY; 4, HT; 5, COR.)  
While working on the quantification of the alkaloidal content, it was found that 
oxindole alkaloids, RHY and COR, were not able to achieve acceptable recovery 
yields. This could be attributable to the rapid isomerisation that occurred when 
dissolved in methanol. The minor peak observed in the chromatogram of degraded 
RHY sample was identified to be isorhynchophylline by using LC-MS (Figure 11), 
which was indeed strong evidence that oxindole alkaloids could undergo readily 
isomerisation in polar solvents36. The complete quantification results are shown in 
Table 4, and it was clear that the total concentration of these 5 alkaloids was enhanced 
from 0.3% in herbs to 70.1% in the extract. However, the yield of the alkaloids 
acquired from Gou Teng (2.8 x 70.1% = 1.96 g) was rather low, around 17.2%, 
considering there were more than 11g of the five alkaloids present in 4 kg of Gou 
Teng (4,000  x 0.28% = 11.36 g). The enhancement in the alkaloidal content 
accompanied by the low yield of obtaining the alkaloidal extract suggested that the 
conventional liquid-liquid extraction represented a selective strategy to isolate the 














alkaline compounds from other non-alkaline compounds, but it did not provide high 





TIC of +EMS: from Sample 7 (rhyn) of rhyn.wiff (Turbo Spray) Max. 2.0e7 cps.



































TWC of DAD Signal Data: from Sample 7 (rhyn) of rhyn.wiff Max. 23.2 mAU.

































 +EMS: 26.871 min from Sample 7 (rhyn) of rhyn.wiff (Turbo Spray) Max. 1.2e6 cps.






















Figure 11 The minor peak observed in the degraded rhynchophylline sample shares 
the molecular weight with the major peak by LC-ESI-MS. (A) TIC of the degraded 
rhynchophylline in methanol; (B) EMS spectra of the two peaks in the TIC of the degraded 
rhynchophylline. 
Table 4 Quantities of five major alkaloids in the crude extract and in the alkaloidal 
extract of Gou Teng 
Components Conc. in Gou Teng (g/100g) Conc. in the alkaloidal extract (g/100g) 
GME 0.12±0.025 26.87±1.23 
HS 0.08±0.013 18.53±1.33 
HT 0.07±0.012 21.69±1.59 
RHY 0.008±0.0011 1.80±0.15 
COR 0.006±0.0012 1.25±0.07 
Total 0.284 70.14 
 
The great enhancement in the alkaloidal content has at least three benefits in terms of 
the suitability for bioactivity screening. First, the biological response would be more 
closely correlated with the components present in the screening samples due to their 
intensive abundance, and the interference and matrix effects resulting from the 
presence of minor constituents would be excluded as far as possible. Second, the 
subsequent isolation of the responsible compound would be much simplified since the 
number of constituents has been greatly reduced. Last but not the least, the interaction 
 +EMS: 30.327 min from Sample 7 (rhyn) of rhyn.wiff (Turbo Spray) Max. 3.4e5 cps.
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between constituents (addition, synergism or antagonism) could be understood if each 
single constituent could also be isolated and investigated in the same screening system. 
Admittedly, there are problems as well with the simplification of the crude extract. 
The major issue would be the potential loss of active components and the interaction 
between components. When initially making the decision to purify the alkaloids from 
Gou Teng, two assumptions were made; one was that the alkaloids would be 
responsible for the effect of Gou Teng associated with neuroprotection (this effect was 
derived from a thorough literature review); the other was that the purer the alkaloidal 
extract, the stronger would be the neuroprotection as would be expected in general 
dose-response relationship. Only if these two assumptions were true, the purification 
of alkaloids from Gou Teng would yield a sample with potential anticonvulsant and 
neuroprotective activity. 
2.1.2.5 Conclusions  
The resultant organic extract was first analyzed by LC-MS and 7 alkaloids were 
detected with their molecular ion peaks, which did not help decipher their identity due 
to the presence of stereoisomers. Subsequently, by utilizing column chromatography, 
six single alkaloids were isolated from this alkaloidal extract and characterized as 
GME, HS, HT, COR, CT and AKU. Except for COR as a tetracyclic oxindole 
alkaloid, the other five were indole alkaloids. GME, HS, HT and CT were classified 
as corynantheidine type while AKU would be the epiallo- ajmalicinoid alkaloid. To 
quantify the major alkaloids present in this extract, a LC-UV method was established 
to achieve baseline separation for the five alkaloids (GME, HS, HT, RHY and COR), 
which were found to account for 70% (w/w) of the extract. This alkaloidal extract was 
considered as highly suitable for screening of bioactivity, with known identity and 
quantity, and would be applied on in vitro and in vivo models to evaluate its 
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antiepileptic and neuroprotective activity. The figure below is shown the complete 
profile of the alkaloidal extract by means of LC-UV with the known identities of the 
major peaks (Figure 12). 
Figure 12A 
 
Figure 12B (magnified from Figure 12A) 
 
Figure 12 The complete chemical profile of the alkaloidal extract by LC-UV.  (A) the 
complete chemical profile; (B) the magnified profile in the retention time ranged from 10-17 
min. (Peak A, GME; Peak B, HS; C, RHY; D, HT; E, COR; F, ISO-RHY(isorhynchophylline); 
G, AKU. ) 
































































2.1.3 The standardized phenolic extract derived from Tian Ma 
As mentioned in section 1.3.2, 4HA derived phenols present in Tian Ma would be the 
compounds of our interest. Recently, the medium-polar extracts prepared from the 
EFME of Tian Ma have been well studied and shown that the EFME possesses a 
variety of pharmacological activities50, closely associated with neuroprotection and 
antiepilepsy. Besides, a similar preparation of Tian Ma using ethyl acetate fraction of 
the methanolic extract has been studied to consist mainly of 4HA derived phenolics 56. 
Therefore, the EFME was proposed to have the most bioactive phenolic compounds. 
The previous procedures would be adopted with modifications to prepare the EFME, 
which would be analyzed for its chemical composition by the hyphenated analytical 
instruments in order to decide if further purification would be required. 
Previous instrumental analysis of constituents in Tian Ma commonly by means of RP-
HPLC-UV has mainly been focused on several phenolic compounds commercially-
available, such as gastrodin, 4HA, 4HD and vanillyl alcohol 91. A GC-MS method 
was also established to simultaneously determine some simple phenols and 
monosaccharides in Tian Ma through acylation of these compounds92. Besides, LC-
MS/MS was employed as an aid to characterize three unknown p-hydroxyphenylic 
compounds found in the impure samples 93 and some minor nucleoside derivatives 
found in Tian Ma 94.  
The preliminary work performed on LC-ESI-MS/MS found that the sensitivity of the 
detection for the compounds in the EFME, under the negative ion mode was fairly 
low. The conceivable reasons could be due to the fact that phenolic compounds found 
in Tian Ma were generally small (MW of 4HA =124 and MW of 4HD = 122), and 
these compounds were not readily ionized as compared to other common phenolic 
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compounds, such as flavonoids, which have a long conjugating system thus to 
facilitate the stabilization of the ionized form. Therefore, GC-electron ionization (EI)-
MS was adopted since EI source yielded higher sensitivity for these compounds and it 
has previously been installed several libraries that could be taken references to.  
2.1.3.1 The preliminary purification and analysis on GC-EI-MS 
Similar to the preparation of the alkaloidal extract, Scheme 6 below was employed to 


















Scheme 6 Preparation of the EFME from Tian Ma. The EFME is purified by repetitive 
liquid extraction on the basis that protonated phenolic compounds by strong alkali are 
soluble in aqueous solution whereas the free phenols are amenable in organic solvents. 
Tian Ma 2 Kg 
Moistened by methanol overnight 
Extracted by methanol 
in reflux Filter, collect filtrate and 
reduced to dryness under vacuum 
Crude extract 
Suspend in water 
Extracted by diethyl ether 3 times 
First ether fraction: organic layer Aqueous layer 
Extracted by 2M NaOH 
Organic layer Aqueous layer 
Acidified with conc. HCl to pH 3, 
extracted by diethyl ether again 
Organic layer Aqueous layer 
Phenolic extract 1.2 g 
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The first diethyl ether fractions as depicted in Scheme 6 were used in previous reports 
as neuroprotective preparations from Tian Ma 50. However, it was found that fatty 
acids were still abundant in this fraction while the attempts were made to isolate the 
major components by using flash column chromatography. To give higher phenolic 
content in the EFME, further purification using alkali and acid on the first ether 
fraction was thus performed. By utilizing the slightly acidic property of phenolic 
compounds, strong base such as sodium hydroxide was used to protonate the phenols 
such that the protonated phenols were made soluble in aqueous solution, which was 
subsequently basified to liberate the free phenols which would become amenable in 
common organic solvents, such as diethyl ether.  
Before injecting the EFME into GC-EI-MS for analysis,  acetyl anhydride was used to 
derivatize the compounds in the EFME to generate the corresponding esters 95. In so 
doing, the volatility of these compounds present in the EFME was improved; and also 
the acetylated EFME gave relatively more symmetrical peaks due to the suppression 
of the tailing effects resulted from the interaction of the phenolic group with siloxane 
(packing material). As shown in Figure 13 and Table 5, there were eighteen phenolic 
compounds and nine non-phenolic compounds found in the EFME of Tian Ma. The 
phenolic compounds were mainly derived from 4HA, 4HD, vanillin, vanillyl alcohol, 
4-hydroxybenzyl methyl ether (HME) and furan aldehyde or their miscellaneous 
combinations 48.  
Table 5 Proposed structures and their characteristic ion fragments 
Compound Retention time(min) 
Characteristic 
Fragment Ions Proposed Structure 
1 8.892 126, 125 5-Hydroxymethyl-furan-2-carbaldehyde   (with standard) 
2 9.838 121, 122, 164 4-hydroxybenzaldehyde       (with standard) 
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3 10.599 107, 138, 180 4-hydroxybenzyl methyl ether (with standard) 
4 12.639 110, 152, 194 Benzene-1,4-diol 
5 12.882 107, 152, 194 Vanillyl alcohol 
6 14.867 137, 138, 179, 210 4-Hydroxy-3-methoxy-benzoic acid 
7 18.344 107, 124, 166, 208 4-hydroxybenzyl alcohol (with standard) 
8 20.972 71 
Propanoic acid, 2-methyl-, 1-(1,1-
dimethylethyl)-2-methyl-1,3-propanediyl 
ester (from library: 95% similarity) 
9 24.441 107, 123, 180, 222 4-Butoxymethyl-phenol 
10 28.124 121, 123, 165 4-(4-Hydroxy-benzyloxy)-benzaldehyde 
11 30.040 107, 123, 214, 256 4-p-Tolyloxymethyl-phenol 
12 30.132 74, 87 Stearic acid methyl ester (from library: 85% similarity) 
13 30.955 87, 140, 182 D-Glucopyranoside- methyl-2,3,4,6-tetraacetate (from library: 62% similarity) 
14 31.933 55, 122, 136 9,12-Octadecadienoic acid (9E,12E)-, methyl ester (from library: 89% similarity) 
15 32.072 67, 81, 95 (11E)-1-Hexadecenal (from library: 86% similarity) 
16 32.151 55, 69 (9E)-9-Octadecenoic acid methyl ester (from library: 87% similarity) 
17 32.467 74, 87 17-methyl-Octadecanoic acid methyl ester (from library: 91% similarity) 
18 34.33 107, 200, 242, 284 4,4’-dihydroxyphenyl methane 
19 35.381 107, 138, 149, 179, 180 
3-(4-Hydroxy-3-methoxy-phenyl)-
propionaldehyde 
20 36.125 59, 72 9-Octadecenamide (from library: 89% similarity) 
21 36.527 107, 108, 123, 150, 214, 256 4-Benzyloxymethyl-phenol 
22 37.441 107, 181, 212, 244, 286 
4-[[4-(methoxymethyl)phenoxy]methyl] 
phenol 
23 38.703 107, 108, 230, 272, 314 Bis-(4-hydroxybenzyl) ether 
24 39.626 107, 149, 166 4-hydroxybenzyl propyl ether 
25 40.701 149, 167 
1,2-Benzenedicarboxylic acid, 1,2-bis(6-
methylheptyl) ester  (from library: 87% 
similarity) 
26 42.168 107, 212, 254 4-[(4-hydroxyphenyl)methyl]-benzaldehyde 
27 42.767 107, 123, 138, 202, 244 
1-(2-furanyl)-2-(4-hydroxyphenyl)-




Figure 13 TIC of the acetylated EFME by GC-EI-MS. Arrows point at the five abundant 
compounds whose identities were proposed on the basis of fragmentation analysis of mass 
spectra under electron ionization. 
As shown in Table 5 and Figure 14, the MW of most of phenolic compounds could be 
estimated by locating [M]+ and [M+42]+ ([M+CH3CO-]) ions. Those compounds 
derived from 4HA moiety also generated high abundance of fragment ions with m/z 
107 which was contributed by a p-OH-PhCH2- group, while low abundance of m/z 
107 normally indicated that compounds were probably derived from 4HD. Another 
characteristic ion for 4HD derived phenolic compound was [M-H]+ which could be 
used for the identification of the phenolic compounds with aromatic aldehyde group. 
 
Compound 3, Retention time: 10.599 min 

























Compound 5, Retention time: 12.822 min 
 
Compound 7, Retention time: 18.344 min 
 
Compound 2, Retention time: 9.838 min 
 
Compound 26, Retention time: 42.168 min 
Figure 14 Typical ion fragments of the compounds in the EFME under positive ion 
mode using EI source. MW of these compounds could be found by locating [M]+ and 
[M+42]+· ions; A to C were generated by compounds derived from 4HA moiety, with m/z of 
107 as a characteristic fragment ion, A was proposed as 4-hydroxybenzyl methyl ether, B as 
vanillyl alcohol, C as 4HA; D to E were generated by compounds derived from 4HD moiety, 
with [M-H] as characteristic fragment ions, D was proposed as 4HD, E as 4-[(4-
hydroxyphenyl)methyl]-benzaldehyde. 
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Besides, as for compounds with two phenyl rings, the m/z 107 signal was more 
intense when the two phenyl rings were connected through ether or carbonyl linkage 
rather than those that were linked by alkyl group which would be more resistant to 
fragmentation under the same condition. As a result, the molecular ion peaks for alkyl 
linked bicyclic systems were stronger (See Figure 15). Moreover, compounds with γ-
hydrogen also produced an m/z 108 peak due to γ-H rearrangement as shown in 
compound 23 (Figure 16)2. As to the compounds derived from vanillin and vanillyl 
alcohol, their characteristic fragment ions with m/z [M-31] due to the loss of a 
methoxy group (-OCH3) could be found, such as compound 22. For non-phenolic 
compounds, most of them were just identified through Wiley library search, and were 
mainly minor hydrocarbon compounds. 
 
Compound 11, Retention time: 30.040 min 
 
Compound 18, Retention time: 34.330 min 
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Compound 23, Retention time: 38.703 min 
Figure 15 Typical ion fragments of phenolic compounds with two phenyl rings using 
EI source. A and C were generated by compounds with two phenyl rings linked by ether bond, 
m/z 107 was distinct in the two compounds; B was generated by compounds with two phenyl 


























Figure 16 Characterization of compound 23 to be bis-(4-hydroxybenzyl ether) based 
on the peak at m/z 108. (A) EI-MS of the compound at retention time 38.703 min with a 
strong fragment ion of  m/z 108; (B) the mechanism of γ-H rearrangement to produce m/z 108.  















The most abundant peaks in this phenolic profile by GC-MS were 4HD, HME, 4HA, 
4,4’-dihydroxyphenyl methane (DHPM) and bis-(4-hydroxybenzyl) ether (BHE). For 
some benzoic acid compounds proposed in this profile, peak 7 and 10, they could be 
the artefacts as a result of the oxidization of benzaldehyde during acylation process. 
The 27th peak, a minor component first found in this phenolic profile was identified as 
compound C in Figure 17, which was isolated and fully characterized by 
spectrometric analysis.  
This phenolic profile clearly demonstrated that most of the components in the EFME 
were 4HA derived phenolic compounds. The five most abundant components, namely 
4HA, 4HD, HME, DHPM and BHE present in the EFME would probably contribute 
largely to the reported neuroprotective activity. To confirm this supposition and to 
compare the pharmacological activity of the whole fraction and that of the major 
components as well, the EFME would subsequently undergo conventional flash 
column chromatography to produce the single major constituents.  
2.1.3.2 Isolation and characterization of single phenolic compounds in the EFME 
Through silica gel chromatography, using varied ratios of chloroform and methanol or 
chloroform and acetone as mobile phase, four phenolic compounds were isolated 
(Figure 17). One of the compounds corresponded to peak 1, 5-Hydroxymethyl-furan-
2-carbaldehyde (HMFC) in the phenolic profile derived by GC-MS, and the second 
compound corresponded to peak 3, HME. Among the two new structures, one of them 
corresponded to peak 27 and the other was not found in the phenolic profile, probably 
due to its limited content. These two new compounds were later reported by another 
research group57, which in a way corroborated our proposal of their structures. 4HA 
and 4HD were two commercial phenols (peak 7 and 2 respectively, in the phenolic 
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profile); hence there were two major peaks found in the profile which were not 
successfully isolated from the EFME, namely DHPM and BHE. The reasons that 
these two abundant constituents were not successfully isolated could be the premature 
technique skills, and the ignorance of compounds without strong UV absorbance 
while detection on thin layer chromatography (TLC). All those isolated compounds 
listed in Figure 17 except for HME had an aromatic aldehyde group which 
contributed to their UV responsiveness and detection under UV lamp, while those two 
major constituents that were not isolated successfully did not have such a 
chromophore. It was suggested that the appropriate stain, such as FeCl3, should be 
applied for the better visualization of these phenolic compounds. 
Compound C, acquired as yellowish oil, exhibited a [M-1] at m/z 201.0593 in HRMS 
using ESI source. High resolution MS (HRMS) and NMR analyses suggested that the 
molecular formula would be C12H10O3. The presence of a phenolic group in the 
structure was indicated by its reaction with FeCl3 which produced the characteristic 
violet colouration. The UV absorption λmax (MeOH) at 270 nm was indicative of an 
aromatic carbonyl structure.  1H NMR of compound C showed resonance of one 
methylene proton at δ 3.99 (2H, s), and seven aromatic protons, four protons 
appearing as AA’BB’ type at δ 6.76 (2H, d, J=6.8 Hz) and at 7.07 (2H, d, J=6.8 Hz), 
three protons appearing as ABX type at δ 7.56 (1H, s), 7.22 (1H, d, J=3.4 Hz) and 
6.48 (1H, t, J=1.9 Hz). Twelve carbon signals that accounted for one carbonyl, one 
methylene, seven aromatic methine and three aromatic quaternary carbons were 
observed in the 13C NMR and heteronuclear multiple quantum coherence (HMQC). 
The above analysis thus suggested a para- substituted benzene, a single substituted 
furan and a carbonyl methylene fragment between the two aromatic rings. The 
relative position of carbonyl and methylene group was proposed as in Figure 17 based 
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on the observation that a deshielded effect made a proton in furan ring shift downshift 
to δ 7.22 while protons on benzene ring were unaffected. Besides, 2- or 3-substituted 
furan ring was justified by the observation that in the HMQC the quaternary carbon in 
furan ring appeared at δ 152 which ought to be 2-substituted. Although no phenolic 
hydroxyl proton was shown in the 1H NMR spectrum, EIMS did show a characteristic 
fragment at m/z 107, suggesting the -OHPhCH2- fragment. Collectively, compound C 
was characterized as 1-(furan-2-yl)-2-(4-hydroxyphenyl)ethanone (FHPE). 
Compound D, acquired as yellowish oil, exhibited a [M-1] at m/z 231.0644 in HRMS 
using ESI source. HRMS and NMR analyses suggested that compound D would have 
the molecular formula of C13H12O4. Similar to compound C, the presence of phenolic 
group in the structure was indicated by its reaction with FeCl3 that produced the 
characteristic violet colouration. The UV absorption λmax (MeOH) at 270 nm was 
indicative of an aromatic carbonyl structure. 1H NMR of compound D showed 
resonance for one phenolic hydroxyl proton at δ 5.57 (disappearing on deuterium 
exchange), two methylene protons  at δ 4.51 (2H, s) and 4.53 (2H, s), and six aromatic 
protons, four protons appearing as AA’BB’ type at δ 6.81 (2H, d, J=6.8 Hz) and at 
7.21 (2H, d, J=6.8 Hz), two protons appearing as AB type at δ 6.52 (1H, d, J=3.4 Hz) 
and 7.22 (1H, d, J=3.4 Hz). Twelve carbon signals due to one carbonyl, two O-
methylene, six aromatic methine and four aromatic quaternary carbons were observed 
in 13C NMR and distortionless enhancement by polarization transfer (DEPT). The 
above analysis confirmed that compound D would consist of a symmetrically 
substituted benzene, a symmetrically substituted furan and a carbonyl carbon 
connected to the furan due to its deshielded effect on furan proton at δ 7.22 ppm. 
Since both aromatic rings were substituted symmetrically, two O-methylene would be 
two methylene groups attached to the same oxygen and each again connected in turn 
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with benzene and furan ring respectively. Interestingly, this structure was found to be 
a combination of the abundant compounds, 4HA and compound A through an ether 
bond between benzyl and furfuryl alcoholic hydroxyl groups. Compound D was also 
verified by using synthesis (Scheme 13). Collectively, compound D was characterized 
as 5-(4-hydroxy-benzyloxymethyl)-furan-2-carbaldehyde (HFC).  



































A: HMFC (90 mg) B: HME (20 mg) C: FHPE (5 mg) D: HFC (10 mg)
 
Figure 17 Isolated single constituents from the EFME of Tian Ma. Their abbreviated 
names and quantities in mg were shown in parentheses. 
The chemical composition of the EFME was determined by GC-EI-MS analysis and 
the conventional column chromatography in preparative scale, the EFME was shown 
to constitute mainly of 4HA-derived phenolic compounds, among which the five 
abundant components based on the GC-MS results were 4HA, 4HD, HME, DHPM 
and BHE, which could contribute largely to the reported neuroprotective activity of 
the EFME. Four single compounds were obtained by flash column chromatography 
and characterized as HMFC, HME, FHPE and HFC. To fulfil the aims of studying the 
relationship between the fraction and its components in terms of their biological 
activities, the major single phenolic components needed to be obtained. However the 
two abundant constituents, namely DHPM and BHE, were not obtained by using flash 
column chromatography. The alternative strategy of acquiring these natural 
compounds would be to synthesize them by a feasible and economical synthetic route.   
2.1.3.3 Synthesis of some phenolic compounds present in Tian Ma 
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The analysis of these phenolics (Figure 18) clearly showed that the shared moieties 
for the phenolics of two ring systems were 4HA and HMFC that were linked through 
ether bond or methylene group, which impelled us to consider the possibility of 
synthesizing them. Synthesis of these phenolics found in Tian Ma has never been 
attempted; however etherification or condensation using 4HA or HMFC as starting 
material would be involved. The target compounds which would be synthesized are as 
shown in Figure 18,  BHE, DHPM, cirsiumaldehyde (CSD),  HFC, 4-((4-























Figure 18 The phenolic compounds in Tian Ma to be synthesized. The common moieties 
are shared in their structures, 4-hydroxybenzyl- and 5-methylene-furan-2-carbaldehyde, 
shown in circles and squares. 
2.1.3.3.1 Retro-synthesis of target compounds  
Due to the alcoholic ether bond which linked the two moieties in BHE, HFC and CSD, 
it was thought they could be synthesized in the same way only with varied 


































Scheme 7 Retro-synthesis of BHE, HFC and CSD. Due to the presence of the common 
ether bonds in BHE, HFC and CSD, the etherification could be performed between the 
activated benzyl alcohols and furan-2-yl-methanol. 
At first glance, the synthesis of HPMP would appear straightforward, since the ether 
bond was formed between an alcoholic and phenolic hydroxyl groups, meaning 
















Scheme 8 Retro-synthesis of HPMP. Williamson etherification is to be employed to 
accomplish the formation of the ether bond between phenolic hydroxyl group and substituted 
benzyl halides. 
2.1.3.3.2 Synthesis of HPMP 
As shown in Route 1, Scheme 9, 4HA was employed as a starting material to react 
with 4-nitrobenzyl bromide under weakly alkali condition, and S-1 was obtained 
nearly quantitatively. S-1 was then reduced to aniline by hydrogenation with a fairly 
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good yield, but the attempt to convert the aniline to phenol by diazotization/hydrolysis 
was unsuccessful. During diazotization, β-naphthol in 10% KOH solution was used to 
test and confirm the formation of the diazonium salt, thus the problematic step could 




























































































Scheme 9 Synthesis of HPMP. Reagents and conditions: a. K2CO3, reflux in acetonitrile 
for 6~8 hrs; b. H2, PtO2, in ethanol; c. dil. HCl, NaNO2, 0~5℃/ H2SO4, 90℃; d. acetic 
anhydride in pyridine, 90℃; e. acetyl chloride in chloroform, room temp, 12 hrs; f. 
ammonium acetate in aqueous methanol (90%), ~70℃, 4 hrs. 
It was presumed that polymerization might have occurred under strong acidic 
condition, since in the previous trial, 4,4’-diaminodiphenylmethane was converted to 
DHPM (shown in Scheme 10) through diazotization/hydrolysis with the yield of less 
than 5%. Besides, in reality 4HA is a very important starting material for polymer, 
phenolic resin. Therefore, instead of using 4-nitrobenzyl bromide, 4-acetoxybenzyl 
77 
 
chloride, with phenolic hydroxyl group protected by an acetyl group, could give the 







Scheme 10 Conversion of 4,4’-diaminophenyl methane to DHPM by 
diazotization/hydrolysis. Reagents and conditions: c. dil. HCl, NaNO2, 0~5℃/ H2SO4, 90℃. 
However, after S-5 was produced, Williamson etherification involving S-5 and 4HA 
was unsuccessful (Route 2, Scheme 9). 4HA was consumed rapidly in the reaction 
mixture, but a very complex reaction mixture was produced with less than 5% of the 
desired product formed.  Surprisingly, it was found that when 4HD was added, the 
reaction went smoothly to produce S-7 with an isolated yield of more than 50%. It 
was also noteworthy that in the reaction mixture another two minor products were 
also isolated and characterized as S-8 and S-9 (Figure 19). Based on the structures of 
S-7, S-8 and S-9, it was not difficult to notice that they were derived from ether bond 
formation between the alcoholic hydroxyl group of 4-acetoxybenzylic alcohol and the 
phenolic hydroxyl group of 4HD, and the only difference was the number of repeating 
units. In this way, S-7 could be viewed as a dimer, while S-8 and S-9 as trimer and 
tetramer respectively. Apparently, isolation of S-8 and S-9 from the reaction mixture 
provided a strong evidence for that polymerization had occurred readily when 4HA or 
4-acetoxybenzyl alcohol was employed in a mild acidic or alkali condition. Therefore, 
it was speculated that S-5 in a weakly alkali condition might have gone through a 
chain extension linked by an ether bond between benzylic and phenolic hydroxyl 
groups, whereas 4HD was able to terminate this chain extension but not 4HA 








































Figure 19 Two isolated side products in route 3, step 2 of Scheme 9. Proposed as a 
















Scheme 11 Proposed mechanisms for route 3, step 2 of Scheme 9. Reagents and 
conditions: a. K2CO3, reflux in acetonitrile for 6~8 hrs.  
To finally obtain the target compound, S-7 was only required to undergo the reduction 
of the aldehyde group and the hydrolysis of the ethyl ester. Unexpectedly, when S-7 
underwent a mild and selective hydrolysis, the ether bond was broken down too. 
Therefore, the hydrolysis should be carried out before the reduction. Sodium 
borohydride is a widely employed reagent for reducing aromatic aldehydes. However, 
it was not able to successfully convert S-7 to its corresponding alcohol. The reason 
could be due to the weak base produced in the reaction which could facilitate 
polymerization. Hydrogenation which normally occurs in neutral medium was thus 
employed as an alternative strategy of reduction, and it produced S-6 with a yield of 
88%.  The accomplished route that yielded HPMP is shown in Route 3 of Scheme 9. 
The synthetic route for the first time provided a feasible and economical means to 
obtain phenolic compound HPMP found in Tian Ma with an acceptable overall yield. 
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2.1.3.3.3 Synthesis of BHE, HFC and CSD 
The synthetic route leading to BHE is illustrated in Scheme 12, route 2. In the same 
way, 4HA was selectively protected for its phenolic hydroxyl with an acetyl group at 
low temperature, and dehydration between benzylic hydroxyl groups was 
accomplished with ytterbium triflate as a catalyst in 1,2-dichloroethane. The condition 
used for hydrolysis was mild, and even an intermediate with hydrolysis of one ester 
could be isolated and characterised as S-13. The synthesis of BHE was thus 




























Scheme 12 Synthesis of BHE. Reagents and conditions: f. ammonium acetate in aqueous 
methanol, ~70℃, 4 hrs; h. ytterbium triflate, reflux in 1,2-dichloroethane for 4 hrs; i. 
triethylamine, acetyl chloride, in 0℃ ethyl acetate, for 6 hrs.  
In contrast to HPMP, BHE was linked by two 4HA moieties through an ether bond 
between benzylic hydroxyl groups. Therefore the conventional Williamson 
etherification was not applicable in this case. Condensation between alcoholic 
hydroxyl group was carried out by Kawada 96 who used ytterbium triflate, a weak 
Lewis acid, as the catalyst to bring about the condensation between 4HA and  2-
isopropoxyethanol. Thus, in the first trial (Scheme 12, route 1), this method was 
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adopted; 4HA was kept but 2-isopropxyethanol was removed. It was found that 4HA 
also underwent the polymerization and the desired product could not be isolated from 
a large number of structurally related compounds. As compared to the reported 
reaction 96, which used 2-isopropoxyethanol in quantity five times that of 4HA such 
that polymerization might be suppressed. Under this reaction condition it was 
postulated that if phenolic hydroxyl group could be protected first, the risk of 
polymerization would also be reduced. As expected, 4-acetoxybenzyl alcohol as a 
starting material went smoothly to produce a clearer reaction mixture, with bis-
acetoxybenzyl ether as the desired product (Scheme 12, route 2). However, the 
reaction proceeded very slowly in tetrahydrofuran. Kim and his co-workers 97 
reported that using 1,2-dichloroethane as solvent could improve self-condensation 
between alcoholic hydroxyl groups. 1,2-dichloroethane was thus chosen, and it was 
found that the reaction was complete within 4 hrs and gave the product with an 
isolated yield of more than 50%. Therefore, an optimized condition for self-
condensation of 4-acetoxybenzyl alcohol was achieved, with ytterbium triflate as a 
catalyst and 1,2-dichloroethane as a medium. In contrast to the synthesis of HPMP, 
the final step of hydrolysis that gave BHE was quantitative and did not have a trace of 
ether bond breakage. This was hypothesized that the ether bond between the alcoholic 
hydroxyl groups should be stronger than the one between the phenolic and benzylic 
hydroxyl groups. 
In a similar way, HFC and CSD were synthesized according to the conditions 
illustrated in Scheme 13. The overall yields of HFC and CSD were found to be 35% 

























Scheme 13 Synthesis of HFC and CSD. Reagents and conditions: f. ammonium acetate in 
aqueous methanol, ~70℃, 4 hrs; h. ytterbium triflate, reflux in 1,2-dichloroethane for 4 hrs; i. 
triethylamine, acetyl chloride, in 0℃ ethyl acetate, for 6 hrs. 
2.1.3.3.4 Synthesis of HMP 
HMP was structurally distinct from the other phenolic compounds, and it was 
synthesized by self-condensation between DHPM and 4HA in acidic or alkali 
condition98. By utilizing this method and varying the pH in the reaction medium, an 




























Scheme 14 Synthesis of HMP. Reagents and conditions: g. 1%  aq. HCl, 100℃, 3 hrs. 
In summary, the six phenolic compounds, HMP, HPMP, DHPM, CSD, HFC and 
BHE were successfully synthesized with acceptable overall yields varying from 17% 
to 77%. Together with isolated phenolics and other phenolic compounds 
commercially available, all 11 phenolic compounds are illustrated in the Figure 20 
with the abbreviated names shown. The relatively low yields of BHE, HPMP, DHPM 
and HMP were probably due to the facile polymerization of 4HA in the presence of 
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trace amount of acid or alkali. This polymerization might be avoided if solid-phase 
synthesis were applied since the hydroxyl group of 4HA could firstly be linked with a 
solid support before the subsequent reactions. However, our successful exploitation of 
conventional liquid-phase synthesis provided an economical way to prepare these 
naturally occurring phenolic compounds in sufficient amount which could contribute 
a lot to carrying out the biological assays and to understanding the active principle(s) 




































Figure 20 Eleven phenolic compounds acquired by isolation and synthesis. The 
structures of all 11 phenolic compounds together with the abbreviated names are 
shown. 
2.1.3.4 Further purification on MAX cartridge and analysis on LC-UV 
The EFME analyzed by Folin-Ciocalteu test 23was found to contain less than 20% 
phenolic compounds, and it was also shown in GC-MS that other non-phenolic 
compounds were still rich in this fraction. To further enhance the phenolic content of 
the EFME, a solid-phase extraction cartridge (MAX, Waters) was employed.  
83 
 
The EFME was first dissolved in 5% aq. ammonia solution, and then was loaded on 
Waters OASIS® sample extractor, MAX as sorbent, prewashed with water. The 
loaded cartridge was washed first using 5% aq. ammonia solution to remove the non-
ionized impurities. Subsequently the cartridge was eluted by 2% formic acid in 
methanol to yield the liberated fraction. This fraction was analyzed by LC-UV, and 





Figure 21 Analysis of purified EFME by LC-UV. (A)LC-UV analysis of the purified 
EFME by SPE; (B) LC-UV analysis of premixed five phenolic compounds: 4HA, 4HD, HME, 








































































Through comparison of retention time with isolated and synthesized structures, five 
major components in this fraction were identified as 4HA, 4HD, HME, BHE and 
DHPM, which happened to be the five most abundant constituents in the EFME 
analyzed by GC-EI-MS. However, the yield recovered from cartridge extraction was 
only 30 mg from 0.4 g EFME. Due to that the major compounds present in this 
fraction were known and acquired in sufficient amount and good purity, it was 
decided to mix the five components according to the proportions present in the 
fraction (Figure 21). The required quantities were 10 mg, 95 mg, 30 mg, 240 mg and 
19 mg for 4HA, 4HD, HME, BHE and DHPM, respectively. The combinatorial 
premix of five compounds was subsequently used as the phenolic extract of Tian Ma 
for biological tests.  
2.1.3.5 Conclusions 
To prepare the standardized phenolic extract, in the beginning the EFME which has 
been extensively studied regarding its neuroprotective activities were prepared and 
analyzed by GC-EI-MS, which was shown that the EFME constituted mainly of the 
4HA derived phenolic compounds. Through conventional flash column 
chromatography, four components found in the EFME were obtained and fully 
characterized by spectroscopic analysis. Since several phenolic compounds abundant 
in the EFME were not acquired through isolation, six phenolic compounds were 
synthesized by the feasible and economical routes with acceptable yields. Further 
purification of the EFME with the aim to improve the phenolic content yielded a purer 
fraction but with limited amount, which was subsequently surrogated by a 
combinatorial premix of five major constituents, namely 4HA, 4HD, HME, BHE and 
DHPM. Therefore, the standardized phenolic extract was composed of the afore-
mentioned five compounds, mixed in a ratio same as that in the purified EFME. 
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Eleven phenolic compounds (4HA, 4HD, HME, BHE, DHPM, HMFC, HFC, CSD, 
HMP, HPMP and FHPE), obtained either through isolation or synthesis, were 
collected as the test compounds for further biological investigations.  
2.1.4 Summary 
The alkaloidal extract with 70% known alkaloids derived from Gou Teng were 
obtained and analyzed qualitatively and quantitatively by LC-MS and LC-UV. From 
this alkaloidal extract six alkaloids were isolated and characterized as GME, HS, HT, 
COR, CT and AKU. The phenolic extract which was composed of mixed five 
phenolic compounds, 4HA, 4HD, HME, BHE and DHPM was obtained from Tian Ma. 
Other single compounds acquired either through isolation or syntheses were HMFC, 
CSD, HPMP, HFC, FHPE and HMP. These two extracts were standardized with 
known composition would be applied on in vitro and in vivo system to evaluate their 
antiepileptic and neuroprotective activity.   
2.2 Antiepileptic activity investigation 
2.2.1 MES and rotorod test  
The alkaloidal extract and the phenolic extract were administered intraperitoneally to 
Swiss albino male mice with a dose ranged from 0.1 mg/kg to 1000 mg/kg 
individually and in combination with a mixed ratio 1:1. 20 min later, the adverse 
effect was evaluated on rotorod test (motor coordination), and the anticonvulsant 
activity was evaluated on the maximal electroshock test. Electroconvulsions were 
produced by means of an alternating current (ear-clip electrodes, 0.2 sec stimulus 
duration and the tonic hindlimb extension taken as the end point)99. The time period 
when the treated mice could stand on the rotating-rod without falling was taken as the 
86 
 
measurement for the adverse effect, and 5 min was taken to be the maximum indicator 
for no secondary effects on motor coordination in the mice. Given the electroshock, 
the tonic hindlimb extension was taken as score 1, meaning the mice experienced the 
full seizure, while the mice free of any sign of seizure was taken as score 4.  
None of the herbal extracts either alone or in combination was able to protect the mice 
against the seizures induced by maximal electroshock, and all the mice exhibited full 
seizure characterized by the hind-limb extension with and without drug treatment. 
However, drug treatment did affect the motor coordination of the mice on the rotorod. 
The alkaloidal extract exerted the stronger effect on the motor-coordination as 
compared to the phenolic extract. It was understandable since Gou Teng has long been 
known for its sedative activity. Moreover, the indole alkaloids are structurally related 
to reserpine (Figure 22), a well-known antihypertensive natural product derived from 
various Rauwolfia species, which might also contribute to the impaired motor 
coordination observed on mice. Unexpectedly, it was observed that there was the 
different trend of dose-response curve occurring at higher and lower doses of the 
alkaloidal extract in terms of the impairment on the motor coordination. At lower dose 
ranged from 5 to 25 mg/kg, there was a negative correlation between dose and the 
impairment on the motor coordination; whereas at higher dose ranged from 25 to 75 
mg/kg, a positive correlation could be observed. The reasons were unknown though, 
presumably at lower dose the sedative effect might be the main force causing the 
damage of motor coordination while at higher dose, the observed effect could be 
















Figure 22 Structure of reserpine. The indole alkaloids in Gou Teng are structurally related 
to the well-known antihypertensive, reserpine. 
To evaluate their combined effects on the motor coordination, Chou’s median-effect 
equation (shown below as equation 1) was employed84.  
log (fa/fu) = m log (D) – m log (Dm); (fa + fu = 1)   equation 1 
In equation 1, D is the dose of a drug, fa is the fraction affected by D, and fu is the 
fraction unaffected. Dm is the median-effect dose that inhibits or affects the system 
under study by 50%, and m is the coefficient signifying the shape of the dose-effect 
relationship, where m =1, > 1 and < 1indicate hyperbolic, sigmoidal and flat 
sigmoidal dose-effect curves. If draw a curve of log (fa/fu) against log (D), there 
should be a linear relationship, where m is the slope and Dm can be generated by the 
slope m and the intercept. The linear correlation coefficient r is used to evaluate the 
conformity and r =1 indicates the perfect conformity. 
When applying this median-effect equation to two drug-effect combination, in a first-
order system, the following equation is generated; 
(fa)1,2 / (fu)1,2 = (fa)1 / (fu)1 + (fa)2 / (fu)2 = (D)1 /(Dm)1 + (D)2 / (Dm)2  equation 2 
Based on this equation, the term of combination index (CI) was introduced for 
quantification of the interactions between any combination of two drugs (addition, 
synergism and antagonism). 
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           CI = (D)1 / (Dx)1 + (D)2 / (Dx)2     equation 3 
In equation 3, CI < 1, = 1 and > 1 indicate synergism, additive effect , and antagonism, 
respectively. In the denominator, (Dx)1 is for D1 alone that inhibits or affects a system 
by x%, and (Dx)2 is for D2 alone that inhibits or affects a system by x%. In the 
numerators, (D)1 + (D)2 in combination also inhibit or affect the system by x%. As for 
the reason why ‘1’ is chosen as a reference to derive the interaction, this is based on 
the hypothesis that the combination of drug 1 and drug 2 should only be additive 
effect (CI = 1) under all circumstances as long as they are the same drug.  
To fit the median-effect equation, the time duration when the mice can stand on the 
rotating-rod was standardized using the following formula, [(300-T) / 300] x 100% (T 
(sec): time when mice stand on the rotating rod without falling), representing the fa; 
300 seconds on the rotating-rod stands for no effect, while 0 second for 100% affected. 
By this way, ED50 (Dm) at which dose mice could stay for 150 seconds on the 
rotating-rod was generated  based on the equation 1(Table 6).  
Table 6 ED50 of the standardized extracts for rotorod test  




Alk (25-75mg/kg) 36.4 y = 3.46x - 5.40 0.953 
Alk (5-25mg/kg) 8.41 y = -0.95x + 0.88 0.955 
Phe (5-75mg/kg) 55.6 y = 2.56x - 4.60 0.990 
(X=logC; Y=log (fa/fu) C: dose mg/kg; fa: the fraction affected by drug treatment; fu: the 
fraction unaffected by drug treatment; fa+fu=1. Alk, the alkaloidal extract; Phe, the phenolic 
extract.) 
It was found in Table 6 that r2 was close to 1 was indicating a good linear relationship, 
thus suggesting the median-effect equation was suitable in this case to derive the ED50. 
Notwithstanding the opposite effect of the alkaloidal extract on the motor-
coordination at higher and lower doses, it was observed a clear trend of dose-
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dependent impairment on motor-coordination when two extracts were applied 
together with a fixed ratio of 1:1.  Besides, the combined use also led to the weakened 
damage in motor coordination as compared to each extract alone, which suggested 
their combined effect was antagonistic, calculated by equation 384. However, this 
antagonism was also dose-dependent (Shown in Figure 23), at higher dose, the 
antagonistic effect was stronger than that at lower dose, where almost an additive 
interaction was observed (CI=1). At lower dose, like 5 mg/kg Alk + 5 mg/kg Phe, 
mice could only stay on the rotating rod for the mean time of 180 sec (fa=0.4), the 
combination index calculated by the median-effect equation was 1.06, interpreted as a 
nearly additive interaction; at higher dose of 75 mg/kg Alk + 75 mg/kg Phe, the time 
on the rotorod was 60 sec in average (fa=0.8), and  the combination index was 2.02, 
interpreted as antagonistic interaction. 
 
Figure 23 The combined effect of the standardized extracts on the motor-coordination 
based on rotorod test. Dose-depended antagonism was observed in the combined used of the 
alkaloidal and phenolic extracts in terms of the impairment on the motor coordination in the 
rotorod test. 
It was beyond the comprehension why there was the antagonism between the 
alkaloidal and phenolic extracts. Presumably, when combined at higher concentration, 

















dose the bioavailability for each extract was not affected. This antagonistic effect on 
the impaired motor coordination might be one of the reasons for the combined use of 
Gou Teng and Tian Ma since the combination might lead to the reduced adverse effect. 
In addition to the co-application of these two extracts, it was also considered that the 
herbal extracts might contribute to reducing the dose of current antiepileptic drugs 
such that the side effect could be reduced too. By using a classic antiepileptic drug, 
phenytoin (PHT) and the herbal extracts were mixed and applied on MES-induced 
mice, and the result is listed in Table 7. The results were statistically tested using 
Kruskal-Wallis one way analysis of variance by ranks considering the limited sample 
size and assumption of normality, and it was found that addition of the herbal extracts 
into phenytoin did not significantly enhance the protective effects owned by 
phenytoin alone (P > 0.21).  
Table 7 Co-application of phenytoin and herbal extracts on MES-induced mice 
Sample mg/kg No. of mice Rotarod (sec) Seizure score 
PHT 10 3 197, 276, 281 3, 3, 4 
PHT 7.5 5 289, 191, 200, 215, 282 1, 1, 1, 3, 1 
PHT 5 12 210, 155, 300, 150, 168, 300, 292, 
300, 275, 218, 166, 300 
1, 1, 1 ,1, 3, 3, 1, 1, 
3, 1, 1, 1 
PHT 1 4 79, 291, 300, 300 1 
PHT+Alk 5+10 3 200, 160, 190 1 
PHT+Phe 5+10 13 300, 176, 276, 271, 300, 300, 226, 
300, 288, 184, 173, 260, 216 
3, 2, 1, 1, 1, 3, 3, 3, 
1, 1, 3, 1, 1 
PHT+Alk+Phe 
5+10+10 
3 88, 167, 199 1 
PHT+Phe 5+20 5 161, 300, 300, 300, 300 1, 1, 3, 1, 3 
PHT+Phe 7.5+7.5 5 186, 140, 196, 156, 298 1, 1, 1, 1, 3 
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2.2.2 Implications for the results of the phytochemical and animal study 
The in vivo investigation of the alkaloidal and phenolic extracts on their 
anticonvulsant activity showed that they had more or less motor-impaired activity but 
lacked the expected protection for MES induced mice. Why was the expected 
anticonvulsant activity turned out to be a big disappointment?  
Based on the literature review, the promise of these two TCMs as potential 
antiepileptic agents was advocated due to the reported neuroprotection, antagonistic 
effects on NMDA receptors, positive modulatory effects on GABAergic system etc. 
Moreover, the fact that Gou Teng and Tian Ma have been mostly prescribed in one 
formulated recipe based on the oriental medicine and the common strategy widely 
used in epilepsy pharmacotherapy – polypharmacy both encouraged us to consider the 
benefits of co-application of Gou Teng and Tian Ma to treat epilepsy.  
2.2.2.1 Justification for choosing the strategy of the purification of the alkaloids and 
phenols over bioassay-guided fractionation 
To start with, the phytochemical study conducted was to obtain a relatively pure 
extract with only one class of major constituents. This chemical class would undergo 
further separation till single major constituent could be acquired (Its main assumption 
being that the pure extract possesses the expected anticonvulsant activity and the 
major constituents within are responsible for such activity). Here was a major 
question, which was to answer why one single class of chemicals had been selected 
before the anticonvulsant activity of this chemical class was even confirmed. In other 
words, there was a question why the generally accepted procedure, bioactivity-guided 
fractionation was not adopted.  
92 
 
There are at least four reasons. Firstly, these two herbs are definitely not new 
medicinal source, and their phytochemical studies could be relied on as 
comprehensive though a few new constituents with limited concentration continue to 
be discovered. Under such precondition, it would be unwise to start our study from 
the scratch, which means that the fractionation can be carried out based on the 
previous results, like the physicochemical properties of major compounds, pKa, 
molecular size or relative polarity. In this way, lots of trouble could be saved and the 
process of fractionation would be guided with a definite target. Secondly, the 
accuracy of biological assessment depends to a large extent on the sample itself. For 
TCMs, due to its chemical complexity and too many interference constituents, the 
robustness of bioassay has always been questioned. The direct and effective solution 
to this question is to purify the extracts till there is interference as few as possible, and 
the more quantitative criteria is to acquire an extract with less than 5 major 
constituents 6-7. Thus the criteria of screening-friendly sample is to purify the extract 
till it is free of interference while at the same time loss of any potential bioactive 
compounds should be avoided as far as possible. However, it should be kept in mind 
that how difficult it would be to simplify an extract without a sacrifice of holism. 
Thirdly, it has been believed that in the natural sources a sort of structure-relationship 
study has been performed on a series of compounds with a similar chemical core5-6, 
which is to assume that a single class of compounds possesses similar 
pharmacological actions with only varied potency. Therefore, it is reasonable to 
purify a single class of compounds with higher concentration, for they basically could 
represent the medicinal herb more than those with limited quantity6. Last but not the 
least, there is indeed a risk of oversimplifying the herbal medicine by only selectively 
focusing on single compounds or a relatively pure extract with less than 5 major 
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constituents, however it is believed that a definitely negative result, in a sense, would 
be better than a false positive. That is, it is valued more that the robustness of the 
bioassay could be assured due to the utilization of pure sample, which though might 
result in a potential risk of losing effective small molecules. 
Therefore, in the phytochemical study, as to Gou Teng, the alkaloidal extract was 
obtained with a concentration of 70% of known alkaloids. As to Tian Ma, the EFME 
was considered as the bioactive part, further purification of which yielded a pure 
phenolic extract composed of five major phenolic constituents. Therefore, in the 
phytochemical work two pure chemical classes were prepared from these two herbs. 
Each chemical class constituted of no more than 6 single components. 
2.2.2.2 Explanations for the lack of antiepileptic activity possessed by the alkaloidal 
and the phenolic extracts 
The next step was to verify the supposition that different classes of these compounds 
might own more or less anticonvulsant activity and their combination would even be 
more effective than the individual class. The lack of antiepileptic activity of these two 
standardized extracts impelled us to explain why traditionally effective medicines 
failed in a well-established seizure model. The reasons are multi-factorial. It is all 
questionable regarding the sample preparation, selection of animal models and the 
unavoidable clash when traditionally prescribed herbs meet a biological screening 
system established by modern western medicine.  
In terms of the sample preparation, no matter how justifiable the strategy of the 
purification of one single chemical class from natural products might sound, the 
purified alkaloids might not fully represent the bioactive principle of Gou Teng, of 
which the complete phytochemical profile should consist of alkaloids, flavonoids and 
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terpenoids. Possibly, the ideal sample preparation for Gou Teng would be to obtain 
the pure fraction for each chemical class (alkaloids, flavonoids and terpenoids). 
Likewise, Tian Ma itself could not be just simplified as the five major 4HA-derived 
phenolic compounds, and some other essential minor compounds such as nucleoside 
derivatives might be critical as well to retain its pharmacological activity. Therefore, 
there could still be a chance that other bioactive components might have been 
sacrificed during our purposeful purification of alkaloids and phenolics.  
Besides, there were two other factors, the selection of animal models and the clash 
between the TCMs and the modern medicine, which might be contributory as well. 
Firstly, there were limitations of MES model used for AEDs screening, and the 
samples not effective in this model could still have chances of being anticonvulsants. 
This model used healthy rodents, which had no guarantee that “neurologically normal” 
animals were capable of effectively embodying “neurologically abnormal” epileptic 
patients. A typical example escaped out of MES test profile was levetiracetam (LEV) 
60. Secondly, currently the animal models were more focused on treatment than 
prevention, while TCMs were generally recognized more as prophylactics than as a 
cure. Therefore, if new animal models which could mimic the epilepsy-prone state, 
the epileptogenesis, Gou Teng and Tian Ma might be proved effective as 
antiepileptogenic agents instead of antiepileptic agents.  
Therefore, the true effects of Gou Teng and Tian Ma might depend on the 
establishment of ideal animal model of epilepsy and epileptogenesis, and also on the 





2.3 In vitro neuroprotective activity assessed on neuro-cell line 
Neuronal cell death may arise from many pathological factors, and excitotoxicity and 
loss of trophic factor are two major hypotheses underlying neuronal cell apoptosis. 
Excitotoxicity is usually inflicted by excess of oxidative stress, a consequence of 
over-production of reactive species (RS); mainly ROS 100. Physiologically, 
homeostasis between production and consumption of ROS is maintained by many 
antioxidant defenses, among which the important systems are thiol-reducing systems 
based on thioredoxin and glutathione101. Pathological models of excessive oxidative 
stress can be established by direct treatment of hydrogen peroxide or glutamate. 
Hydrogen peroxide is a ROS, but it does not directly produce a fatal threat to the 
living neural cells. Its toxicity is mostly due to its conversion to the highly reactive 
hydroxyl radical via Fenton-reaction or Haber-Weiss reaction, and the formed 
hydroxyl radical is so reactive that almost all biological molecules at its site of 
formation will be reacted102.  Oxidative stress by treatment of glutamate is based on 
its competition with cystine at glutamate / cystine antiporter, leading to the depletion 
of cellular glutathione whose biosynthesis requires cystine 103.  Another pathway of 
glutamate–induced excitotoxicity is through glutamatergic system. To defend the 
rising oxidative stress caused by high dose of hydrogen peroxide, the application of 
direct antioxidants, such as flavones, the naturally occurring free radical scavengers 
remains one of the typical defenses69a, b.  Notably, though natural polyphenols are 
scavengers of ROS, these polyphenols are also able to induce the activity of phase II 
enzyme, which means that their antioxidant activity is both direct and indirect.  
Loss of trophic factors represents another type of pathological factors leading to cell 
death. Serum-withdrawal is one of the ways to test cells survival in the absence of 
neurotrophic factors; and generally those agents able to rescue neuronal cells from 
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serum-free induced apoptosis are growth factors or growth factor like agents, such as 
neuronal growth factor (NGF), insulin, insulin-like growth factors I and II 104. Other 
agents acting as neurotrophic agents include Forskolin activating protein kinase A 
(PKA), some cAMP analogs activating cAMP-dependent protein kinase(s) 105, and 
Panaxytriol involving protein kinase C (PKC) 106. Therefore, it has been proposed that 
prevention of cell death inflicted by serum-withdrawal could involve the regulation of 
protein kinase activity 104. 
2.3.1 Effects on cell viability in the absence of neurotoxins  
To examine the effect of the samples derived from Gou Teng and Tian Ma on cell 
viability, SH-SY5Y, a neuroblastoma cell line was selected as a model since it has 
been reported to be sensitive to oxidative stress 69b, 107.  Firstly, the effect of test 
samples on the cell viability in the absence of any neurotoxins was evaluated. Treated 
with various concentrations (10, 30, 70 and 100 µM) for 24 hrs in a normal culture 
medium, the cell viability was determined by 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay and expressed as percentage of the 
untreated control. All the test samples evaluated in above bioassay include the 
alkaloidal extract, the phenolic extract and all single constituents either obtained 
through isolation or synthesis (found in Gou Teng: GME, HS, HT, COR, CT, AKU; 
found in Tian Ma: 4HA, 4HD, HME, BHE, DHPM, HMFC, CSD, HPMP, HFC, 
FHPE and HMP.) 
Except for HMP, DHPM and HFC, the other compounds did not exhibit any impact 
on cell viability at all test concentrations. HFC was shown weakly antiproliferative 
activity at higher concentrations (Figure 24), while HMP and DHPM enhanced the 




Figure 24 The effect of HFC on SH-SY5Y cell viability in normal medium. At 
concentrations of 70 and 100 µM, HFC reduced the cell viability to 70% and 50% of control. 
Results are expressed as Mean ± SEM; ## represents when compared to control, 
p<0.01.(n=3) 
To ascertain the cell growth boosting effect, several more experiments were carried 
out with 7 concentrations. It was found that DHPM could potentiate the cell growth to 
120-200% of control at concentrations of 25 to 100 µM, whereas HMP exhibited cell 
toxicity at higher concentrations but promoted cell growth when the concentration 
was decreased to 10-25 µM (Figure 25). 
 
Figure 25 The effect of DHPM and HMP on SH-SY5Y cell viability in normal 
medium. At concentrations of 25-75 µM, DHPM potentiated cell growth; while HMP 
reduced cell viability at concentrations of 75-100 µM, but increased the cell viability at 
concentrations of 10-25 µM; ** & ## represent p<0.01 when compared to control; * 






















































HFC has been reported to inhibit DNA topoisomerases I and II, which could 
contribute to its antiproliferative activity 57. DHPM and HMP are polyphenols, which 
can be susceptible to facile oxidation-reduction reactions, such that quinones can be 
produced (Figure 26) 108. The resultant quinones with Michael acceptor are effective 
inducers for phase II enzymes, especially quinone reductase 109. The potential 
induction of phase II enzymes by DHPM and HMP might be accountable for their 
ability to promote cell growth. As for cell toxic effects of HMP, it might be due to the 
excess of HMP and its oxidized product could react with some protective enzymes, 
such as thioredoxin reductase, therefore lead to apoptosis 110. HMP has one more 









Figure 26 Proposed mechanism for promoting cell growth of DHPM associated with 
the production of Michael acceptor moieties. Facile oxidation-reduction reactions 
convert the polyphenols into quinones, which are potent phase II enzymes and could account 
for promoting cell growth. 
2.3.2 Effects on cell viability in the presence of hydrogen peroxide 
By co-application of test compounds with 300 µM hydrogen peroxide, the protective 
activity of these compounds was assessed on the SH-SY5Y cells. To avoid any direct 
reaction occurring between hydrogen peroxide and samples, test compounds were 
given 3 hrs prior to the treatment of hydrogen peroxide. Oxidative-stress caused by 
hydrogen peroxide resulted in a decrease in cell viability to 28.6±5.6% of control 
group. However, none of the test compounds could rescue cells from this oxidative 
stress-induced apoptosis. Though HMP and DHPM demonstrated weak free-radical 
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scavenging ability in the preliminary work using 2,2-di(4-tert-octylphenyl)-1-
picrylhydrazyl (DPPH) free radical scavenging test, they still could not prevent 
hydrogen-peroxide induced cell death. The conceivable reasons could be, firstly their 
free-radical scavenging activity was rather weak, less than 10% of quercetine; 
secondly our experimental conditions were turned out to be fairly harsh considering 
the high dose (300 µM) and long incubation time (20 hrs) of hydrogen peroxide so 
that the screening results could be more rigorous and reliable.  
2.3.3 Effects on cell viability in the serum-deprived medium 
SH-SY5Y cells were starved in serum-free medium for 48 hrs, and the cell viability 
was decreased to 40-50% of control. All test compounds were given in serum-free 
medium at four concentrations (10, 30, 70 and 100 µM); 48 hrs later cell viability was 
also determined using MTT to evaluate whether they could protect cells from 
apoptosis induced by trophic factor deprivation. The preliminary screening results 
suggested that the phenolic extract derived from Tian Ma could protect serum-starved 
cell death at 70 and 100 µM. To identify which component or components could have 
contributed to this protective activity, all constituents found in Tian Ma were 
individually assessed at 7 concentrations (1, 5, 10, 25, 50, 75 and 100 µM). The 
results showed that BHE, DHPM and the phenolic extract could significantly increase 
the cell viability at concentrations of 70 and 100 µM (Figure 27), and moreover BHE 




Figure 27 Concentration-dependent protective effects of phenolic compounds in Tian 
Ma on serum-starved SH-SY5Y cells. At concentrations of 75-100 µM, the phenolic 
extract, BHE and DHPM protected apoptosis induced by serum deprivation; while HMP 
reduced cell viability at concentrations of 50-100 µM, but increased the cell viability at 
concentrations of 1-10 µM; ** & ## represent P<0.01 when compared to serum-starved cells; 
* represents p<0.05 when compared to serum-starved cells. (n=4) 
One recent report also investigated some phenolic compounds found in Tian Ma on 
serum-starved PC12 cells, and a similar structure to BHE was found to possess potent 
protective ability (Figure 28)58. Due to that the most abundant constituent in the 
phenolic extract is BHE, the phenolic extract also showed slightly lower protective 









Figure 28 Reported structure with protective ability against serum-starved apoptosis 
similar to BHE. Reported structure with potent neuroprotective activity on serum-starved 
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As for DHPM it was proposed that its protective activity could probably be arising 
from its ability to potentiate cell growth in normal medium. Interestingly, HMP was 
found to protect serum-starved cell death at even lower concentrations of 1-10 µM, 
while at higher concentrations of 50-100 µM it exacerbated the cell-death to much 
below serum-starved apoptosis (Figure 27). Its protection could still be due to 
promote cell growth, while the conceivable reason for its toxicity could be that under 
serum-deprived condition where the phase II enzyme might have been activated in 
some way, the potentially strong promoting effect of HMP on phase II enzyme might 
be converted from protection to toxicity, since over-activation of these enzymes could 
be fatal.  
Neuroprotective activity of the alkaloids and phenolics has been evaluated in cell 
culture inflicted either by over-dosed hydrogen peroxide or serum-withdrawal. 
Alkaloids could not rescue cell death inflicted by these two insults, but some phenolic 
compounds, namely HMP, BHE and DHPM were able to prevent serum-starved cell 
apoptosis.  
In a related study of alkaloids found in U. sinensis, GME, HS, HT, RHY and ISO-
RHY, all exhibited more or less protective action on high dose of glutamate induced 
cell death using cultured cerebellar granule cells from rats 111, and it was also 
hypothesized this protection could be due to the regulation of intracellular Ca2+ 
homeostasis. As mentioned above, similar to hydrogen peroxide, glutamate is also 
able to cause the accumulated ROS, hence the oxidative stress. The slight difference 
was that the primary culture was used in their experimental design where the 
cerebellar granule cells might express glutamate receptor, thus the toxicity in their 
case might not just be a consequence of oxidative stress but also due to glutamate 
receptor channel open leading to much more Ca2+ inward flow. Presumably, the 
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observed protection against glutamate-induced toxicity might be due to antagonize 
glutamate receptor and reduce channel opening thus fewer Ca2+ inward flow. In this 
way, alkaloids present in Gou Teng might not be acting as potent free-radical 
scavengers since they were ineffective in rescuing hydrogen peroxide-induced cell 
death, however, their effects on glutamate-induced cell apoptosis could suggest their 
antagonistic role in glutamate receptor or regulatory role in intracellular Ca2+ 
homeostasis. 
BHE was found to be able to rescue cell death inflicted by serum-free milieu, and it 
was also found to be the dominant constituent in Tian Ma. Therefore, its 
neuroprotection could, to some degree, account for therapeutic applications of Tian 
Ma in the treatment of CNS disorders. HMP and DHPM were found to be minor 
compounds, but their structure characteristics, specifically the presence of potential 
Michael acceptor, enable them to be acting as inducers of phase II enzymes, which in 
some way also could contribute to their protective effects. Together with other 
constituents in Tian Ma reported to be able to prevent serum-withdrawal induced cell 
death58, the neuroprotective effects of Tian Ma have been further ascertained.  
In this cell culture model, there was no direct evidence to ascertain the 
neuroprotective effects of Gou Teng; however, other related reports have clearly 
shown its neuroprotection 3, 33-34, 111-112. In contrast, Tian Ma has been exhibited to 
promote cell growth in the absence of neurotrophic factors. Coupled with the results 
from MES and rotorod tests, it has been proposed that Gou Teng and Tian Ma might 
not possess direct anticonvulsant activity but they could have the potential to repair 
the damaged neuronal cells, to reduce the severity of further seizure activity or to 
correct the epileptogenic state. Future studies may involve more pathological models 
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closely associated with neuroprotection and antiepileptogenesis to fully understand 
these two CTMs and to put them into better therapeutic use.  
2.4 Design and synthesis of potential antagonists at Gly/NMDA receptor and in vitro 
neuroprotective activity 
2.4.1 Design of novel antagonists of Gly/NMDAR 
2-oxindole as a core structure, two libraries were proposed on the basis of the 
hypothetical qualitative pharmacophore for antagonists at Gly/NMDAR (shown in 
Figure 29A). The 3-substituted aromatic ring in 2-oxindole was rendered planar or 
nearly planar relative to 2-oxindole ring by introducing a double bond (either a 
methylene or carbonyl group).  
On the basis of the qualitative pharmacophore for the antagonists at the Gly/NMDAR 
(shown in Figure 1), the potential interactions between the proposed structures in the 
libraries and the Gly/NMDAR are depicted in the Figure 29B. Hence, when the 
methylene group introduced at 3-substituent of 2-oxindole, furan instead of benzene 
ring was introduced considering the oxygen in furan ring might hydrogen-bond with 
the hydrogen bond donor of the Gly/NMDAR. 3-phenyl (furan) ring π system might 




































































Library 1 Library 2
Figure 29 Two libraries proposed based on the hypothetical qualitative 
pharmacophore for antagonists at Gly/NMRAR. (A) Two libraries were proposed with 
the introduction of methylene or carbonyl group at 3-substituent of 2-oxindole; (B) The 
hypothetic pharmacophore for library 1and library 2.   
To support the hypothesis, recently resolved crystal structures of NMDA receptor 
NR1 ligand-binding core80 were utilized, and the NR1 S1S2-5,7-dichlorokynurenic 
acid (DCKA) co-crystal was employed. With the aid of Autodock program, DCKA 
and the water molecules surrounding the protein removed from the co-crystal, the left 
open-cleft was assumed to be the glycine binding site for potential antagonists. By 
changing the conformation and position of test compounds in this open-cleft, an 
optimal position for a test compound was achieved to yield the minimal free energy. 
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To test whether this open cleft was suitable to accommodate potential antagonists, 
L701,324, one of the most potent antagonists of the Gly/NMDAR was allowed to 
dock in the cleft of the receptor.  
As shown below in Figure 30, the essential interactions between DCKA and the 
glycine site predicted by docking process were similar to that interactions existing in 
the co-crystal of NR1 S1S2-DCKA elucidated by X-ray diffraction 80. The carboxylate 
of DCKA formed a salt link with Arg131 and a hydrogen bond with amino group of 
Thr126. The amino group of DCKA formed a hydrogen bond with the carbonyl 
oxygen of Pro124. The quinoline ring of DCKA was involved in the π-stacking 
interaction with Phe92, while two chlorine atoms of DCKA were in van der Waals 
contact with the neighboring Phe16 and Trp223. In contrast to DCKA, L701,324 
though participated in some of the above interactions, the attraction was not as strong 
as with DCKA. For an instance, the salt link between carboxylate group of DCKA 
and Arg131 would be much stronger than the hydrogen bond between carbonyl in 
L701,324 and hydroxyl group of Arg131. As a consequence, the effective inhibiting 
concentration estimated by docking process for L701,324 was only 5.6 µM (Table 8), 
which was similar to DCKA, 4.9 µM, even though in fact DCKA was experimentally 
validated 100-fold weaker as an antagonist than L701,324 through the experiment of 













Figure 30 Essential interaction between DCKA (A) and L701,324 (B) with NMDA 
receptor NR1 S1S2. (A) The essential interactions between DCKA and glycine site shown 
by X-ray diffraction was reproduced by the docking process; (B) L701,324 was not shown 
more favorable interaction with the glycine site as compared to DCKA based on the docking 
results. 
The other two known antagonists, L689,560 and GV196771A, and three candidate 
structures proposed in the libraries were also docked to the receptor, in order to 
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compare the binding affinity between these new structures and the known antagonists. 
Docked free energy, estimated dissociation constant (KI) and experimental IC50 based 
on displacement of [3H] glycine 81, 114are shown in Table 8. It is apparent that the 
docking data is not always consistent with experimental outcome, thus the resolved 
NR1 S1S2-DCKA co-crystal architecture could not be universally applicable for 
screening of potential antagonists at Gly/NMDAR, and the glycine site on NR1 might 
be greatly flexible so that different antagonists bound at glycine site would produce 
distinct conformations.  
Table 8 Comparison of estimated data by docking with experimental data 
Compound Autodock Experimental
81, 113-114 
E (Kcal/mol) KI (µM) Binding [3H]Gly IC50 (µM) 
DCKA -7.24 4.91 0.200 
L701,324 -7.17 5.57 0.002 
L689,560 -6.77 10.91 0.008 
GV196771A -5.83 52.90 0.028 
compound 3 -6.00 39.74 - 
compound 20 (E) -6.38 20.96 - 
compound 20 (Z) -7.18 5.49 - 
 
2.4.2 Synthesis of 2-oxindole derivatives  
2.4.2.1 Synthesis of 3-[(substituted furan-2-yl)methylidenyl] 2-oxindoles 
Library 1 (Table 9) which constituted 3-[(substituted furan-2-yl)methylidenyl] 2-
oxindoles was prepared by condensing substituted 2-oxindole and 5-substituted-furan-
2-carboxaldehyde in the presence of catalytic amount of base, in this case piperidine. 
The conventional refluxing in alcohol was replaced by microwave irradiation, which 
enabled the temperature to reach 110℃ and greatly shortened the reaction time from 
several hours to 40 min (Scheme 15).  
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Compound code R1 R2 
1 H H 
2 Cl H 
3 H CH2OH 
4 Cl CH2OH 

























Except for furan-2-carboxaldehyde and 5-hydroxymethyl-furan-2-carboxaldehyde, the 
other furan-2-carboxaldehydes were not commercially available. To prepare these 
aldehydes, the key step was to form the ether linker between the furan and phenyl 
rings. A method which utilized rare earth metal trifluoromethanesulfonate as the 
catalyst to activate benzyl alcohol was adopted to initiate the formation of ether 
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between benzyl alcohol and other alcohols 96. To improve the yield, several common 
solvents were selected and it was found that in 1,2-dichloroethane the reaction went 
smoothly to a completion within 1 hour and led to a clearer reaction mixture as 




































Scheme 15 Synthesis of 3-[(substituted furan-2-yl)methylidenyl] 2-oxindole. Reagents 
and conditions: a). acetyl chloride, ~0℃ in ethyl acetate, 4 hrs; b). 5-hydroxymethyl-furan-2-
carboxaldehyde, ytterbium triflate, reflux in 1,2-dichloroethane;c). Ammonium acetate, 90% 
methanol in water, 60℃, 4 hrs; d). 2-oxindole or 6-chloro-2-oxindole, MW 110℃ in ethanol, 
40min. 
In library 1 (Table 9), the configuration of 3-substituted 2-oxindole may exist as the E 
or Z isomer. For this series of structures, it was reported that 4- proton would shift 
downfield to 8.2-8.4 ppm in a trans configuration, since oxygen in the furan ring 
would be adjacent to 4- proton which resulted in drop in electro-density of the 
chemical environment of 4- proton115. Since the 4- proton for all the compounds in 
this library existed in 8.28-8.41 ppm, it was a strong indication of E isomer. To 
confirm the trans configuration, 2D NOESY was employed and it was observed that 
there was no NOE effect between H-4 and vinyl hydrogen, and a weak NOE effect 
observed between H-6’ (if there is any) and H-4. The preferred E isomer was mainly 
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due to the possible repulsion between oxygen in carbonyl group and the furan ring in 
















Scheme 16 Favorable E-configuration of 3-[(substituted furan-2-yl)methylidenyl] 2-
oxindoles due to the possible electrostatic repulsion in Z-configuration.  
A few compounds (1 to 4) in this library were synthesized previously and found to be 
weak tyrosine kinase inhibitor, and the weak activity was explained to be due to the 
predominance of E isomer and less electron-density in furan ring as compared to a 
pyrrole or thiophene ring115. Here in this paper, it was envisaged that this E isomer 
might expose the oxygen such that it could be reachable for hydrogen bonding with 
Gly/NMDAR. However it would also be a concern that the less electron-richness of 
furan ring would also hamper the proposed ion-dipole interaction with positively 
charged group in Gly/NMDAR. 
2.4.2.2 Synthesis of substituted-3-benzoyl (furoyl)-2-oxindoles 
Library 2 (Table 10 & 11) which constituted substituted-3-benzoyl (furoyl)-2-
oxindoles was prepared through nucleophilic substitution between substituted benzoyl 
(furoyl) chloride and 2-oxindole or 6-chloro-2-oxindole. The reaction (Scheme 16) 
was performed as described by Monge et al. 116 except that microwave irradiation was 
applied such that the temperature in the closed vessel could reach 175℃ and reaction 
was shortened to 40 min. In the case of the unavailability of substituted benzoyl 
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chloride, oxalyl chloride in anhydrous toluene was used to convert the corresponding 
substituted benzoic acid with a quantitative yield.  





















R1 R2 R3 
11 H H H 
12 Cl H H 
13 H 4’-Cl H 
14 Cl 4’-Cl H 
15 H 4’-benzoyl H 
16 Cl 4’-benzoyl H 
17 H 4’-phenoxy H 
18 Cl 4’-phenoxy H 
19 H 3’-phenoxy H 
20 Cl 3’-phenoxy H 
21 H H acetyl 
 















22 H H 
23 Cl H 

























Scheme 17 Synthesis of substituted-3-benzoyl (furoyl)-2-oxindoles. Reagents and 
conditions: a). Oxalyl chloride, DMF, in toluene, RT, 5~10 hrs; b). 2-oxindole or 6-chloro-2-
oxindole, Ca(OH)2, in 1.4-dioxane, MW 175 ℃, 40 min. 
The compounds in library 2 were very interesting, since there was the possibility of 
keto-enol tautomerism, and E or Z isomer when enol was present. Take compound 20 
for instance; three possible isomers are listed in Figure 31. Among these isomers, 
structure C (enol, E isomer) would be ideal in terms of interacting with the glycine 
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Figure 31 Compound 20, three possible isomers due to tautomerization between 
ketone and enol, and possible E or Z configuration present in enol.  
To differentiate the two possibilities of the core structure, 2-oxindole (enol form) or 2-
hydroxy-indole (keto form) in library 2, the acetylated products for compound 11 and 
22 were prepared by reacting with acetyl anhydride in pyridine, with the aim to 
observe how many active hydrogens could be substituted and what their identities 
were. The resultant compounds were compound 21 and 24, and their NMR data 
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suggested only one active proton was replaced by acetyl group, and 7- proton was 
shifted downfield from about 7.2 ppm to about 8.3 ppm due to the acylation, which 
strongly suggested that the acetyl group was attached on the amine group and its 
deshielding effect on the neighboring proton (7-H) could account for the shifting 
downfield. Hence, it was highly likely that the compounds in library 2, 2-oxindole 
predominated over 2-hydroxy-indole. Once the 2-oxindole ring was established, what 
was left to confirm was the geometric configuration, either E or Z. Structure B 
adopting cis configuration would be more energetically favorable, and some 
spectroscopic data also supported this supposition. First of all, 1H NMR of compound 
22 and 23 showed a doublet at around 8.2 ppm, probably belonging to H-4 which 
shifted much downfield due to the deshielding effect of oxygen in furan ring, thus 
strongly suggesting Z configuration.  For other compounds with 3-benzoyl substituent, 
2’,6’- protons were located at about 7.4 ppm in 1H NMR, which implied that these 
two protons were not deshielded by 2-carbonyl group of 2-oxindole ring, thus 
supporting a Z configuration too115.  
To support the supposition, compound 18 was sent for X-ray crystallographic analysis, 
which clearly showed that enolic hydroxyl group was present instead of ketone, and it 
adopted a cis configuration, which was stabilized by an intra-molecular hydrogen 
bond between this enolic hydroxyl group and ketone at 1-position. 3-substituted 
methylene was nearly planar relative to 2-oxindole ring, with a dihedral angle 3.7(3)° 
(Figure 32) . 
The cis configuration would not be favourable as mimicry of L701,324 since it 
twisted the phenyl ring into another orientation such that the ion-dipole attraction 
between phenyl π ring and positively charged group on Gly/NMDA would be 
disrupted. However, as discussed by Sun and coworkers115, this type of structure 
114 
 
tended to isomerize between cis and trans configurations, and resulted in an 
equilibrated mixture in polar solvents. It was observed that in 13C NMR spectra the 
peaks of these compounds when dissolved in DMSO-d6 were prone to broadening and 
overlapping with the neighbouring peaks which led to the spectra with poor resolution. 
However, when dissolved in acetone-d6, it seemed that such isomerisation would halt 
or slow down in a way that could not be detected by NMR. It was thus speculated that 
acetone might stabilize the intra-molecular hydrogen bond due to the presence of 
hydrogen-bond acceptor, while DMSO might disrupt this attraction resulting in the 
disappearance of one favourable configuration (Z isomer) and the exchange between 
two isomers. Notwithstanding the uncertainty, Z isomer would still predominate even 
in polar solvents. 
 
Figure 32 Molecular structure of compound 18 elucidated by X-ray crystallography. 
The X-ray crystallography indicated the presence of enolic hydroxyl group which adopts a cis 
configuration in the structure of compound 18. 
3-(hydroxyl-phenyl-methylene)-2-oxindoles were reported to possess analgesic and 
anti-inflammatory activity as a consequence of inhibiting cyclooxygenase and 
lipoxygenase 83, but the amine group in the oxindole ring was usually substituted by 
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acyl, carboxamide or other groups, which in our view would  not be beneficial for the 
hydrogen bonding with the hydrogen acceptor in Gly/NMDAR. Hence, only 3-and 6- 
substituents were varied in this library. 
It was apparent in library 2 that the rigidity in 4-hydroxy-quinolones was modified to 
the 3-(hydroxyl-phenyl-methylene)-2-oxindoles which thus had a certain degree of 
flexibility due to the existence of exo-circular double bond. It, in our view, would not 
favour the binding with the Gly/NMDAR.  
2.4.3 Neuroprotective activity evaluation on SH-SY5Y neuroblastoma cell line 
Nowadays, a great variety of mechanisms have been discovered that contributed to 
neuroprotection, such as stabilization of mitochondrial membrane (Coenzyme Q10), 
free radical scavengers (quercetine), NMDA antagonism (ketamine) etc 117. To 
examine the protective activity of the newly synthesized compounds on neuronal cell 
apoptosis, cell culture-based assay with death being the end point was employed as a 
screening tool, which has been proved effective and efficient as an initial screening 
for potential neuroprotective drugs 69a.  
2.4.3.1 Effects of 2-oxindole derivatives on cell viability in the absence of neurotoxins 
To examine the effect of the 24 synthesized 2-oxindole derivatives on cell viability, 
the SH-SY5Y cells were treated with various concentrations of 2-oxindole derivatives 
for 24 hrs in a normal culture medium. The cell viability was determined by MTT 
assay and expressed as percentage of the untreated control. Except for compounds 17, 
18, 19 and 20, the others did not show any effect on cell viability with the 
concentration ranged from 10 to 100 µM. The antiproliferative activity observed in 
compounds 17-20 only happened at the quite high concentrations, 70 µM and 100 µM 
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(Shown in Figure 33). Compared 17 with 18 and 19 with 20, it seemed that 
antiproliferative effect was stronger with the presence of 6-chloro substituent. 
However, generally speaking, all these 2-oxindole derivatives appeared innoxious to 
the growth of cells under normal condition.  
 
Figure 33 Effects of compounds 17, 18, 19 and 20 on viability of SH-SY5Y cells. 
Viability is expressed as Mean ± SEM; **represents p<0.01 while *represents p<0.05 as 
compared to vehicle treated cells. (n=3) 
2.4.3.2 Effects of 2-oxindole derivatives on cell viability in the presence of hydrogen 
peroxide 
By co-application of test compounds with 300 µM hydrogen peroxide, the protective 
ability of these compounds was assessed. To avoid any direct reaction occurring 
between hydrogen peroxide and samples, test compounds were given 3 hrs before 
hydrogen peroxide given. Oxidative-stress caused by hydrogen peroxide resulted in a 





































Figure 34 Protective effects of 10 compounds in library 2 against hydrogen peroxide 
induced cell apoptosis. Viability is expressed as Mean ± SEM; * indicates p<0.05 as 
compared to H2O2 treated cells. (n=4-6) 
Except for compounds 21-24, other compounds in library 2 all showed rescuing 
ability for oxidative-stress induced cell apoptosis in a dose-dependent manner. 
Therefore, N-substitution and furan ring at 3-substituent were not beneficial for 
neuroprotective activity against oxidative stress. Notably, compounds 17 and 19 at 
concentration of 70 µM nearly rescued the cells to the level of untreated cells, 
92.4±2.33% and 96.7±4.13% of control, respectively. But at concentration of 100 µM 
they did not show better protective effects than at 70 µM. In addition, compounds 18 
and 20 have significantly protective activity at concentrations ranged from 30 to 70 
µM, but at 100 µM they could not prevent such cell death by oxidative stress. The 
reason could be  that these compounds showed antiproliferative effects at higher 
concentrations (refer to Figure 33), which even exceeded their protective ability so 
that only antiproliferative effects were shown at higher concentrations (100 µM); 




















































protective effects against hydrogen peroxide would finally been exhibited. Quercetine 
was selected as a positive control in this study, since it is a well-studied flavone 
possessing potent free radical scavenging and neuroprotective activity23, 118. As was 
found in this study, quercetine was able to protect hydrogen peroxide induced cell 
death at 10 to 100 µM, and the test compounds though did not exhibit significant 
protection at 10 µM, they were capable of protecting cells to the control level. Since 
quercetine is a good free radical scavenger, it was reasonable to investigate whether 
test compounds would also behave as free radical scavengers to exhibit their 
protective activity against oxidative stress. To prove this supposition, the following 
experiment was carried out.  
2.4.3.3 DPPH free radical scavenging assay 
Consistent with the results of hydrogen peroxide as neurotoxin (Table 12), all 
compounds in library 2 showed free radical scavenging ability, and the most potent 
anti-oxidative compounds among them were 17 and 19. However, their scavenging 
ability only represented 20-40% that of quercetine, suggesting their protection against 
oxidative stress might have other mechanisms. The observed free radical scavenging 
ability of compounds in the library 2 could be explained by their structural 
resemblance to flavonols (3-hydroxy-2-phenylchromen-4-one) (shown in the Figure 
35). The hypothesized essential structural units for free radical scavenging activity are 
marked as red. Moreover, that the double bond located outside the 2-oxindole ring 
caused structural flexibility could also partly account for their antioxidant property 
thus further for their protection against hydrogen-peroxide induced cell toxicity. The 
exceptions were compounds 21-24, which were also equally active as free radical 
scavengers even though they did not show any prevention against hydrogen peroxide. 
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Presumably, free radical scavenging activity could not fully account for protective 
















Figure 35 The structural resemblance of compounds in library 2 to flavonols. The 
hypothesized essential structural units for free-radical scavenging activity were marked as 
red. 
Table 12 Antioxidant activity of compounds in library 2 by DPPH free radical test 
Compound code  EC50 µM  Qeq  
11 33.9±1.24 0.32 
12  40.5±3.98 0.27 
13  31.7±0.97 0.35 
14  46. 3±1.99 0.24 
15  33. 1±3.37 0.35 
16  45.9±8.34 0.28 
17  31.6±1.54 0.40 
18  39.3±4.53 0.28 
19  27.6±1.70 0.33 
20  39.0±3.53 0. 26  
21  31.4±3.96 0.35 
22  36.3±4.73 0.30 
23  31.4±2.65 0.35 
24  34.4±1.25 0.32 
Quercetine  10.9±1.15 1.00 
Data expressed as Mean ± SEM, Qeq calculated by IC50 test compound/IC50 quercetine. (n=3) 
Based on the above findings, It was decided that compound 20 would be examined for 
its effects on NMDA receptor expressed on Xenopus oocytes. One consideration was 
its structural resemblance with the currently characterized antagonist L701,324, and 
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the other was that it showed relatively higher activity in above bioassays (compound 
20 in the following experiments was abbreviated as 3112). 
2.4.4 Electrophysiological characterization of 3112 on Xenopus oocytes expressing 
NR1/NR2B 
The voltage-clamp readings showed that 3112 behaved as a weak partial agonist 
acting at the glycine site of NR1/NR2B receptor expressed on Xenopus oocytes. The 
initial trial (Figure 36) with 10 µM 3112 alone or in the presence of 100 µM 
glutamate suggested that 3112 did not possess intrinsic activity by itself; it did 
potentiate the inward current response evoked by glutamate though it was unclear 
whether it acted as a partial agonist or an antagonist.  
 
Figure 36 3112 lacks intrinsic activity on glutamate-evoked current response. A typical 
experimental record showing digitized whole-cell currents from a voltage-clamped 
NR1/NR2B receptor expressed on Xenopus oocytes. The responses were elicited by gravity-
fed (0.5 min) perfusion of 10 µM 3112 alone, 10 µM 3112 and 100 µM glutamate, 
supramaximal 100 µM glycine and 100 µM glutamate as indicated above. (n=2-3) 
The next experiment was to investigate the effect of the increased concentrations of 
3112 (10 µM to 200 µM) on the inward current in the presence of 30 µM glutamate. 
The data showed that there was a trend on the potentiated current response with the 
increased concentrations of the test compound (Figure 37). This strongly indicated its 
putative co-agonistic role in the current response induced by glutamate; however even 
in the presence of 3112 at 200 µM, the glutamate response was less than 30% of those 
obtained in the presence of 1 µM glycine, suggesting that it possessed a rather weak 
co-agonistic effect on NMDA receptor. Due to the solubility issue at concentration 
beyond 200 µM, we were unable to achieve the saturable level in the concentration-
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response curve thus unable to calculate its effective dose for half-maximal response 
and also unable to confirm if it would behave as a full agonist as glycine or a partial 
agonist like D-cycloserine 119at a theoretically even higher concentration.  
Figure 37A 
 
Figure 37B  
 
Figure 37 Dose-dependent current potentiation by 3112 at recombinant NR1/NR2B 
receptor. (A) Typical current traces recorded on the voltage-clamped Xenopus oocytes 
expressed NR1/NR2B receptor was increasing in a 3112 concentration-dependent manner in 
the presence of 30 µM glutmate. (B) The trend of current potentiation by 3112 was shown as 
the mean of the steady state current at different 3112 concentrations.  (** represents p<0.05 
as compared to the basal current, n=3-6). 
The next question was to investigate the binding site of 3112 since it did exhibit mild 
co-agonistic effect. To show whether 3112 could affect the concentration-response 
curve for glycine, first we would like to know the concentration-response curve for 
glycine at the recombinant NR1/NR2B NMDA receptor. As shown in Figure 38, a 
glycine dose-dependent current increase was observed with a calculated EC50 = 0.201 


























subsequent experiment would be to test the effect of 3112 on the 0.3 µM and 10 µM 
glycine evoked current response. 
 
Figure 38 Concentration-response curve for glycine on the recombinant NR1/NR2B 
receptors. In the presence of 30 µM glutmate, current response was recorded as glycine 
given at 0.03 µM to 10 µM. The calculated EC50 = 0.201 ± 0.032 µM for glycine at the 
recombinant NR1/NR2B receptor. (n=3) 
In the presence of 30 µM glutamate, glycine 0.3 µM was added with or without 10 or 
25 µM 3112 to the perfusion on the recombinant NMDA receptor. It was found that 
the inward current induced by 30 µM glutamate and 0.3 µM glycine was significantly 
enhanced by ~15% (p<0.05, n=4-7) due to the addition of 10 µM 3112 (Figure 39), 
which once again confirmed its co-agonistic effect. However, when 25 µM applied, 
there was no significant current increase observed (p=0.538, n=5-7). The seemingly 
contradictory results could be explained by the supposition that 3112 might behave as 
a partial agonist rather than a full one. At relatively lower concentration, it occupied 
the receptors which glycine at 0.3 µM did not thus to exert its agonistic effect, 
whereas at a slightly higher concentration it might be able to displace the receptors 
which had been occupied by glycine but it could not open the channel as fully as 
glycine, thus leading to the reduction in the inward current. Another observation that 
in the presence of 30 µM glutamate and 10 µM glycine neither 10 µM nor 25 µM 
could affect the inward current induced by the high concentration of glycine could be 





















co-agonistic effect could be surmounted by the application of high concentration of 
glycine. Notwithstanding this, we did not rule out the possibility that this compound 





Figure 39 3112 acting at glycine site as a partial agonist. (A) A typical experimental 
record showing digitized whole-cell currents from a voltage-clamped NR1/NR2B receptor 
expressed on Xenopus oocytes. The responses were elicited by gravity-fed (0.5 min) perfusion 
of 0.3 µM glycine alone, 0.3 µM glycine and 10 µM 3112, 10 µM glycine alone, 10 µM glycine 
and 10 µM 3112 as indicated above. (B) The partial co-agonistic role of 3112 was shown in 
the significant current increase in perfusion of 0.3 µM glycine with addition of 10 µM 3112 as 
compared to 0.3 µM glycine alone (** represents p<0.05, n=4-7), and as well as shown in the 
no significant difference in current response between 0.3 µM glycine alone and 0.3 µM 
glycine with addition of 25 µM 3112 (p=0.538, n=5-7). The binding site of 3112 was 
tentatively supported by surmountable current increase by 10 µM glycine (p=0.392 & 0.757 
respectively for 10 µM glycine with addition of 10 µM 3112, 10 µM glycine with addition of 
25 µM 3112, as compared to 10 µM glycine alone, n=3-5) 
In this electrophysiological study performed on the voltage-clamped Xenopus oocytes 


















Gly  0.3µM 0.3µM                         0.3µM 0.3µM                      10µM  10µM  10µM
3112 0      10µM                          0        25µM                   0     10µM 25µM
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NMDA receptor partial co-agonist which possibly resulted from a competitive 
interaction at the glycine binding site. 3112 was shown rather weak co-agonistic 
effect, presumably due to its weak binding affinity to the glycine site, which was 
inconsistent with the docking results that 3112 could be interacting with the glycine 
site as favorably as DCKA. This might reflect the stereo-specificity of the glycine site 
to the ligand, since the Z configuration incumbent in 3112 was probably against the 
high binding affinity as previously mentioned. Moreover, the weak binding affinity 
leading to agonistic effect was unexpected as well, which might be explained by the 
sensitivity of the glycine site to the minor change in the ligand structure. The exo-
cycle double bond in the synthesized 2-oxindoles though assured the nearly planar 
core structure, produced the structural flexibility and thus led to the unfavorable 
interaction with the binding site and the unexpected activity.  
This was a preliminary study concerning the electrophysiological behavior of one of 
the newly synthesized 2-oxindoles. More stringent experimental design, such as to 
establish a concentration-response curve for glutamate in the presence of 0.3 µM 
glycine with or without adding 3112, in this way the effect of 3112 on glutamate 
binding site could be understood; surmountable or unsurmountable by the increasing 
glutamate concentrations? Furthermore, since the likelihood was not excluded that 
3112 might act at a regulatory allosteric site on either NR1 or NR2B subunit, more 
experiments such as to mutate these regulatory sites followed by investigation on the 
effect of 3112 on the concentration-response curve for glycine, such that the binding 
site of 3112 on the NMDA receptor could be validated.  
The possible therapeutic application of a partial agonist could be in the treatment of 
NMDA receptor related disorders. If the glycine modulatory site in vivo was saturated 
by endogenous ligand(s), the antagonistic properties of a partial agonist might provide 
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an effective means to down-regulate NMDA receptor function without the risk of 
fully blocking. If this glycine site was not saturated in vivo, binding to the partial 
agonist might lead to enhanced NMDA receptor function without the chance of over-
activation of the receptor. The preliminary results that 3112 behaved as a partial co-
agonist might stimulate the more studies regarding its effects on NMDA receptor 
related disorders, such as epilepsy, stroke, learning and memory dysfunction and so 
on.  
2.4.5 Conclusions 
Based on the structures found in the known antagonists at Gly/NMDAR, it was 
proposed that 2-oxindole derivatives, resembling to 4-hydroxy-2-quinolones, would 
behave as NMDA receptor antagonists acting at the glycine binding site. Several 
exemplar structures were proposed and selected to examine their binding affinity to 
the glycine site by means of autodock with recently deciphered co-crystal structure of 
NR1 SS1-DCKA as the binding pocket. It was found that one of the proposed 
structures could bind as favorably as DCKA, but this docking procedure failed to 
distinguish DCKA and other known antagonists, such as L701,324, in terms of their 
binding affinity. Therefore, it was speculated the resolved co-crystal architecture was 
not applicable in estimating the binding affinity by means of autodock program, and 
the glycine site could be greatly flexible in that different antagonists bound could lead 
to distinct conformations.  
Two libraries, 3-[(substituted furan-2-yl)methylidenyl] 2-oxindoles and substituted-3-
benzoyl (furoyl)-2-oxindoles, were acquired through condensation between 2-
oxindole, substituted furaldehydes and substituted benzoyl (furoyl) chloride with the 
aid of microwave irradiation. Subsequently, these 2-oxindole derivatives were 
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screened regarding their neuroprotective activity on hydrogen-peroxide insulted SH-
SY5Y neuroblastoma with cell viability as the end point. The results showed that only 
some compounds in library 2 could prevent cell apoptosis inflicted by hydrogen-
peroxide, and this protective effect was proposed to be partly resulting from their free 
radical scavenging ability by DPPH assay.  
Selected from library 2 as a potent free radical scavenger and neuroprotectant, 3112 
(compound 20) was subsequently investigated by the electrophysiological recordings 
on Xenopus oocytes expressing the recombinant NR1/NR2B receptor, and it was, 
opposite to the expected outcome, characterized as a weak partial agonist at the 
glycine site of NMDA receptor, which might be explained by the Z configuration 
dominant in 3112 and the stereo-specificity of the glycine site to the ligands. 
Hence, 2-oxindole, when substituted at 3- position could generate compounds with 
potential antagonistic activity at Gly/NMDAR, but the structural flexibility caused by 
the exo-cycle double bond should be overcome, perhaps by the introduction of a tri-
cyclic core structure to constrain the hydroxyl group at an optimal position to favor 









3. Concluding remarks 
This thesis involved studies that attempted to find effective therapeutics and 
prophylactics for epilepsy from two TCMs, Gou Teng and Tian Ma, and to explore 
the possibility that 2-oxindole, a core structure found in a group of alkaloids in Gou 
Teng could be used as a chemical scaffold to generate new compounds with potential 
antiepileptic or neuroprotective activity. At the beginning of this project, sample 
preparation was focused on alkaloidal constituents of Gou Teng and phenolic 
compounds found in Tian Ma. The standardized extracts were successfully obtained 
through acid-base processing, solid phase extraction and the synthesis of some known 
structures. The alkaloidal extract purified from Gou Teng contained more than 70% 
known alkaloids, as quantified by means of HPLC-UV. While the phenolic extract 
purified from Tian Ma was composed of solely phenolic compounds, and five major 
constituents were characterized by comparison either with the isolated single 
component or with products acquired through synthesis. Based on what has been 
known so far, this is the first time that effective parts of Gou Teng and Tian Ma 
(alkaloidal and phenolic extracts) have been purified and standardized with such a 
high purity before application on any bioassays. As is well-known, the purity of 
samples derived from natural products is positively correlated with the rigor of 
bioassay, whereas the complexity of chemical structures existing in herbal medicines 
challenges the process of purification. By carefully profiling each fraction which was 
obtained in the course of purification, and by means of synthesizing some components 
which could not be acquired through conventional separating techniques, these two 




According to literature, there are three types of small molecules found in Gou Teng, 
flavonoids, terpenoids and alkaloids; while in Tian Ma, phenolic compounds are 
nearly the only bioactive chemicals found so far. Ideally, a comprehensive study of 
one medicinal herb requires a full chemical profile. Therefore, for Gou Teng, the three 
types of structures should be harvested altogether in order to maintain completeness 
and to prevent any loss of potential active constituents and loss of interaction between 
different chemical classes. The major concern is that alkaloids rather than flavonoids 
or terpenoids have been reported to be effective in the treatment of abnormalities 
associated with CNS. Besides, introducing more than one chemical class may confuse 
the process of purification. Another limitation during the sample preparation was that 
there might be some loss of active compounds during purification, though the purity 
of the extracts has been guaranteed. Undoubtedly, there is always a controversy over 
that which is more related in the discovery of new therapeutic agents, sample purity or 
completeness of chemical structure existing in the medicinal herb.  
In future work, it is also desirable that flavonoids and terpenoids could be acquired 
with a certain degree of purity, based on the physical and chemical properties of these 
two chemical classes, such as pKa, cLogP and molecular size. In this way, not only 
has the involvement of varied structures been assured, but also the interaction 
between these three chemical classes could be understood.  
Following sample acquisition, the two purified extracts were applied on albino mice 
to evaluate the protection against seizure activity induced by acute MES stimuli. To 
evaluate their impact on motor activity, mice which had been administered test 
compounds were placed on a rotating rod (rotorod test) to assess the impairment on 
their motor coordination. These findings suggested that neither alkaloidal nor 
phenolic extracts could protect mice from the seizures induced by MES, nor could the 
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combined extracts. In addition, these two extracts showed varied degree of motor 
impairment, indicating their activity on CNS. These results suggested that although 
the application of these two medicinal herbs in control of acute convulsive activity 
was limited, the possibility of other applications in treatment of other CNS diseases, 
perhaps in anxiety treatment, was implied due to their effects associated with motor-
coordination impairment. MES model is a typical and classic model mimicking 
generalized seizure activity in human brain, and their effectiveness in screening 
hydantoins as anticonvulsants has long been acknowledged. However, it is not a 
universally applicable model to evaluate all kinds of antiepileptics, and one good 
example is LEV, which escapes detection by MES. LEV is particularly effective in 
some Kindling model which employs sub-convulsive dose of electroshock or 
convulsants in a long period to generate the ultimate recurrent status of seizures 121. 
Therefore, ineffectiveness in MES model does not necessarily negate the use of these 
two extracts as anticonvulsants. Another disadvantage in the experimental design, as 
mentioned earlier, is that we may have sacrificed some potentially active compounds 
during purification.  
In addition to explore the antiepileptic activity of Gou Teng and Tian Ma by using 
MES-induced seizure model in mice, neuroprotective activity was also investigated 
by using cell culture inflicted by two types of neurotoxins, namely hydrogen peroxide 
and serum-withdrawal. Neither the alkaloids nor phenolics were shown any protective 
effects against hydrogen peroxide induced cell apoptosis in SH-SY5Y cell line, but 
some phenolic compounds, especially the abundant constituent BHE was exhibited 
the significant promoting ability to cell growth in the conditions of lacking 
neurotrophic factors. No other investigations, based on the current knowledge, have 
found the cell growth promoting effect of BHE, though a similar structure also found 
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in Tian Ma was exhibited the same effect58. Failure of alkaloids to protect hydrogen 
peroxide inflicted cell apoptosis seemed to contradict with the findings that these 
alkaloids were able to rescue the high-dose glutamate induced cell death111, and the 
possible explanation is based on the difference between application of immortal single 
cell line and primary culture involving various types and hence the different receptors 
expressed on these cells. Therefore the mechanisms of the alkaloids protecting 
glutamate-induced toxicity might be more associated with antagonism at glutamate 
receptors than their direct free-radical scavenging activity3. The cell work has only 
provided preliminary information whether these two CTMs were able to protect 
against two common neurotoxins induced cell apoptosis, further investigations needed 
to be performed on the well-established in vitro and in vivo ischemic models, such as 
middle cerebral artery occlusion model of focal cerebral ischemia and bilateral carotid 
artery occlusion of global ischemia, to ascertain their application in neuroprotection.  
On the basis of the findings in the MES test on mice and neuroprotection test on the 
immortal cell line, the therapeutic use of Gou Teng and Tian Ma in the treatment of 
acute convulsions is limited, which, however does not negate their therapeutic value 
in other types of seizures. Likewise, their reported neuroprotection together with our 
finding of BHE rescuing cell apoptosis from serum withdrawal has clearly shown 
their promise as neuroprotectants or antiepileptogenic agents. Therefore, in future 
studies some other models which have different mechanisms from MES model should 
be employed too, such as Kindling model,  to validate the efficacy of these two herbs 
as antiepileptics.  If these two extracts do fail to exert any effects on acute convulsive 
stimuli, is there a possibility that they could be employed as prophylactics rather than 
a cure? Since these two medicinal herbs have shown a strong promise in treatment of 
brain damage by ischemia33, 51-52, which is an essential cause for the development of 
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epileptogenesis62, their potential to prevent epilepsy caused by ischemia will be an 
interesting topic for future investigation. 
The second part of the thesis was diverted from natural products to synthetic 
derivatives which was based on the core structure of 2-oxindole, present in oxindole 
alkaloids of Gou Teng. The structure-based design of NMDA receptor antagonists and 
more specifically antagonists at glycine site of NMDA receptor produced two 
libraries, one of which constituted substituted-3-benzoyl (furoyl)-2-oxindoles. This 
library was shown to protect hydrogen-peroxide induced cell apoptosis in SH-SY5Y 
cells, and such protection was also believed to partly result from their free radical 
scavenging ability, evaluated by DPPH free radical assay. Besides, one potent active 
compound 20 (3112) in these above two bioassays was studied for their effects on 
Xenopus Oocytes expressed NR1/NR2B NMDA receptor by using voltage-clamped 
electrophysiological study. Based on these results compound 20 was characterized as 
weak partial co-agonists acting at glycine site on the recombinant NR1/NR2B 
receptor.  
The free radical scavenging ability of compounds in library 2 could be explained by 
their structural resemblance to flavonols (3-hydroxy-2-phenylchromen-4-one). 
Moreover, that the double bond located outside the 2-oxindole ring causes structural 
flexibility could also partly account for their antioxidant property thus further for their 
protection against hydrogen-peroxide induced cell toxicity. The resultant agonistic 
effects which are opposite to the initial anticipation is possibly the consequence of 
predominant Z isomer which twists the enolic hydroxyl group to point at ketone of 
amide hence to disrupt the optimal interaction with hydrogen accepting group of the 
protein, and this contrast with the expectation also could be an evidence that the 
active pocket of glycine site of NMDA receptor is extremely stereo-specific; a slight 
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change in geometric configuration would lead to dramatically opposite 
pharmacological response. 
This is only a preliminary trial to realize the hypothesis that 2-oxindole derivatives 
could act as antagonists at Gly/NMDAR, and hence the synthesized structures were 
not tested on animal study to investigate their potential in the therapeutic applications 
of antiepilepsy. In addition, 2-oxindole as a template for the synthesis of these 
compounds has caused the structural flexibility, the exo-cycle double bond which 
does not benefit for the optimal interaction between small molecules and the active 
site in proteins. This preliminary study has implied that 2-oxindole might replace 4-
hydroxyquinonone to be acting as a template for the discovery of new series of 
antagonists at Gly/NMDAR if the hydrogen accepting group at 3-substituent could be 
constrained to be preferably interacting with the amino acid residues of the target 
protein. Therefore, future study would involve design and synthesis of proposed 
structures to increase the structural rigidity and hence to optimize the position of 
hydroxyl group. These structures would be evaluated also on voltage-clamped 
Xenopus Oocytes with regard to their antagonistic effects, and further tested on 
animals to assess their antiepileptic and neuroprotective potential.  
This thesis consists of two seemingly distinct parts. One is to search for potential 
drugs or drug combination from natural herbs, representing a random exploration only 
based on the folk medicine and previously associated investigations; the other is to 
design and synthesize new compounds based on a well-defined molecular target, 
representing a rational drug design utilizing modern computing program and organic 
synthetic techniques. The bridge to link these two methods is NMDA antagonism, 
which happens to be one of mechanisms of Gou Teng to protect neuronal damage and 
to be the rational basis on which the synthetic libraries were built. Although in the 
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attempt to find antiepileptic and neuroprotective agents both ways did not produce 
fruitful results, they represented the mainstream of drug discovery and would continue 
their critical contribution. The following lessons were learned in the endeavor of this 
project. On the one hand, though it appeared that drug discovery from natural 
products was a more passive process as compared to molecular target based drug 
design, with the aid of organic chemistry the natural compounds could be turned into 
an active participation. By synthesizing natural compounds with or without 
modification, the demand for large quantities for downstream biological testing can be 
met. In the same way, pure synthetic libraries though are products of the active 
thinking and practicing by organic chemists, learning from the diverse natural 
compounds is necessary to meet the requirement of drug discovery for the great 
number and diversity of structures. It is hard to imagine a successful discovery just 




















Materials and reagents 
The stems with curved hooks of Gou Teng were purchased in Singapore; wild and 
cultivated types of Rhizoma Gastrodia (Tian Ma) were purchased from Sichuan 
province, China. Their authenticity was examined by Prof. Wang Tian Zhi (Sichuan 
University, Chengdu, China). Rhynchophylline as a reference standard (>98%) was 
obtained from China (State Food and Drug administration, Beijing). The other 
compounds used in quantification were obtained by isolation from herbs, and 
identified by spectroscopic techniques. All reagents were analytical-reagent grade 
purchased from Sigma-Aldrich Chemical Company Inc. (St. Louis, MO, USA) and 
used without further purification, except for methanol and acetonitrile, which were 
HPLC grade, obtained from Fisher Scientific Co. (Fair Lawn, NY, USA). Water was 
purified by use of direct-Q3 water purification system (Millipore Company, Billerica, 
MA, USA). Acetone-d6, DMSO-d6 and Chloroform-d1 for NMR analysis was 
supplied by Sigma-Aldrich (St. Louis, MO, USA). Thin layer chromatography was 
carried out on Merck Silica 60 F254 plates. Flash chromatography was carried out 
using Merck silica gel, 0.040-0.063 mm.  
General equipments for synthesizing and characterizing small molecules 
Melting points were measured on a Gallenkamp melting point apparatus and reported 
as uncorrected value. Mass spectra were captured on an LCQ Finnigan MAT fitted 
with a chemical ionization (APCI probe) and m/z ratios for the molecular ion were 
reported. 1H and 13C NMR spectra were determined on a Bruker-Spectrospin 300 
Ultrashield spectrometer and referenced to TMS. IR spectra were performed on a 
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Jasco FT-IR-430 spectrometer in KBr pellets. HRESI-MS spectra were recorded with 
a JEOL JMS SX 102 mass spectrometer operating at 70 eV. Initiator® microwave 
synthesizer (Biotage, Sweden) was employed to aid in the condensation between the 
2-oxindoles, aldehydes and substituted benzoyl chloride (or furoyl chloride). 
4.2 Phytochemistry 
4.2.1 Prepare the standardized extracts 
4.2.1.1 The alkaloidal extract from Gou Teng 
The milled powder of Gou Teng (4 kg) was moistened with saturated Ca(OH)2 for 
overnight, and subsequently was refluxed three times in toluene (20 L, 15 L and 15 L), 
each time for 2 hrs. The filtrates were dried on evaporator via vacuum; the residues 
were re-dissolved in 2 L ethyl acetate, and the resultant solution was extracted three 
times by 2% aqueous sulfuric acid (2 L, 1 L and 1 L). The aqueous layers were 
combined and followed by basification using conc. ammonia solution, and extracted 
by chloroform three times (2 L, 1 L and 1 L). 2.8 g of the final alkaloidal extract was 
acquired by drying the chloroform layer on evaporator via vacuum.  
4.2.1.2 The phenolic extract from Tian Ma 
Preparation of the EFME  
Milled cultivated Tian Ma powder (2 kg) was refluxed three times with methanol (6 L, 
6 L and 4 L) in a 10 L round bottom flask connected with a condenser for 1 hr, 1 hr 
and 30 min respectively. The infusion was filtered through Whatman No.1 filter paper 
and concentrated under vacuum to dryness and stored overnight in vacuum oven. The 
concentrated extracts were suspended in 1 L distilled water and extracted three times 
using DE (diethyl ether) (1 L, 1 L and 0.5 L). The combined DE fractions were 
concentrated under reduced pressure to about 0.5 L, and the resulted 0.5 L DE 
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fractions were extracted again by 2 M NaOH aqueous solution three times (0.5 L, 0.5 
L and 0.4 L). The combined aqueous layers were acidified by concentrated HCl to 
about pH 3. The acidified aqueous layers were extracted once more by DE three times 
(1 L, 1 L and 0.5 L), to give the final DE fractions, which were dried over anhydrous 
sodium sulphate followed by concentration under vacuum to yield 1.2 g of the EFME.  
Further purification of the EFME by Waters OASIS® MAX cartridge 
0.4 g of the EFME was dissolved in 80 mL of 5% aq. ammonia solution, and filtered 
through 0.45 µm membrane to obtain the clear filtrate. The cartridge (6 cc, 500 mg) 
was first moistened by 30 mL water, and loaded with 15 mL of the EFME. The first 
wash by 20 mL of 5% aq. ammonia solution was discarded and the second wash by 
20 mL of 2% formic acid in methanol was collected. In total five cartridges were used, 
and their second eluents were combined and concentrated for LC-UV analysis. 
4.2.2 Instrumental analysis of the extracts 
4.2.2.1 Qualitative analysis of the alkaloidal extract by LC-ESI-MS 
2 mg of the alkaloidal extract was dissolved in 25 mL methanol and filtered through 
0.45 µm membrane for qualitative analysis. In addition, two herbal samples purchased 
from Singapore (each 1g) were finely milled, and then marinated in methanol-
conc.HCl (100:1) 20ml overnight. Extraction in sonicator for 20min, after filtration 
the residues were extracted in the same way twice. The combined filtrate was reduced 
to dryness under vacuum, then redissolved in methanol-H2O (1:1) and transferred into 
a 10ml volumetric flask. 
5 µL analyzed on a QTRAP 2000 (hybrid triple quadrupole linear ion trap) 
LC/MS/MS system from Applied Biosystems/MDS Sciex (Concord, ON, Canada) 
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coupled to an Agilent 1100 HPLC system (Agilent Technologies, Palo Alto, CA). 
Separations were accomplished on a Waters XBridge® ODS column (100 x 2.1 mm, 5 
µm). The separation was carried out using a gradient elution that involved a mobile 
phase of 5 mM ammonia acetate: methanol (20:80→60:40 in 45 min) operating at a 
flow rate of 0.2 mL/min.  The mass spectrometer was operated in the positive ion 
mode with a TurboIonSpray source. The parameter conditions were optimized as 
follows: CUR (curtain gas), 30 (arbitrary units); GS1 (ion source gas 1), 50 (arbitrary 
units); TEM (source temperature), 250 ℃; DP (declustering potential), 5.0 V; CE 
(collision energy), 35 eV; and EP (entrance potential), 10 V. EMS (Enhanced Q3 
single MS) was used to obtain structural information. The MS full-scan was set to m/z 
50 to 600. The mass spectrometer and the HPLC system were controlled by Analyst 
1.4.1 software from Applied Biosystems/MDS Sciex.  
4.2.2.2 Quantitative analysis of the alkaloidal extract by LC-DAD 
An Agilent 1100 series HPLC system consisting of autosampler, quartpump, on-line 
degasser, DAD-detector (Palo Alto, CA, USA) was used. The HP ChemStation 
Software was used to analyze data. XBridge® ODS column (3.5 µm, 150 x 4.6 mm) 
was from Waters company, USA. Ammonium acetate was also added in the mobile 
phase. The pH and concentration of ammonia acetate were examined to optimize the 
mobile phase. The separation was carried out using a gradient elution programme that 
involved a mobile phase of 0.1 M ammonia acetate: methanol (30:70→50:50 in 30 
min) operating at a flow-rate of 0.8 mL/min. Column temperature was set at 30 ℃ and 




Through the external standard method, six non-zero samples with concentration 
ranged from 10 to 140 µg/ml for GME, HS and HT, from 2 to 20 µg/ml for RHY and 
COR were used to establish a standard calibration curve that covered the expected 
range. Calibration curves (y=ax+b), represented by the plots of the peak area (y) of 
the analyte versus the spiked concentration (x) of the calibration standards, were 
generated using linear least squares regression.  
Precision and recovery 
Intra-day precision were determined by the analysis of one single mixed standard 
solution (GME, HS and HT at 75 µg/ml; RHY and COR at 10 µg/ml). Three 
replicates of this standard solution were analyzed at 0, 2h, 6h, 12h and 24h for this 
purpose. Inter-day precision were evaluated by the analysis of this standard solution, 
carried out on three consecutive days. Precision was expressed by the relative 
standard deviation (RSD). 
Moreover, 6 herbal samples, each 1g, were prepared accordingly to evaluate 
reproducibility and accuracy of this method. In addition, 3 herbal samples, each 0.5g, 
were spiked with suitable volume of stock solution, after same extraction procedure, 
to evaluate the recovery yield (%).  
4.2.2.3 Qualitative analysis of the EFME by GC-EI-MS 
Acylation of the EFME 
2-3 mg of the EFME was dissolved in 0.5 mL anhydrous pyridine with nitrogen filled 
in the reaction apparatus. Then 0.5 mL acetic anhydride was added and mixture was 
heated to 90 °C upon stirring for 4 hrs. In the end of reaction, mixture was allowed to 
cool down and diluted with sodium bicarbonate solution till carbon dioxide bubbles 
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ceased. Subsequently the solution was extracted with ethyl acetate for three times (10 
mL, 10 mL and 5 mL). The combined ethyl acetate fraction was washed three times 
with 1 M HCl, 10 mL each time, and dried over anhydrous sodium sulphate. The 
sample for GC-MS analysis was prepared by dissolving the final product in 5 mL 
methanol and the solution was filtered through 0.45 µm membrane before injecting 
into GC for analysis.  
GC-EI-MS method 
A Shimadzu QP2010 GC-MS was used and the sample was separated on a fused silica 
HP-5 MS capillary column (5% phenyl-95% methyl siloxane; 30 m × 0.25 mm 
internal diameter capillary and 0.25 µm thickness), in a temperature program from 
60 °C (kept for 3 min) to 120 °C (kept 15min) with a rate at 15 °C /min, then to 
220 °C (kept 13 min) with a rate at 10 °C /min. The injector temperature was 220 °C, 
and the flow rate of the carrier gas, helium, was 1.10 mL/min. The interface keeping 
the capillary column end into the ion source block, was kept at 250 °C. Data 
acquisition system was controlled by GC-MS real-time analysis. Full scan mass 
spectra were collected, m/z ranged from 50 to 300. MS analysis was performed by 
electron impact (EI) ionization and 70 ev was applied as bombarded energy. 
4.2.2.4 Quantitative analysis of the EFME by LC-DAD 
An Agilent 1100 series HPLC system consisting of autosampler, quartpump, on-line 
degasser, DAD-detector (Palo Alto, CA, USA) was used. The HP ChemStation 
Software was used to analyze data. XBridge® ODS column (3.5 µm, 150 x 4.6 mm) 
was used and obtained from Waters company, USA.  
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The separation was achieved by using a gradient elution programme that involved the 
mobile phase of Milli Q water: acetonitrile (30:70→70:30 in 25 min) operating at a 
flow-rate of 0.5 mL/min. Column temperature was set at 30 ℃ and detection was 
carried out at 230 nm.  
Linear regression 
Through the external standard method, five non-zero samples with concentration 
ranged from 5 to 50 µg/ml for 4HA, 4HD, HME and DHPM, from 20 to 200 µg/ml 
for BHE were used to establish a standard calibration curve that covered the expected 
range. Calibration curves (y=ax+b), represented by the plots of the peak area (y) of 
the analyte versus the spiked concentration (x) of the calibration standards, were 
generated using linear least squares regression.  
4.2.3 Spectroscopic analysis of the isolated compounds 
Single compounds isolated from the alkaloidal extract 
GME, brown amorphous powder; 1H NMR (300 MHz, CDCl3) δ (in ppm) 1.67 (3H, d, 
J = 7 Hz, H-18), 2.00 (1H, m, H-14), 2.36 (1H, m, H-14), 3.70 (3H, s, -COOMe), 3.76 
(3H, s, -CHOMe), 3.93 (1H, d, H-21), 5.43 (1H, m, H-19), 7.08-7.13 (2H, m, H-10, 
11), 7.28 (1H, d, J = 7.8 Hz, H-12), 7.47 (1H, d, J = 7.8 Hz, H-9), 7.50 (1H, d, J = 
7.3Hz, H-17), 7.84 (1H, brs, -NH). 13C NMR (75 MHz, CDCl3) δ (in ppm) 13.0 (C-
18), 21.4 (C-6), 34.2 (C-14), 36.4 (C-15), 51.4 (-COOMe), 58.8 (C-5), 61.7 (C-3, -
CHOMe), 64.5 (C-21), 108.3 (C-7), 110.7 (C-12), 112.5 (C-16), 118.1 (C-19), 119.2 
(C-9), 120.5 (C-11), 121.2 (C-10), 127.3 (C-8), 134.0 (C-2), 134.8 (C-13), 136.1 (C-
20), 159.6 (C-17), 168.6 (-COOMe). 
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HS, brown amorphous powder; 1H NMR (300 MHz, CDCl3) δ (in ppm) 0.76 (3H, m, 
H-18), 0.85 (1H, m, H-19), 1.25 (1H, m, H-19), 1.98 (1H, brs, J = 13.4 Hz, H-14), 
2.17 (1H, m, H-20), 2.36 (1H, m, H-15), 2.48 (1H, m, H-21), 2.53 (1H, m, H-14), 
2.59 (1H, m, H-6), 2.79 (1H, m, H-21), 2.98 (1H, m, H-6), 3.28 (2H, m, H-5), 3.68 
(3H, s, -COOMe), 3.73 (3H, s, -CHOMe), 4.45 (1H, brs, H-3), 7.09 (2H, m, H-10, 11), 
7.34 (2H, m, H-9, 12), 7.48 (1H, d, J = 7.2 Hz, H-17), 8.13 (1H, brs, -NH). 13C NMR 
(75 MHz, CDCl3) δ (in ppm) 11.3 (C-18), 16.9 (C-6), 24.2 (C-19), 31.7 (C-14), 34.9 
(C-15), 39.0 (C-20), 50.7 (C-21), 51.2 (C-5), 51.4 (-COOMe), 54.1 (C-3), 61.4 (-
CHOMe), 107.8 (C-7), 111.0 (C-12), 111.8 (C-16), 117.9 (C-9), 119.2 (C-11), 121.1 
(C-10), 127.9 (C-8), 133.2 (C-2), 135.9 (C-13), 159.7 (C-17), 168.9 (-COOMe). 
HT, brown amorphous powder; 1H NMR (300 MHz, CDCl3) δ (in ppm) 2.00 (1H, m, 
H-14), 2.35 (1H, m, H-15), 2.41 (1H, m, H-14), 2.53 (1H, m, H-6), 2.66 (2H, m, H-
21), 2.97 (1H, m, H-6), 3.01 (1H, m, H-20), 3.27 (1H, m, H-5), 3.66 (3H, s, -COOMe), 
3.73 (3H, s, -CHOMe), 4.46 (1H, brs, H-3), 4.88 (2H, m, H-18), 5.37 (1H, m, H-19), 
7.10 (2H, m, H-10, 11), 7.35 (2H, m, H-9, 12), 7.49 (1H, d, J = 7.3 Hz, H-17), 8.21 
(1H, brs, -NH). 13C NMR (75 MHz, CDCl3) δ (in ppm) 16.9 (C-6), 31.0 (C-14), 34.0 
(C-15), 43.0 (C-20), 51.2 (C-21, 5), 51.3 (-COOMe), 54.0 (C-3), 61.4 (-CHOMe), 
107.8 (C-7), 111.1 (C-12), 111.6 (C-16), 115.2 (C-18),  117.9 (C-9), 119.2 (C-11), 
121.2 (C-10), 127.8 (C-8), 132.9 (C-2), 135.9 (C-13), 139.4 (C-19), 159.6 (C-17), 
168.7 (-COOMe). 
COR, brown crystals; 1H NMR (300 MHz, CDCl3) δ (in ppm) 1.90 (1H, m, H-14), 
2.11 (1H, m, H-15), 2.20 (1H, m, H-14), 2.41 (1H, m, H-6), 2.41 (1H, m, H-6), 2.57 
(2H, m, H-21), 2.92 (1H, m, H-20), 3.29 (1H, m, H-6), 3.35 (1H, m, H-5), 3.60 (3H, s, 
-COOMe), 3.70 (3H, s, -CHOMe), 4.92 (2H, m, H-18), 5.51 (1H, m, H-19), 6.92 (1H, 
d, J = 7.5 Hz, H-10), 7.03 (1H, m, H-11), 7.23 (3H, m, H-9, 12, 17), 8.94 (1H, brs, -
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NH). 13C NMR (75 MHz, CDCl3) δ (in ppm) 28.8 (C-14), 34.8 (C-6), 38.5 (C-15), 
42.0 (C-20), 51.1 (-COOMe), 54.8 (C-7), 56.1 (C-5), 58.7 (C-21), 61.4 (-CHOMe), 
75.0 (C-3), 109.6 (C-12), 111.6 (C-16), 115.4 (C-18), 122.4 (C-10), 123.1 (C-9), 
127.8 (C-11), 133.7 (C-8), 139.4 (C-19), 141.2 (C-13), 159.7 (C-17), 168.6 (-
COOMe), 181.8 (C-2). 
CT, brown amorphous powder; 1H NMR (300 MHz, CDCl3) δ (in ppm) 2.04 (1H, m, 
H-14), 2.14 (1H, m, H-5), 2.33 (1H, m, H-14), 2.58-2.82 (2H, m, H-21), 3.00-3.14 
(2H, H-6, 20), 3.31 (1H, m, H-5), 3.69 (3H, s, -COOMe), 3.76 (3H, s, -CHOMe), 5.01 
(2H, m, H-18), 5.60 (1H, m, H-19), 7.07 (2H, m, H-10, 11), 7.27 (2H, m, H-9, 12), 
7.46 (1H, d, J = 7.2 Hz, H-17), 7.79 (1H, brs,-NH). 13C NMR (75 MHz, CDCl3) δ (in 
ppm) 21.7 (C-6), 33.4 (C-14), 38.6 (C-15), 42.8 (C-20), 51.3 (-COOMe), 52.9 (C-5), 
60.0 (C-3), 61.3 (C-21), 61.5 (-CHOMe), 108.0 (C-7), 110.7 (C-12), 111.6 (C-16), 
115.5 (C-18), 119.3 (C-11), 121.2 (C-10), 127.4 (C-8), 134.8 (C-2), 136.0 (C-13), 
139.3 (C-19), 159.8 (C-17), 169.1 (-COOMe). 
AKU, brown amorphous powder; 1H NMR (300 MHz, CDCl3) δ (in ppm) 1.33 (3H, d, 
J=6.4Hz, H-18), 1.86 (1H, brs, H-20), 2.13 (1H, br, H-14), 2.62 (1H, m, H-21), 2.66 
(1H, m, H-6), 2.74 (1H, br, H-15), 2.94 (1H, m, H-5), 2.98 (dd, 1H, H-21), 3.04 (1H, 
m, H-14), 3.05 (1H, m, H-6), 3.13 (1H, dd, H-5), 3.73 (3H, s, -COOMe), 3.78 (1H, br, 
H-3), 7.05-7.15 (2H, m, H-10, 11), 7.32 (1H, d, J = 7.5 Hz, H-12), 7.47 (1H, d, J = 
7.8 Hz, H-9), 7.55 (1H, d, J = 7.3 Hz, H-17), 8.30 (1H, brs, -NH). 13C NMR (75 MHz, 
CDCl3) δ (in ppm) 18.5 (C-18), 25.8 (C-15), 30.8 (C-14), 37.3 (C-20), 51.1 (-
COOMe), 52.3 (C-5), 54.6 (C-3), 107.7 (C-16), 111.0 (C-12), 117.9 (C-9), 119.2 (C-
10), 121.3 (C-11), 127.4 (C-8), 135.9 (C-13), 155.3 (C-17), 167.8 (-COOMe). 
Single compounds isolated from the EFME 
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Compound A, 90 mg, was identified as HMFC. 
Compound B, 20 mg, was identified as HME. 
The spectral data (1H, 13C NMR) of HMC and HME were reported elsewhere122.  
Compound C, 5 mg, was proposed as 1-(furan-2-yl)-2-(4-hydroxyphenyl)ethanone 
(FHPE): HRMS calcd for C12H10O3 202.0630, found 202.0593. 1H NMR (300 MHz, 
CDCl3) δ (in ppm) 3.99 (s, 2H, H-6), 7.56 (s, 1H, H-1), 7.21-7.22 (d, 1H, H-3, J = 
3.39 Hz), 7.06-7.08 (d, 2H, H-9, 11, J = 6.78 Hz), 6.75-6.77 (d, 2H, H-8, 12, J = 6.78 
Hz), 6.48-6.49 (m, 1H, H-2, J = 3.4 &1.8 Hz); 13C NMR (75 MHz, CDCl3) δ (in ppm) 
44.40 (C-6), 188.12 (C-5), 112.58 (C-2), 115.77( C-9,11), 118.86 (C-3), 125.22 (C-7), 
130.61 (C-8,12), 147.16 (C-1), 152.04 (C-4), 155.31 (C-10).  
Compound D, 10 mg, was proposed as 5-(4-hydroxy-benzyloxymethyl)-furan-2-
carbaldehyde (HFC): HRMS calcd for C13H12O4 232.0736, found 232.0644. 1H NMR 
(300 MHz, CDCl3) δ (in ppm) 4.52-4.54 (d, 4H, H-6, 7), 5.57 (s, 1H, phOH), 6.52-
6.53 (d, H-4, J = 3.39 Hz), 6.80-6.83 (d, 2H, H-10, 12,  J = 6.42 Hz) 7.20-7.26 (d, d, 
2H, 1H, H-9, 13,  J = 6.42 Hz, H-3, J = 3.39 Hz), 9.60 (s, 1H, CHO); 13C NMR (75 
MHz, CDCl3) δ (in ppm) 63.77 (C-6), 72.64 (C-7), 111.36 (C-4), 115.43 (C-10, 12), 
122.26 (C-3), 129.23 (C-8), 129.88 (C-9, 13), 152.58 (C-2), 155.76 (C-11), 158.68 
(C-5), 177.89 (C-1).  
4.3 Computational method – Molecular docking 
To aid in the screening for potential antagonists at Gly/NMDAR, molecular docking 
simulations were performed using the flexX program in Sybyl 7.0 software based on 
the X-ray crystal structure of NR1 S1S2-DCKA complex80. The docking and 
subsequent scoring were performed using the default parameters of the FlexX 
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program, and the binding gorge of NR1 S1S2 composed of the central pocket and 
peripheral sites were taken as the binding site for docking.  
The crystal structure of the NR1 S1S2-DCKA was retrieved from the Brookhaven 
Protein Data Bank (http://www.rcsb.org/pdb/). Ligand structures were generated in 
pdb-format using Sybyl 7.0. The advanced docking program AutoDock 3.0 was used 
to perform the automated molecular docking. The whole docking operation could be 
stated as follows. First, the ligand molecules were checked for polar hydrogens and 
assigned for Gasteiger-Hükel partial atomic charges. Flexible torsions were defined 
with the help of AutoTors. This allowed the conformational search of ligands during 
the process of docking. The PDBQ file was created for ligands. For macromolecules 
NR1 S1S2, polar hydrogens were taken. Second, the 3-D grid of 0.3 Å resolutions 
was centered on the active site using AutoGrid algorithm to evaluate the interaction 
energies between the ligands and NR1 S1S2. In this stage, the NR1 S1S2 was 
embedded in the 3-D grid and a probe atom was placed at each grid point. The affinity 
and electrostatic potential grid were calculated for each type of atom in the ligands. 
Third, a series of the docking parameters were set on. Not only the atom types but 
also the generations and the number of runs for GA algorithm were edited and 
properly assigned. The number of generations, energy evaluations, and GA runs were 
set of 27,000, 250,000 and 20, respectively. Finally, the docked complexes of ligand-
receptor were selected according to the criteria of interacting energy combined with 
geometrical matching quality. These complexes were used for comparative study and 
correlation between activity and its structural conformations. On the basis of the 
traditional molecular force field model of interaction energy, a new score function at 
the level of binding free energy was derived and adopted in the version of AutoDock 
3.0. The total binding free energy was empirically calibrated based on the above-
145 
 
stated terms and set of coefficient factors. The total binding free energy and 
corresponding inhibitory constant were calculated according to the algorithm in the 
AutoDock 3.0 program.  
4.4 Synthetic chemistry 
4.4.1 Synthetic procedures 
Synthesis of some phenolic compounds found in Tian Ma 
S-1 (4-(4-nitrobenzyloxy)phenyl)methanol 
4-nitrobenzylbromide (45 mmol, 9.72 g) and 4HA (40 mmol, 4.9 g) was added in 300 
mL acetonitrile in the presence of potassium carbonate (80 mmol, 11 g), the mixture 
was kept under reflux with flow of nitrogen gas. Reaction was monitored by TLC till 
the full consumption of 4HA. Reaction mixture was cooled to room temperature and 
small volume of acetone was added to prevent product from precipitating out, and 
filtered off potassium carbonate to obtain the filtrate which would be evaporated to 
dryness under vacuum. The residue was re-crystallized by using hexane-ethyl acetate 
as solvent. The isolated yield was around 75%.  
S-2 (4-(4-aminobenzyloxy)phenyl)methanol 
S-1 (17.2 mmol, 3.95 g) was suspended in 200 mL ethanol, and 120 mg platinum 
oxide (3% w/w) was added into ethanol. The mixture underwent hydrogenation by 
use of Parr hydrogenator under 30 psi hydrogen pressure for 2 to 3 hrs. Reaction 
mixture was filtered off the catalyst cautiously (prevent reduced catalyst from 
catching fire), and the filtrate was evaporated to dryness, which would be separated 
on a basic aluminium oxide column with chloroform-methanol (9:1) as mobile phase. 
The isolated yield was around 65%. 
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S-3 4-(4-nitrobenzyloxy)benzyl acetate 
S-1 (32 mmol, 8.29 g) was dissolved in 25 mL pyridine, and stirred under nitrogen 
gas. 25 mL acetic anhydride was added slowly for more than 10 min. The reaction 
mixture was kept at 90 ℃ for overnight. Mixture was cooled to room temperature, and 
saturated sodium bicarbonate solution was added slowly to react with unconsumed 
acetic anhydride (beware of large quantity of carbon dioxide produced) till the pH of 
the solution was adjusted to around 8, and then it was transferred into a separating 
funnel and extracted by ethyl acetate three times, 500 mL each time. The combined 
ethyl acetate layer was washed three times with 1M HCl solution to remove pyridine. 
The final ethyl acetate layer was dry on anhydrous sodium sulphate and evaporated to 
dryness to obtain the product. The yield was around 98%. 
S-4 4-(4-aminobenzyloxy)benzyl acetate 
Follow the procedure to yield S-2. 
Typical procedure for diazotization 
Compounds with aromatic amino group were dissolved or suspended in 30% H2SO4, 
and the solution or suspension was cooled in salt ice bath to around 0 ℃. Monitor the 
temperature during reaction to maintain it below 5 ℃. Sodium nitrite dissolved in 
small volume of ice water was dropwise added for over 15 min, and stirred the 
reaction for another 30 min. After the diazonium salt was formed, the reaction was 
warmed gradually to 60-70 ℃ till there was no obvious gas produced from reaction, 
and kept for another 30 min. The reaction mixture was filtered off the tarry substance 
while it was hot, and the filtrate was cooled and the crystals could be collected. 
S-5 4-(chloromethyl)phenyl acetate 
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4HA (30 mmol, 3.72 g) was suspended in chloroform, and 20 mL acetyl chloride was 
added slowly while stirring. The reaction was maintained under nitrogen gas flow for 
another 12 hrs. After 4HA was completely consumed, the solution was extracted three 
times with saturated sodium bicarbonate, 50 mL each time (beware of large quantity 
of carbon dioxide produced). Chloroform layer was dried over anhydrous sodium 
sulphate and evaporated to dryness. The pure compound was acquired through 
column chromatography using hexane-ethyl acetate as mobile phase. The isolated 
yield was around 80%. 
S-7 4-((4-formylphenoxy)methyl)phenyl acetate 
4HD (10 mmol, 1.22 g) and S-5 (12 mmol, 2.21 g) was added in 100 mL acetonitrile, 
and potassium carbonate (20 mmol, 2.8 g) and 5 mg potassium iodide were also added. 
The reaction was maintained in reflux with a flow stream of nitrogen gas for around 4 
hrs. The mixture was filtered off potassium carbonate and evaporated to dryness, 
which was re-dissolved in hexane-ethyl acetate mixture. The first precipitate was 
acquired after the solution was put in fridge overnight and identified as S-9, and the 
filtrate was separated on silica gel using hexane-ethyl acetate as mobile phase, S-7 
and S-8 thus obtained. The isolated yield for compound S-7 was around 50%. 
S-6 4-((4-(hydroxymethyl)phenoxy)methyl)phenyl acetate 
S-7 (3.3 mmol, 600 mg) was suspended in 30 mL EtOH, and 30 mg platinum oxide 
(~5%) was added. The mixture was maintained under 30 psi hydrogen for 2 hrs. Filter 





S-6 (2.8 mmol, 490 mg) was suspended in 50 mL MeOH-H2O (9:1); 2 g ammonium 
acetate was added. The mixture was kept under mild reflux for 16 hrs. The reaction 
mixture was evaporated to dryness and re-dissolved in ethyl acetate. Filter off the 
insolubles, and the filtrate was concentrated to dryness. The expected compound was 
isolated through silica gel separation with chloroform-acetone as mobile phase. The 
isolated yield was around 40%. 
HMP, 2,4-bis[(4-hydroxyphenyl)methyl]-phenol  
4-(4-hydroxybenzyl)phenol, phenolic compound 7 (5 mmol, 1 g) and 4HA (1.5 mmol, 
0.186 g) were added to 125 mL water, then 1 mL of conc. HCl was added too. 
Maintain the solution under mild reflux for 5 hrs. Cool the reaction and extract with 
ethyl acetate three times, 20 mL each time. The ethyl acetate layer was concentrated 
to dryness and separated on silica gel using hexane-ethyl acetate as mobile phase to 
obtain the target compound. The isolated yield was around 30%. 
S-11 4-(hydroxymethyl)phenyl acetate 
To a suspension of 4-hydroxybenzyl alcohol (60 mmol, 7.5 g) in 100 mL ethyl acetate 
at 0 ℃ ice bath under nitrogen flow was added triethylamine (60 mmol, 8.4 mL) 
followed by acetyl chloride (60 mmol, 4.7 mL), dissolved in 50 mL ethyl acetate. The 
mixture was stirred for 5 hrs, after which time the precipitate was filtered off and the 
solvent was evaporated under reduced pressure. The product was isolated from the 
residue by column chromatography using hexane and ethyl acetate as mobile phase. 
The isolated yield was around 60%. 
S-12 Bis-(4-acetoxybenzyl) ether 
S-11 (10 mmol, 1.66 g) was dissolved in 25 mL 1,2-dichloroethane, and 35 mg of 
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ytterbium triflate (2% w/w) was added. The mixture was refluxed mildly for 20 hrs 
till starting material disappeared on TLC. Reaction was cooled to room temperature 
and a small volume of 1,2-dichloroethane was added; after filtering off the catalyst, 
reaction mixture was evaporated to dryness which was subjected to separation on 
flash column to yield the desired product, with an isolated yield of around 50%. 
S-14 Acetic acid 4-(5-formyl-furan-2-ylmethoxymethyl)-phenyl ester 
S-11 (2 mmol, 0.33 g) was dissolved in 10 mL 1,2-dichloroethane, and 5-
Hydroxymethyl-furan-2-carbaldehyde (10 mmol, 1.26 g) was added too. The mixture 
was heated to mild reflux, and then 10 mg ytterbium triflate (3% w/w) was added. 
Reaction mixture was stirred for about 20 min till S-11 disappeared on TLC. Reaction 
was cooled to room temperature and a small volume of 1,2-dichloroethane was added; 
after filtering off the catalyst, reaction mixture was evaporated to dryness which was 
subjected to separation on flash column using hexane-ethyl acetate as mobile phase to 
yield the desired product, with an isolated yield of around 60%. 
HFC, 5-(4-Hydroxy-benzyloxymethyl)-furan-2-carbaldehyde 
S-14 (2 mmol, 0.46 g) was suspended in 10 mL methanol-water mixture (9:1), 
ammonium acetate (10 mmol, 0.78 g) was added too. Reaction mixture was heated to 
~60 ℃ for 4 hrs, after that it was evaporated under reduced pressure to dryness and re-
suspended in ethyl acetate, and this ethyl acetate was washed by water three times and 
evaporated to dryness to yield the desired product, with a yield of around 90%. 
CSD, Cirsiumaldehyde 
5-Hydroxymethyl-furan-2-carbaldehyde (2 mmol, 0.25 g) was dissolved in 10 mL 
1,2-dichloroethane, followed by addition of 10 mg ytterbium triflate (3% w/w). 
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Reaction mixture was heated to mild reflux for 2 hrs till starting material disappeared 
on TLC. After filtering off the catalyst, reaction mixture was dried over rotatory 
evaporator and was subjected to flash column with hexane and ethyl acetate as mobile 
phase to obtain the product, with an isolated yield of around 77%. 
Synthesis of 2-oxindoel derivatives, library 1 
To a solution of substituted furan-2-carbaldehydes (1 mmol) and 2-oxindole or 6-
chloro-2-oxindole (1 mmol) in absolute alcohol (5 mL) was added piperidine (5 µL). 
The reaction mixture was heated through microwave irradiation to 110 ℃ for 40 min, 
after which time it was slowly cooled to room temperature and put into 4 ℃ fridge 
overnight. The resulting crystals were collected and washed by cold alcohol to yield 
the products, with varied yields of 40 to 82%.  
Synthesis of 2-oxindole derivatives, library 2 
Intermediates: 3 or 4-substituted benzoyl chloride 
To a suspension of 3 or 4-substituted benzoic acid (5 mmol) in anhydrous toluene (15 
mL) was added oxalyl chloride (6 mmol) followed by dimethylformamide (5 µL). The 
reaction mixture was stirred under nitrogen for 5 hrs till the solution became clear. 
The mixture was then evaporated to dryness under reduced pressure to give the 
products with quantitative yields.  
Final products 
To a solution of 2-oxindole or 6-chloro-2-oxindole (1 mmol) in anhydrous 1,4-
dioxane (2 mL) was  dropwise added the solution of substituted-benzoyl- (furoyl-) 
chloride (1.2 mmol) in anhydrous 1,4-dioxane (3 mL), followed by calcium hydroxide 
(5 mmol). The mixture was heated using microwave irradiation to 175 ℃ for 45 min, 
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after which time the mixture was cooled to room temperature and poured into ice cold 
3 M HCl solution, and the resultant suspension was stirred for 2 hrs to filter off 
solution and to obtain filter cake, which was subsequently re-crystallized in hot 
methanol to give products with a variety of yields of 34 to 57%.  
4.4.2 Characterization data of synthesized compounds 
Synthesis of phenolic compounds 
S-1 Yellowish solid. mp.121-123 ℃. IR γmax cm-1: 3323, 2924, 2854, 1610, 1518, 
1348, 1247. 1H NMR (300 MHz, in Acetone-d6) δ (in ppm) 8.26~8.29 (2H, d, J = 8.7 
Hz, H-2, 6), 7.75~7.78 (2H, d, J = 8.7 Hz, H-3, 5), 7.28~7.31 (2H, d, J = 8.7 Hz, H-10, 
12), 6.98~7.01 (2H, d, J = 8.7 Hz, H-9, 13), 5.31 (2H, s, H-7), 4.54~4.56 (2H, d, J = 
5.6 Hz, H-14), 4.05~4.09 (1H, t, J = 5.6 Hz, -phCH2OH). 13C NMR (75 MHz, in 
DMSO-d6): δ (in ppm) 146.8 (C-1), 123.4 (C-2, 6), 127.8 (C-3, 5), 145.1 (C-4), 67.8 
(C-7), 156.6 (C-8), 114.3 (C-9, 13), 128.0 (C-10, 12), 135.0 (C-11), 62.3 (C-14). 
S-2 Yellow solid. mp:113-114 ℃. IR γmax cm-1: 3359, 3289, 3212, 1613, 1520, 1507, 
1382, 1243. 1H NMR (300 MHz, in Acetone-d6) δ (in ppm) 7.23~7.26 (2H, d, J = 8.7 
Hz, H-10, 12), 7.14~7.16 (2H, d, J = 8.3 Hz, H-3, 5), 6.91~6.93 (2H, d, J = 8.3 Hz, H-
2, 6), 6.65~6.67 (2H, d, J = 8.3 Hz, H-9, 13), 4.90 (2H, s, H-7), 4.53 (2H, s, H-14), 
4.02 (1H, br, -phCH2OH) , 4.67 (2H, br, -phNH2). 13C NMR (75 MHz, in DMSO-d6): 
δ (in ppm) 148.4 (C-1), 114.2 (C-2, 6), 129.2 (C-3, 5), 134.2 (C-4), 69.5 (C-7), 157.3 
(C-8), 113.4 (C-9, 13), 127.7 (C-10, 12), 123.6 (C-11), 62.4 (C-14). 
S-3 Yellow solid. mp: 84-86 ℃.  1H NMR (300 MHz, in Acetone-d6) δ (in ppm) 
7.30~7.33 (2H, d, J = 8.7 Hz, H-10, 12), 7.69~7.72 (2H, d, J = 8.7 Hz, H-3, 5), 
7.00~7.03(2H, d, J = 8.7 Hz, H-9, 13), 8.24~8.27 (2H, d, J = 8.4 Hz, H-2, 6), 5.28 
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(2H, s, H-7), 4.98 (2H, s, H-14), 2.02 (3H, s, -OAc). 13C NMR (75 MHz, in DMSO-
d6): δ (in ppm) 146.9 (C-1), 123.5 (C-2, 6), 129.9 (C-3, 5), 144.9 (C-4), 67.9 (C-7), 
157.6 (C-8), 114.6 (C-9, 13), 128.0 (C-10, 12), 128.7 (C-11), 65.0 (C-14). 
S-4 Yellowish solid. mp: 99-101 ℃ 1H NMR (300 MHz, in DMSO-d6) δ (in ppm) 
7.26~7.29 (2H, d, J = 8.4 Hz, H-10, 12), 7.06~7.09 (2H, d, J = 8.1 Hz, H-3, 5), 
6.94~6.97(2H, d, J = 8.7 Hz, H-2, 6), 6.53~6.56 (2H, d, J = 8.4 Hz, H-9, 13), 4.86 
(2H, s, H-7), 4.98 (2H, s, H-14), 2.02 (3H, s, -OAc), 5.12 (2H, br, -phNH2). 13C NMR 
(75 MHz, in DMSO-d6): δ (in ppm) 170.2 (-COCH3), 158.4 (C-8), 148.5 (C-1), 123.3 
(C-11), 127.8 (C-4), 129.3 (C-10, 12), 129.4 (C-3, 5), 114.6 (C-2, 6), 113.5 (C-9,13), 
69.7 (C-7), 65.2 (C-14), 20.7 (-COCH3).  
S-6 Colourless plates crystallized from ethanol. mp: 127-128 ℃ 1H NMR (300 MHz, 
in Acetone-d6) δ (in ppm) 7.49~7.52 (2H, d, J = 8.7 Hz, H-3, 5), 7.26~7.29 (2H, d, J = 
8.6 Hz, H-10, 12), 7.12~7.15 (2H, d, J = 8.7 Hz, H-2, 6), 6.95~6.98 (2H, d, J = 8.6 Hz, 
H-9, 13), 5.08 (2H, s, H-7), 4.43~4.45 (2H, d, J = 5.6 Hz, H-14), 5.05(1H, t, J=5.6, -
OH), 2.26 (3H, s, -OAc). 13C NMR (75 MHz, in DMSO-d6): δ (in ppm) 169.1 (-
COCH3), 20.7 (-COCH3), 149.9 (C-1), 121.7 (C-2, 6), 128.6 (C-3, 5), 134.7 (C-4), 
68.4 (C-7), 157.0 (C-8), 114.3 (C-9, 13), 127.8 (C-10, 12), 134.6 (C-11), 62.4 (C-14). 
S-7 Colourless plates crystallized from hexane-ethyl acetate. mp: 113-115 ℃  1H 
NMR (300 MHz, in Acetone-d6)  δ (in ppm) 9.91 (1H, s, -phCHO), 7.87~7.90 (2H, d, 
J = 8.7 Hz, H-10, 12), 7.53~7.55 (2H, d, J = 8.7 Hz, H-3, 5), 7.15~7.22 (4H, dd, J = 
8.7 Hz, 0.3, H-2, 6 & H-9, 13), 5.25 (2H, s, H-7), 2.26 (3H, s, -Ac). 13C NMR (75 
MHz, in Acetone-d6): δ (in ppm) 190.8 (-phCHO), 169.3 (-COCH3), 164.2 (C-8), 
151.4 (C-1), 134.6 (C-4), 131.0 (C-11), 132.2 (C-10, 12), 129.4 (C-3, 5), 122.5 (C-2, 
6), 115.7 (C-9,13), 69.9 (C-7), 20.6 (-COCH3). 
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S-8 4-((4-((4-formylphenoxy)methyl)phenoxy)methyl)phenyl acetate White precipitate 
from hexane-ethyl acetate. mp: 131.5-133℃. 1H NMR (300 MHz, in Acetone-d6)  δ 
(in ppm) 9.86 (1H, s, -phCHO), 7.86~7.89 (2H, d, J = 8.7 Hz, H-10, 12), 7.50~7.53 
(2H, d, J = 8.7 Hz, H-3, 5), 7.45~7.43 (2H, d, J = 8.7 Hz, H-16, 18), 7.14~7.17 (2H, d, 
J = 8.7 Hz, H-9, 13), 7.18~7.22 (2H, d, J = 8.7 Hz, H-2, 6), 7.04~7.07 (2H, d, J = 8.7 
Hz, H-15, 19), 5.14 (2H, s, H-20), 5.11 (2H, s, H-7), 2.26 (3H, s, -Ac). 13C NMR (75 
MHz, in Acetone-d6) δ (in ppm) 190.8 (-phCHO), 169.3 (-COCH3), 164.4 (C-8), 
159.4 (C-14), 151.2 (C-1), 135.4(C-4), 130.9 (C-11), 129.4 (C-17), 132.1 (C-10, 12), 
130.1 (C-16, 18), 129.2 (C-3, 5), 115.7 (C-9,13), 115.4 (C-15, 19), 70.3 (C-20), 69.6 
(C-7), 20.6 (-COCH3). 
S-9 4-((4-((4-((4-formylphenoxy)methyl)phenoxy)methyl)phenoxy)methyl)phenyl 
acetate White precipitate from hexane-ethyl acetate. mp: 140-146 ℃, 1H NMR (300 
MHz, in Acetone-d6) δ (in ppm) 9.86 (1H, s, -phCHO), 2.26 (3H, s, -Ac), 7.12~7.20 
(4H, dd, J = 8.7 Hz, H-2, 6 & H-9, 13), 7.46~7.49 (2H, d, J = 8.7 Hz, H-3, 5), 5.02 
(2H, s, H-7), 7.85~7.88 (2H, d, J = 8.7 Hz, H-10, 12), 7.00~7.05 (4H, dd, J = 8.7 Hz, 
H-15, 19 & H-15’, 19’), 7.36~7.42 (4H, dd, J = 8.7 Hz, H-16, 18 & H-16’, 18’), 5.10 
(2H, H-20), 5.13 (2H, s, H-20’). 13C NMR (75 MHz, in DMSO-d6) δ (in ppm) 192.2(-
phCHO), 170.1 (-COCH3), 21.7 (-COCH3), 151.0 (C-1), 122.7 (C-2, 6), 129.8 (C-3, 
5), 135.5 (C-4), 69.6 (C-7), 164.3 (C-8), 115.7 (C-9, 13), 132.7 (C-10, 12), 130.1 (C-
11), 159.2 (C-14), 115.6 (C-15, 19), 130.4 (C-16, 18), 129.2 (C-17), 69.9 (C-20), 
158.9 (C-14’), 116.2 (C-15’, 19’), 130.6 (C-16’, 18’), 70.4 (C-20’). 
S-10 4-(methoxymethyl)phenol Colourless crystal from hexane-ethyl acetate. mp: 92-
94 ℃, 1H NMR (300 MHz, in Acetone-d6) δ (in ppm) 7.13~7.16 (2H, d, J = 8.3 Hz, 
H-4, 8), 6.79~6.82 (2H, d, J = 8.3 Hz, H-5, 7), 3.26 (3H, s, -OMe), 4.31 (2H, s, H-9). 
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S-11 4-acetoxybenzyl alcohol Colourless oil. 1H NMR (300 MHz, in Acetone-d6) δ (in 
ppm)  7.35~7.38 (2H, d, J =8 .3 Hz, H-4, 8), 7.08~7.11 (2H, d, J = 8.3 Hz, H-5, 7), 
2.25 (2H, s, H-1), 4.68 (2H, s, H-9). 
S-12 Bis-(acetoxybenzyl) ether Colourless crystal from hexane-ethyl acetate. mp: 113-
115 ℃,1H NMR (300 MHz, in Acetone-d6) δ (in ppm) 2.25 (3H, s, -COCH3), 
7.09~7.12 (4H, d, J = 8.7 Hz, H-2, 6 & H-2’, 6’), 7.38~7.41 (4H, d, J = 8.7 Hz, H-3, 5 
& H-3’, 5’), 4.57 (4H, s, H-7, 7’). 
S-13 4-((4-hydroxybenzyloxy)methyl)phenyl acetate Colourless crystal from hexane-
ethyl acetate. mp: 109-110 ℃, 1H NMR (300 MHz, in Acetone-d6) δ (in ppm) 2.24 
(3H, s, -COCH3), 7.07~7.10 (2H, d, J = 8.7 Hz, H-2, 6), 7.36~7.39 (2H, d, J = 8.7 Hz, 
H-3, 5), 6.80~6.83 (2H, d, J = 8.7 Hz, H-2’, 6’), 7.19~7.22 (2H, d, J = 8.7 Hz, H-3’, 
5’), 4.51 (2H, s, H-7), 4.46 (2H, s, H-7’), 8.32 (1H, b, -ArOH). 
S-14 Acetic acid 4-(5-formyl-furan-2-ylmethoxymethyl)-phenyl ester Yellowish oil. 1H 
NMR (300 MHz, in CDCl3) δ (in ppm) 2.30 (3H, s, -COCH3), 9.63 (1H, s, -CHO), 
7.35~7.38 (2H, d, J = 8.4 Hz, H-3, 5), 7.20-7.21 (1H, d, J = 3.3 Hz, H-3’), 7.06~7.09 
(2H, d, J = 8.4 Hz, H-2, 6), 6.52~6.53 (1H, d, J = 3.3 Hz, H-4’). 13C NMR (75 MHz, 
in CDCl3) δ (in ppm) 177.7 (C-1’), 169.4 (-COCH3), 158.1 (C-5’), 152.6 (C-2’), 150.3 
(C-1), 134.8 (C-4), 128.9 (C-3, 5), 121.6 (C-2, 6), 111.3 (C-3’), 111.3 (C-4’), 72.2 (C-
7), 64.1 (C-6’). 
BHE Colourless crystal from acetone. mp: 95-96 ℃, 1H NMR (300 MHz, in Acetone-
d6) δ (in ppm) 6.79~6.82 (4H, d, J = 8.7 Hz, H-2, 6 & H-2’, 6’), 7.17~7.20 (4H, d, J = 
8.7 Hz, H-3, 5 & H-3’, 5’), 4.40 (4H, s, H-7, 7’).  
HPMP White powder. mp: 147~149℃. 1H NMR (300 MHz, in DMSO-d6) δ (in ppm) 
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7.18~7.24 (4H, d, J = 8.3 Hz, H-3, 5, &H-10,12), 6.90~6.93 (2H, d, J = 8.7 Hz, H-2, 
6), 6.73~6.76 (2H, d, J = 8.7 Hz, H-9, 13), 4.92 (2H, s, H-7), 5.01~5.03 (2H, d, J = 
5.6 Hz, H-14), 4.38~4.40(1H, t, J = 5.6 Hz, -OH), 9.44 (1H, s, -phOH). 13C NMR (75 
MHz, in Acetone-d6) δ (in ppm) 156.9 (C-1), 114.6 (C-2, 6), 129.4 (C-3, 5), 134.4 (C-
4), 69.1 (C-7), 157.2 (C-8), 114.2 (C-9, 13), 127.7 (C-10, 12), 127.1 (C-11), 62.4 (C-
14). 
HMP See ref.  123for detailed spectral analysis. 
CSD Yellowish crystal. 1H NMR (300 MHz, in DMSO-d6) δ (in ppm) 9.63 (2H, s, H-
1), 7.38~7.39 (2H, d, J = 3.3 Hz, H-3), 6.70~6.71 (2H, d, J = 3.3 Hz, H-4), 4.67 (4H, s, 
H-6).  
HFC Colourless oil. 1H NMR (300 MHz, in CDCl3) δ (in ppm) 4.52~4.54 (4H, d, H-
6’, 7), 5.57 (1H, s, PhOH), 6.52~6.53 (1H, d, J = 3.3 Hz, H-4’), 6.80~6.83 (2H, d, J = 
6.42 Hz, H-2, 6), 7.20~7.26 (2H, 1H, d, d, J = 6.42 Hz, H-3, 5, J=3.3, H-3’), 9.60 (1H, 
s, -CHO). 
Synthesis of 2-oxindole derivatives 
1. [E]-3-Furan-2-ylmethylene-1,3-dihydro-indol-2-one 
Pale yellow crystals, yield: 76%; mp: 190.5-191.5℃; 1H NMR (300MHz, DMSO-d6) 
δ (in ppm) 10.55 (s, 1H, NH-1), 8.35 (d, J = 7.92 Hz, 1H, H-4), 8.16 (s, 1H, H-5’), 
7.33 (s, H-vinyl), 7.23~7.28 (m, 2H, H-3’, 6), 6.99~7.04 (dt, J=7.53, 1.13Hz, 1H, H-
5), 6.87 (d, J=7.53, 1H, H-7), 6.79 (dd, J = 1.89 Hz, 1.50Hz, 1H, H-4’).  13C NMR 
(75MHz, DMSO-d6) δ (in ppm) 169.2, 150.6, 147.2, 142.5, 129.6, 124.4, 122.1, 121.3, 




Yellow crystals, yield: 72%; mp: 281-282℃; 1H NMR (300MHz, DMSO-d6) δ (in 
ppm) 10.73 (s, 1H, NH-1), 8.34 (d, J = 8.28 Hz, 1H, H-4), 8.17 (s, 1H, H-5’), 7.37 (s, 
1H, H-vinyl), 7.30 (d, J = 3.39 Hz, H-3’), 7.05 (dd, J = 8.09 Hz, 1.86, 1H, H-7), 6.88 
(d, J = 1.89 Hz, 1H, H-5), 6.82 (dd, J = 1.50 Hz, 1.89, 1H, H-4’). 13C NMR (75MHz, 
DMSO-d6) δ (in ppm) 169.3, 150.4, 149.7, 143.7, 133.4, 125.9, 122.4, 121.1, 120.2 
(x2), 120.0, 110.6, 109.5. MS (APCI) m/z [M+1]+ 246.3. 
3. [E]-3-(5-Hydroxymethyl-furan-2-ylmethylene)-1,3-dihydro-indol-2-one 
Red crystals, yield: 82%; mp: 243-244℃; 1H NMR (300MHz, DMSO-d6) δ (in ppm) 
10.53 (s, 1H, NH-1), 8.39 (d, J = 7.17 Hz, 1H, H-4), 7.29 (s, 1H, H-vinyl), 7.19~7.26 
(m, 2H, H-6, 3’), 7.00 (t, J = 7.92 Hz, 1H, H-5), 6.86 (d, J = 7.92 Hz, 1H, H-7), 6.61 
(d, J = 3.39 Hz, 1H, H-4’), 5.56 (s, 1H, H-OH), 4.61 (s, 2H, H-CH2O). 13C NMR 
(75MHz, DMSO-d6) δ (in ppm) 169.3, 160.0, 149.9, 142.4, 129.4, 124.8, 121.7, 121.6, 
121.4, 121.3, 119.3, 110.5, 109.6, 56.1. MS (APCI) m/z [M+1]+ 242.0. 
4. [E]-6-Chloro-3-(5-hydroxymethyl-furan-2-ylmethylene)-1,3-dihydro-indol-2-one 
Red crystals, yield: 67%; mp: 247-249℃; 1H NMR (300MHz, DMSO-d6) δ (in ppm) 
10.69 (s, 1H, NH-1), 8.38 (d, J = 8.31 Hz, 1H, H-4), 7.33 (s, 1H, H-vinyl), 7.24 (d, J 
= 3.00 Hz, 1H, H-3’), 7.04 (dd, J = 7.74 Hz, 1.89Hz, 1H, H-5), 6.88 (d, J = 1.89 Hz, 
1H, H-7), 6.63 (d, J =3.78 Hz, 1H, H-4’), 5.59 (s, 1H,  H-OH), 4.61 (s, 2H, H-CH2O). 
13C NMR (75MHz, DMSO-d6) δ (in ppm) 169.3 (C-1), 160.4 (C-5’), 149.7 (C-2’), 
143.7 (C-2), 133.4 (C-6), 125.9 (C-4), 122.4 (C-3’), 121.1 (C-3), 120.2 (C-5, 8), 120.0 





Yellow crystals, yield: 58%; mp: 157-159℃; 1H NMR (300MHz, DMSO-d6) δ (in 
ppm) 10.54 (s, 1H, NH-1), 8.35 (d, J = 7.53 Hz, 1H, H-4), 7.24~7.31 (m, 4H, H-vinyl, 
6, 10’), 7.21 (d, J = 3.39 Hz, 1H, H-3’), 6.75~6.92 (m, 3H, H-5, 9’), 6.75 (d, J = 3.39 
Hz, 1H, H-4’), 4.64 (s, 2H, H-6’), 4.52 (s, 2H, H-7’), 3.74 (s, 3H, H-OMe). 13C NMR 
(75MHz, DMSO-d6) δ (in ppm) 169.2, 158.8, 155.9, 150.6, 142.6, 129.7, 129.6, 
129.3(x2), 124.7, 122.2, 121.2(x3), 119.1, 113.6(x2), 112.5, 109.6, 71.2, 63.4, 55.0. 
MS (APCI) m/z [M+1]+ 362.0. 
6.[E]-6-Chloro-3-[5-(4-methoxy-benzyloxymethyl)-furan-2-ylmethylene]-1,3-
dihydro-indol-2-one 
Yellow crystals, yield: 49%; mp: 167-168℃; 1H NMR (300MHz, DMSO-d6) δ (in 
ppm) 10.73 (s, 1H, NH-1), 8.30 (d, J = 8.28 Hz, 1H, H-4), 7.33 (s, 1H, H-vinyl), 7.30 
(d, J = 8.67 Hz, 2H, H-10’), 7.25 (d, J = 3.39 Hz, 1H, H-3’), 6.90 (d, J = 8.67 Hz, 2H, 
H-9’), 6.87 (d, J = 1.89 Hz, 1H, H-7), 6.83 (dd, J = 7.89 Hz, 1.86Hz, 1H, H-5), 6.76 
(d, J =3.39 Hz, 1H, H-4’), 4.66 (s, 2H, H-6’), 4,52 (s, 2H, H-7’), 3.74 (s, 3H, H-OMe). 
13C NMR (75MHz, DMSO-d6) δ (in ppm) 169.1, 158.8, 156.2, 150.3, 143.8, 133.5, 
129.8, 129.4(x2), 125.8, 121.9, 120.9(x2), 120.1, 119.8, 113.6 (x2), 112.5, 109.5, 71.3, 
63.5, 55.0. MS (APCI) m/z [M+1]+ 396.0. 
7. [E]-3-[5-(4-Hydroxy-benzyloxymethyl)-furan-2-ylmethylene]-1,3-dihydro-indol-
2-one 
Yellow crystals, yield: 66%; mp: 200-201℃; 1H NMR (300MHz, DMSO-d6) δ (in 
ppm) 10.54 (s, 1H, NH-1), 9.40 (s, 1H, H-OH), 8.37 (d, J = 7.53 Hz, 1H, H-4), 7.29 (s, 
1H, H-vinyl), 7.16~7.27 (m, 4H, H-6, 3’, 10’), 6.92 (t, J = 7.53 Hz, 1H, H-5), 6.86 (d, 
J = 7.14 Hz, 1H, H-7), 6.72~6.74 (m, 3H, H-4’, 9’), 4.62 (s, 2H, H-6’), 4.46 (s, 2H, 
H-7’). 13C NMR (75MHz, DMSO-d6) δ (in ppm) 169.2, 157.0, 156.0, 150.6, 142.6, 
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129.6, 129.5(x2), 128.0, 124.7, 122.2, 121.2(x3), 119.1, 115.0(x2), 112.5, 109.6, 71.5, 
63.3. MS (APCI) m/z [M+1]+ 348.0. 
8.[E]-6-Chloro-3-[5-(4-hydroxy-benzyloxymethyl)-furan-2-ylmethylene]-1,3-
dihydro-indol-2-one 
Yellow crystals, yield: 63%; mp: 217-218℃; 1H NMR (300MHz, DMSO-d6) δ (in 
ppm) 10.71 (s, 1H, NH-1), 9.42 (s, 1H, H-OH), 8.32 (d, J = 9.03 Hz, 1H, H-4), 7.33 (s, 
1H, H-vinyl), 7.25 (d, J = 3.39 Hz, 1H, H-3’), 7.18 (d, J = 8.64 Hz, 2H, H-10’), 6.90 
(d, J = 2.25 Hz, 1H, H-7), 6.88 (td, J = 4.53 Hz, 2.25Hz, 1H, H-5), 6.72~6.75 (m, 3H, 
H-4’, 9’), 4.63 (s, 2H, H-6’), 4.46 (s, 2H, H-7’).  13C NMR (75MHz, DMSO-d6) δ (in 
ppm) 169.1, 157.0, 156.4, 150.3, 143.8, 133.5, 129.5(x2), 128.0, 125.8, 121.9, 




Yellow crystals, yield: 45%; mp: 188-190℃; 1H NMR (300MHz, DMSO-d6) δ (in 
ppm) 10.54 (s, 1H, NH-1), 9.55 (s, 1H, H-CHO), 8.33 (d, J = 7.53 Hz, 1H, H-4), 7.51 
(d, J = 3.75 Hz, 1H, H-10’), 7.29 (s, 1H, H-vinyl), 7.20~7.25 (m, 2H, H-6, 3’), 6.95 (t, 
J = 7.92 Hz, 1H, H-5), 6.87 (d, J = 7.53 Hz, 1H, H-7), 6.75~6.78 (dd, J = 3.75 Hz, 
3.03 Hz, 2H, H-4’, 9’), 4.73 (s, 2H, H-6’), 4.67 (s, 2H, H-7’).  13C NMR (75MHz, 
DMSO-d6) δ (in ppm) 178.2, 169.1, 157.5, 155.1, 152.3, 150.7, 142.6, 129.6, 124.7, 






Yellow crystals, yield: 40%; mp: 195-196℃; 1H NMR (300MHz, DMSO-d6) δ (in 
ppm) 10.71 (s, 1H, NH-1), 9.55 (s, 1H, H-CHO), 8.31 (d, J = 8.28 Hz, 1H, H-4), 7.51 
(d, J = 3.39 Hz, 1H, H-10’), 7.32 (s, 1H, H-vinyl), 7.24 (d, J = 3.39 Hz, 1H, H-3’), 
6.97 (dd, J = 8.31, 1.89 Hz, 1H, H-5), 6.88 (d, J = 1.86 Hz, 1H, H-7),  6.74~6.78 (m, 
2H, H-4’, 9’), 4.73 (s, 2H, H-6’), 4.67 (s, 2H, H-7’). 13C NMR (75MHz, DMSO-d6) δ 
(in ppm) 178.2, 169.2, 157.5, 155.5, 152.3, 150.5, 143.8, 133.7, 125.9, 123.7, 121.8, 
121.1, 121.0, 120.1, 119.7, 113.0, 112.2, 109.6, 64.0, 63.6. MS (APCI) m/z [M+1]+ 
384.1. 
11. [Z]-3-(Hydroxy-phenyl-methylene)-1,3-dihydro-indol-2-one 
Yellow crystals, yield: 53%; mp: 201-204℃; 1H NMR (300MHz, Acetone-d6) δ (in 
ppm) 10.18 (s, 1H, NH), 7.81-7.84 (dd, 2H, H-2’, J = 7.8 & 1.5 Hz), 7.61-7.65 (m, 3H, 
H-3’&4’), 7.12-7.16 (dt, 2H, H-4&6, J = 7.5 & 7.8 Hz), 7.00-7.02 (d, 1H, H-7, J = 7.8 
Hz), 6.86-6.91 (t, 1H, H-5, J = 7.5 Hz). 13C NMR (75MHz, Acetone-d6) δ (in ppm) 
174.5, 172.6, 138.2, 135.3, 132.3, 129.7 (x2), 129.1 (x2), 126.9, 122.8, 122.3, 120.4, 
111.3, 102.4. MS (APCI) m/z [M+1]+ 238.3. 
12. [Z]-6-Chloro-3-(hydroxy-phenyl-methylene)-1,3-dihydro-indol-2-one 
Yellow crystals, yield: 47%; mp: 255-257℃; 1H NMR (300MHz, CDCl3) δ (in ppm) 
8.06 (s, 1H, NH), 7.76-7.78 (dd, 2H, H-2’, J1 = 7.8 & 1.9 Hz), 7.52-7.60 (m, 3H, H-
3’&4’), 7.05-7.08 (d, 1H, H-4, J = 8.3 Hz), 6.99 (d, 1H, H-7, J = 1.9 Hz), 6.84-6.87 (d, 
1H, H-5, J = 8.3 Hz). 13C NMR (75MHz, Acetone-d6) δ (in ppm) 174.4, 173.1, 139.5, 
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134.9, 132.4, 131.3, 129.7 (x2), 128.9 (x2), 121.8, 121.5, 121.1, 111.4, 101.7. MS 
(APCI) m/z [M+1]+ 272.2. 
13. [Z]-3-[(4-Chloro-phenyl)-hydroxy-methylene]-1,3-dihydro-indol-2-one 
Yellow crystals, yield: 47%; mp: 226-228℃; 1H NMR (300MHz, CDCl3) δ (in ppm) 
8.04 (s, 1H, NH), 7.74-7.77 (d, 2H, H-3’, J = 8.6 Hz), 7.51-7.54 (d, 2H, H-2’, J = 8.3 
Hz), 7.13-7.17 (dt, 2H, H-4&6, J = 7.8 & 1.9 Hz), 6.97-6.99 (d, 1H, H-7, J = 7.5 Hz), 
6.88-6.93 (t, 1H, H-5, J = 8.3 Hz). 13C NMR (75MHz, Acetone-d6) δ (in ppm) 174.0, 
170.8, 138.4, 137.2, 133.8, 130.7(x2), 129.7(x2), 126.7, 122.2, 122.0, 120.1, 111.3, 
102.5. MS (APCI) m/z [M+1]+ 272.2. 
14. [Z]-6-Chloro-3-[(4-chloro-phenyl)-hydroxy-methylene]-1,3-dihydro-indol-2-one 
Yellow crystals, yield: 52%; mp: 280-282℃; 1H NMR (300MHz, CDCl3) δ (in ppm) 
7.81 (s, 1H, NH), 7.71-7.74 (d, 2H, H-2’, J = 8.7 Hz), 7.51-7.54 (d, 2H, H-3’, J = 8.3 
Hz), 7.05-7.07 (d, 1H, H-4, J = 8.3 Hz), 6.98 (d, 1H, H-7, J = 1.5 Hz), 6.86-6.89 (dd, 
1H, H-5, J = 8.3 & 1.5 Hz). 13C NMR (75MHz, Acetone-d6) δ (in ppm) 172.2, 170.9, 
138.4, 136.1, 133.1, 132.7, 130.3(x2), 129.9(x2), 128.8, 121.1, 121.3, 110.2, 101.1. 
MS (APCI) m/z [M+1]+ 306.3. 
15. [Z]-3-[(4-Benzoyl-phenyl)-hydroxy-methylene]-1,3-dihydro-indol-2-one 
Yellow crystals, yield: 43%; mp: 207-209℃; 1H NMR (300MHz, CDCl3) δ (in ppm) 
8.09 (s, 1H, NH), 7.91-7.99 (dd, 4H, H-2’&7’, J = 8.3 Hz), 7.85-7.88 (d, 2H, H-3’, J 
= 7.2 Hz), 7.62-7.67 (t, 1H, H-9’, J = 7.5 Hz), 7.51-7.55 (d, 2H, H-8’, J = 7.5 Hz), 
7.16-7.19 (m, 2H, H-4&6, J = 7.5 & 7.8 Hz), 7.01 (d, 1H, H-7, J = 7.5 Hz), 6.88-6.93 
(t, 1H, H-5, J = 7.5 & 1.5 Hz). 13C NMR (75MHz, Acetone-d6) δ (in ppm) 195.2, 
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172.6, 170.1, 139.2, 137.4, 137.3, 136.6, 133.0, 129.9, 129.7(x2), 128.7(x2), 128.3, 
126.2, 121.5, 121.0, 119.4, 110.6, 101.8. MS (APCI) m/z [M+1]+ 342.0. 
16. [Z]-3-[(4-Benzoyl-phenyl)-hydroxy-methylene]-6-chloro-1,3-dihydro-indol-2-
one 
Yellow crystals, yield: 34%; mp: 274-276℃; 1H NMR (300MHz, CDCl3) δ (in ppm) 
8.04 (s, 1H, NH), 7.91-7.99 (dd, 4H, H-2’&7’, J = 8.3 Hz), 7.85-7.87 (d, 2H, H-3’, J 
= 7.2 Hz), 7.60-7.67 (t, 1H, H-9’, J = 7.5 Hz), 7.53-7.56 (d, 2H, H-8’, J = 7.5 Hz), 
7.07-7.09 (d, 1H, H-4, J = 8.7 Hz), 6.99 (d, 1H, H-7, J = 1.5 Hz), 6.87-6.90 (t, 1H, H-
5, J = 8.3 & 1.5 Hz). 13C NMR (75MHz, Acetone-d6) δ (in ppm) 195.7, 174.3, 172.2, 
140.1, 139.4, 138.2, 137.5, 137.0, 133.5, 131.1, 130.5, 130.3(x2), 129.2(x2), 129.0, 
121.7, 121.5, 111.0, 102.2. MS (APCI) m/z [M+1]+ 376.2. 
17. [Z]-3-[Hydroxy-(4-phenoxy-phenyl)-methylene]-1,3-dihydro-indol-2-one 
Yellow crystals, yield: 52%; mp: 210-212℃; 1H NMR (300MHz, DMSO-d6) δ (in 
ppm) 11.3 (s, 1H, NH), 7.80-7.83 (d, 2H, H-2’, J = 8.3 Hz), 7.46-7.51 (t, 2H, H-7’, J 
= 7.9 Hz), 7.23-7.28 (t, 1H, H-8’, J = 7.5 Hz), 7.11-7.23 (m, 6H, H-3’,6’, 4 & 6), 
7.00-7.02 (d, 1H, H-7, J = 7.5 Hz), 6.87-6.92 (t, 1H, H-5, J = 7.5 Hz). 13C NMR 
(75MHz, Acetone-d6) δ (in ppm) 174.5, 172.1, 161.4, 156.8, 138.1, 131.3(x2), 
131.1(x2), 129.7, 126.8, 125.4, 122.9, 122.3, 120.9(x2), 120.5, 118.6(x2), 111.3, 
102.1. MS (APCI) m/z [M+1]+ 330.3. 
18. [Z]-3-[Hydroxy-(4-phenoxy-phenyl)-methylene]-6-chloro-1,3-dihydro-indol-2-
one 
Yellow crystals, yield: 42%; mp: 208-210℃; 1H NMR (300MHz, Acetone-d6) δ (in 
ppm) 10.3 (s, 1H, NH), 7.83-7.86 (d, 2H, H-2’, J = 8.3 Hz), 7.45-7.51 (t, 2H, H-7’, J 
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= 7.9 Hz), 7.16-7.28 (m, 6H, H-3’, 6’, 8’ & 4), 7.09-7.10 (d, 1H, H-7, J = 1.9 Hz), 
6.89-6.93 (dd, 1H, H-5, J = 8.3 & 1.9 Hz). 13C NMR (75MHz, Acetone-d6) δ (in ppm) 
174.4, 172.4, 161.5, 156.6, 139.1, 131.5, 131.3(x2), 131.1(x2), 129.2, 125.4, 122.1, 
121.7, 121.4, 120.8(x2), 118.6(x2), 111.3, 101.3. MS (APCI) m/z [M+1]+ 364.2. 
19. [Z]-3-[Hydroxy-(3-phenoxy-phenyl)-methylene]-1,3-dihydro-indol-2-one 
Yellow crystals, yield: 55%; mp: 184-185℃; 1H NMR (300MHz, Acetone-d6) δ (in 
ppm) 10.1 (s, 1H, NH), 7.62-7.67 (t, 1H, H-5’, J = 7.5 & 7.9 Hz), 7.55-7.58 (d, 1H, 
H-6’, J = 7.5 Hz), 7.40-7.46 (t, 2H, H-9’, J = 7.5 & 8.3 Hz), 7.35 (s, 1H, H-2’), 7.28-
7.31 (d, 1H, H-4’, J = 8.3 Hz), 7.11-7.20 (m, 5H, H-8’, 10’, 4 & 6), 7.04-7.06 (d, 1H, 
H-7, J = 7.5 Hz), 6.85-6.90 (t, 1H, H-5, J = 7.5 Hz). 13C NMR (75MHz, Acetone-d6) δ 
(in ppm) 174.4, 171.5, 158.9, 157.5, 138.3, 137.0, 131.5, 131.0(x2), 127.0, 125.0, 




Yellow crystals, yield: 51%; mp: 189-190℃; 1H NMR (300MHz, Acetone-d6) δ (in 
ppm) 10.1 (s, 1H, NH), 7.62-7.67 (t, 1H, H-5’, J = 7.5 & 7.9 Hz), 7.54-7.57 (d, 1H, 
H-6’, J = 7.5 Hz), 7.41-7.46 (t, 2H, H-9’, J=7.5 & 8.6 Hz), 7.29-7.32 (d, 2H, H-2’ & 
4’, J = 8.3 Hz), 7.11-7.20 (m, 4H, H-8’, 10’ & 4), 7.07-7.08 (d, 1H, H-7, J = 1.5 Hz), 
6.85-6.90 (dd, 1H, H-5, J = 8.3 & 1.5 Hz). 13C NMR (75MHz, Acetone-d6) δ (in ppm) 
174.0, 171.7, 158.6, 157.0, 138.8, 136.3, 131.4, 131.2, 130.7(x2), 124.7, 123.3, 122.1, 




Brownish crystals, yield: 92%; mp: 133-134℃; 1H NMR (300MHz, CDCl3) δ (in ppm) 
13.7 (s, 1H, OH), 8.28-8.31 (d, 1H, H-7, J = 8.3 Hz), 7.63-7.76 (dd, 2H, H-2’, J = 7.9 
& 1.5 Hz), 7.52-7.62 (m, 3H, H-3’ & 4’), 7.17-7.23 (dd, 1H, H-6, J = 1.5 & 8.7 Hz), 
7.05-7.07 (d, 1H, H-4, J = 7.1 Hz), 6.95-7.00 (dd, 1H, H-5, J =7.1 & 0.75 Hz) 2.80 (s, 
3H, -COCH3). 13C NMR (75MHz, CDCl3) δ (in ppm) 173.0, 172,9, 170.5, 135.5, 
133.4, 131.8, 128.8(x2), 128.3(x2), 126.6, 124.3, 122.0, 119.1, 116.4, 101.4, 27.0. MS 
(APCI) m/z [M+1]+ 280.1. 
22. 3-(Furan-2-yl-hydroxy-methylene)-1,3-dihydro-indol-2-one 
Yellow crystals, yield: 50%; mp: 214-216℃; 1H NMR (300MHz, CDCl3) δ (in ppm) 
8.26-8.29 (d, 1H, H-4, J = 7.9 Hz), 7.97 (s, 1H, NH), 7.82-7.83 (d, 1H, H-4’, J = 0.75 
Hz), 7.33-7.35 (dd, 1H, H-2’, J = 0.75 & 3.8 Hz), 7.18-7.24 (ddd, 1H, H-6, J = 1.0, 
7.5 & 7.9 Hz), 7.08-7.14 (ddd, 1H, H-5, J = 7.5, 7.9 & 1.5Hz), 6.98-7.01 (d, 1H, H-7, 
J = 7.9 Hz), 6.68-6.70 (dd, 1H, H-3’, J = 1.5 & 3.4 Hz). 13C NMR (75MHz, DMSO-
d6) δ (in ppm) 173.7, 158.5, 147.8, 147.5, 136.9, 125.9, 121.6(x2), 120.9, 117.2, 112.8, 
110.2, 98.8. MS (APCI) m/z [M+1]+ 228.1. 
23. 3-(Furan-2-yl-hydroxy-methylene)-6-chloro-1,3-dihydro-indol-2-one 
Yellow crystals, yield 44%, mp: 258-260℃; 1H NMR (300MHz, CDCl3) δ 8.19-8.21 
(d, 1H, H-4, J=8.3Hz), 7.82 (d, 1H, H-4’, J=1.5Hz), 7.35-7.36 (d, 1H, H-2’, J=3.8Hz), 
7.06-7.10 (dd, 1H, H-5, J=8.3 & 1.9Hz), 7.00 (d, 1H, H-7, J=1.9Hz), 6.69-6.71 (dd, 
1H, H-3’, J=3.4 & 1.5Hz). 13C NMR (75MHz, Acetone-d6) δ 175.1, 160.1, 149.2, 





Yellow crystals, yield 95%, mp: 141-143℃; 1H NMR (300MHz, CDCl3) δ (in ppm) 
14.2 (s, 1H, OH), 8.32-8.37 (dd, 1H, H-4, J = 0.75 & 8.3 Hz), 8.23-8.26 (dd, 1H, H-7, 
J = 1.1 & 7.9 Hz), 7.82 (d, 1H, H-4’, J = 1.5 Hz), 7.38-7.39 (d, 1H, H-2’, J = 3.4 Hz), 
7.18-7.30 (m, 2H, H-5 & 6), 6.69-6.71 (dd, 1H, H-3’, J = 1.5 & 3.4 Hz), 2.78 (s, 3H, -
COCH3). 13C NMR (75MHz, CDCl3) δ (in ppm) 174.0, 170.5, 159.7, 148.3, 146.2, 
135.3, 126.6, 124.7, 121.7, 121.3, 118.3, 116.0, 112.8, 99.4, 27.1. MS (APCI) m/z 
[M+1]+ 270.2. 
4.4.3 X-ray crystallographic analysis of compound 18 
Crystals of [Z]-3-[Hydroxy-(4-phenoxy-phenyl)-methylene]-6-chloro-1,3-dihydro-
indol-2-one (compound 18) were grown in solvent mixture of methanol and acetone 
and mounted on glass fibers. X-ray data were collected with a Bruker AXS SMART 
APEX diffractometer, using Mo Kα radiation at 223K, with the SMART suite of 
Programs (SMART version 5.628 (2003), Bruker AXS Inc., Madison, WI). Data were 
processed and corrected for Lorentz and polarization effects with SAINT (SAINT + 
version 6.22a (2001) Bruker AXS Inc., Madison, WI), and for absorption effect with 
SADABS (SADABS, version 2.10 (2001), University of Göttingen). Structural 
solution and refinement were carried out with the SHELXTL, suite of programs 
(SHELXTL, version 6.14 (2000), Bruker AXS Inc., Madison, WI). The structure was 
solved by direct methods to locate the heavy atoms, followed by difference maps for 
the light, non-hydrogen atoms. All non-hydrogen atoms were generally given 
anisotropic displacement parameters in the final model whereas H-atoms were placed 
at calculated positions.  
4.5 Bioactivity investigations 
4.5.1 DPPH free radical scavenging test 
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The measurement of antioxidant activity was performed according to a procedure 
described previously with minor modification 124. Quercetine was used as the standard 
antioxidant sample. DPPH and EtOH were used as stable free radical agent and blank, 
respectively. The sample stock solutions were prepared in DMSO at concentration of 
100 mmol, and subsequently diluted by EtOH to the test concentrations. 20 µL of 
each compound at five concentrations (10-100 µM) was transferred to the vials in the 
96-well plates which contained DPPH solution (0.2 mg/mL, 180 µL/vial). The 
reaction was kept in the dark for 2 hrs. The antioxidant activity was measured as the 
decrease of the absorbance of DPPH and expressed as the percentage of the 
absorbance of a control DPPH solution with the addition of EtOH 20 µL.  
4.5.2 Determination of total free phenolic compounds by Folin-Ciocalteu test 
The amount of total phenolic compounds in the samples was determined using Folin-
Ciocalteu method125. Briefly, a calibration curve was prepared from gallic acid 
solution with concentration ranged from 0.03-0.09 mg/mL. In this method, 5 mL 
distilled water was added into a 10 mL volumetric flask.  Samples each 1 mL with 
average concentrations of 1.25 mg/mL was transferred into the volumetric flask to 
obtain absorbance in the range of the prepared calibration curve. 0.2 mL of Folin-
Ciocalteu reagent was added and mixed well for oxidation. After 3 min, the reaction 
was neutralized with 0.4 mL satd. sodium carbonate (Na2CO3) solution. The solution 
is mixed well and made up to volume with distilled water. After a 1 hr reaction in the 
dark, the absorbance was measured at 725 nm using Shimadzu UV-1601 UV-Visible 
Spectrophotometer. The results were expressed as gram of gallic acid equivalent 
(GAE) per 100 g of dry weight (DW) of the extracts 126. 
4.5.3 MES and Rotorod test 
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Animals and drug administration 
Swiss albino mice (male, 20-30 g) were obtained from University Laboratory Animal 
Holding Unit at least two days prior to experimentation. They were kept under a 
natural light-dark cycle with food and water available. All animal experiments under 
the project No. R-148-000-049-112 were formally approved by the NUS institutional 
animal care and use committee (IACUC). Test samples were dissolved in 
dimethylsulfoxide (DMSO) and administered by intraperitoneal injection at 5 mL/kg 
body weight. Mice were then subjected to Rotorod and MES tests for 
pharmacological activities 15-30 min after injection. Prior to drug administration, the 
mice were put on an accelerating rotating treadmill which accelerated from 2-20 
rotations per min in 5 min, and those that could pass this test by staying on the 
rotating rod for more than 5 min of the testing period were considered qualified for 
the following tests.  
Rotorod test 
20 min after drug administration, mice were put on the rotating rod, and the time 
duration when the mice could stand on the accelerating treadmill was recorded and 
used as a measure of impact on motor coordination.  
 MES test 
Mice were shocked electrically with auricle electrodes at 40 mA for 0.2 sec. At his 
magnitude, all control (vehicle-injected) mice exhibited characteristic clonic-tonic 
convulsion which can be briefly described by four stages: clonus, tonic flexor, full 
tonic extensor (hindlimbs), and a pre-recovery period with loss of righting reflex. 
Under the influence of a drug with anticonvulsant activity, mice may show seizure 
167 
 
activities up to different stages depending on the dose and the efficacy of the drug 
used. Therefore, mice that showed the full range of seizure activities were arbitrarily 
assigned an “anticonvulsant score” of 1, while mice with seizure up to the flexor 
phase, 2; clonus, 3; and no seizure, 4.  
4.5.4 Cell culture and cell viability test 
SH-SY5Y cell culture and experimental treatment of hydrogen peroxide 
Human neuroblastoma SH-SY5Y cells were obtained from American Type Culture 
Collection (Rockville, MD, USA). Cells were routinely cultured in MEM-Eagle/F-12 
(HAM) (1:1), containing 10% FBS and a mixture of 2.5% sodium bicarbonate. Cell 
cultures were incubated at 37℃ in a humid 5% CO2-95% air environment. For 
experiments with H2O2, SH-SY5Y cells (6x103/well) were seeded in the cultured 
medium and allowed to attach for 24 hrs before drug treatment. Test samples were 
prepared at 100 µM in DMSO as stock. The sequential dilution using culture medium 
was to attain the required concentration. Test samples were added to the culture 
medium 3 hrs before H2O2 treatment and cells were further incubated for 20 hrs. 
Vehicle-treated cultures were used as controls.  
Experimental treatment of serum deprivation 
SH-SY5Y cells were seeded (5x103/well) in 96-well plates and allowed to attach for 
24 hrs before drug treatment. Serum-free medium was applied after removing medium 
in each well, and drugs dissolved in serum-free medium were given simultaneously. 
Cells were further incubated for 48 hrs. Vehicle-treated cultures were used as controls.  
Cell viability assay (MTT assay) 
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The MTT assay is based on the conversion of MTT to purple formazan crystals by 
viable cells. Briefly, after treatment the medium was removed and replaced with a 
fresh medium (100 µL/well). 10 µL of MTT (5 mg/mL) was added to each well. After 
incubation at 37 ℃ for 4 hrs, the medium was removed and replaced with 100 µL 
DMSO. Absorbance was measured at 570 nm using a Tecan® microplate reader 
(Switzerland) after automatic subtraction of background readings. Cell viability was 
expressed as a percentage of control, untreated cells. 
4.5.5 Electrophysiological study of compound 20 (3112) on Xenopus oocytes 
expressing NR1/NR2B 
cRNA for rat NR1-1a (hereafter NR1) and NR2B were synthesized in vitro and 
injected (5-10 ng) into stage V-VI Xenopus laevis oocytes, isolated as previously 
described127. Two electrode voltage-clamp current recordings were made 2-7 days 
post injection. The recording solution contained (in mmol) 90 NaCl, 3 KCl, 10 
HEPES, 0.5 BaCl2, 0.01 EDTA, 0.05 glycine (23 ℃); pH was adjusted to 7.3 with 
NaOH. EDTA (10 µM) was added to chelate contaminant extracellular divalent ions, 
including trace amounts of Zn2+. Solution exchange was computer controlled through 
an 8-modular valve positioned (Digital MVP Valve, Hamilton Company, Reno, NV). 
Voltage and current electrodes were filled with 0.3 and 3.0 M KCl, respectively, and 
current responses recorded at a holding potential of -50 mV. Data acquisition and 
voltage control were accomplished with a two-electrode voltage-clamp amplifier 
(OC-725, Warner Instruments, Hamden, CT). Current response was expressed as the 





ED50 values were calculated using Chou’s median-effect equation84. The seizure score 
obtained in the MES test were statistically evaluated using Kruskal-Wallis non-
parametric ANOVA. In other cases, parametric ANOVA followed by Dunnett’s test 
was performed to compare the effects of drug treatment with the control. Difference 
between control and treatment would be considered statistically significant if P value 
was less than 0.05. All statistical tests were performed using commercially available 
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